生体内の微小環境情報に基づいた物性制御による環境応答型インテリジェントナノ DDS の創成
平成 25 年度〜平成 29 年度
私立大学戦略的研究基盤形成支援事業
研究成果報告書

平成 30 年 5 月
学校法人

京都薬科大学大学名

京都薬科大学

研究組織名

京都薬科大学
ナノ DDS 開発チーム

研究代表者

加藤

伸一

はしがき
京都薬科大学における文部科学省私立大学戦略的研究基盤形成支援事業「生体内の微小環境情報に基づいた物性制御による環境応答型インテリジェントナノ DDS の創成」は、 平成 25 年度にスタートし平成 29 年度に終了しました。ここに、5 年間の研究活動に関する成果報告書を公表いたします。
文部科学省私立大学戦略的研究基盤形成支援事業は、私立大学が各大学の経営戦略に基づいて行う研究基盤の形成を支援するため、研究プロジェクトに対して重点的か
つ総合的に文部科学省が補助を行う事業であり、その成果としてわが国の科学技術の進展に寄与することを目的としています。これを受けて、各大学が最先端の研究や地域に根差した研究などの観点から研究プロジェクトを計画・申請し、文部科学省が厳正な審査のうえで選定を行い、その中から採択された当該プロジェクトを遂行するための研究拠点に対して、文部科学省が研究施設・設備整備費や研究費を一体的に補助します。研究期間としては、「研究拠点を形成する研究」については 5 年間となり、開始から 3 年目に中間評価が、また最終年度には事後評価が実施され、研究活動の成果が一般社会を含めて幅広く公表されます。
本プロジェクトは、生体内の微小環境情報に基づいた物性制御による環境応答型インテリジェントナノ DDS の創成を目指し、研究拠点を形成する研究として 5 年間の予定で申請し、採択されました。腫瘍など重篤な疾患治療のためには、マクロ的視点
では明らかにできなかったミクロな環境、すなわち疾患微小環境の特異性を解明することが重要であります。このことは、疾患の病態機能分子を同定することに加えて、従来の DDS では困難であった疾患部位特異的な薬物送達の開発に繋がることが期待されます。他方、in vitro 研究と in vivo 研究間の大きなギャップが問題となっていますが、これは生体を「均質なもの」として捉えてしまっていることが大きな原因と考えられます。そのため、生体のヘテロ性（特異な微小環境）を正確に捉え、それに基づいた疾患の病態解析ならびに DDS 戦略の立脚が重要であります。本研究では、疾患微小環境情報を探索し、その特異性に応答可能な革新的インテリジェントナノ
DDS の創成を目的とした研究拠点形成を目指しています。開発を目指すインテリジェントナノ DDS は、腫瘍・メタボリックシンドローム・感染症等の多様な病態・疾患に適用可能な新しい治療法の提案に繋がり、わが国の健康・福祉への大きな貢献が期待されます。
本研究は、3 つの研究班で構成され、各班が連携して研究を推進し、革新的インテ
リジェントナノ DDS の創成を目指し研究を行ってきました。1 班では、疾患微小環境情報を探索、2 班がインテリジェントナノ DDS の開発、3 班が機能性評価を行う
ことで、互いの成果をフィードバックすることにより疾患に対応したインテリジェン
トナノ DDS の完成を目指してきました。
5 年間の研究期間において、平成 25 年 10 月のキックオフシンポジウムをはじめ、
平成 26 年 3 月および 11 月には年次成果発表会が開催され、また平成 27 年 8 月には中間発表会が 2 名の外部評価者を招き開催されました。これらの発表会では学内外から多くの方にご参加頂き、最新の研究成果の発表と活発なディスカッションが行われました。また、いずれの発表会においても、多くの大学院生および学部学生が参加、発表を行い、研究活動を通した教育にも大きく貢献しました。
本プロジェクトの研究成果については、原著論文が 88 報、図書が 12 冊、学会発表が国内外を合わせて 472 件、さらに学会等における各賞受賞が 51 件であり、大きな成果を挙げることができたと考えられます。
今後も引き続き本プロジェクトを基盤とした共同研究を続けることで、難治性疾患の克服に向けたさらなる研究の展開および発展に繋げていきたいと考えています。
本研究の遂行に際し、ご尽力頂いた関係各位に厚くお礼を申し上げますとともに、
京都薬科大学のさらなる発展のために、ご指導ご鞭撻を賜りますよう、この場を借りてお願い申し上げます。
平成 30 年 5 月
京都薬科大学
病態薬科学系 薬物治療学分野
教授

加藤

伸一

（研究代表者）Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ŃƆ щь ńŌՎŃƆ щѐ ńŌҝˏ˝îāƈʚʮʿ˚ÜʴřƆƲƬȗҞпʿ˚ƆǸà´ǝș͸ппԱп āȃɇ ®п п п п ϧ͢ˑîāп п п п п п п п п Բп îā®п п п п п ϧ͢ˑîāп п п п п п п п ппԳп ʿ˚˿̗®п п п п ϧ͢ˑîāп ԀԄ љљѧ ϾʫӺԧԖп п п п п п п п п п п п п п п п п п п п п п п ппԴп ԍԢӱӠӨӾƊÒÔп п п ϧĻĬˑťЇ ^ʕԵʛÔп п п п п п п п п п п п п п п п п п п п п п п ппԵп ʿ˚ԍԢӱӠӨӾ®п ʎ7^ӃŧĠʌåźàӁÜһҠҶɽŲqťӁӑӔʌåŮˤ×ӝԤӼпԟӱӠԤӾԀԄ љљѧ ӃyƆппԶп ʿ˚Ϳɷп п п п ʿ˚ƘɷӘřƆҰӔʿ˚п п п п п п п п п п п п п п п п п п п п ппԷп ʿ˚'̣ͯпʿ˚'̣ͯ®пƊĪϥĦ®п̧®п|ͥп 1п͢ɽɂʨāiϯпƷƢппԸп ԍԢӱӠӨӾ|ʿ˚̣ƺп п шьп ®ппԹп ΍Řĕǿiп п п п ʈĹԦźàп п п п п ʎɽԦȬп п п п ппԱ԰п ʿ˚ԍԢӱӠӨӾӁ|ҰӔӀʿ˚̣пʿ˚̣®п|ͥп 1пĬǪп ǋпͺп ͏ȩпȪп ͐ŚпͥĊп ЏŔпͷ£п Ĺ©пмͥп ɋŃпƊĪԦ̧®п

ƼԦˇ.п пԍԢӱӠӨӾҽӃʿ˚ΕХпԍԢӱӠӨӾҽӃŞxп͢ɽɂʨɕ ˦˯́ʡéӃŧĠɕ ˦˯́ʡéӃŧĠʌåāiϯԦƷʌåӃźàАҾ΁ǵ
Ӄ΁ǵп
Ƣп
ӁΥʁп
ª˖ʠŸŧĠʌåŮˤ͢ u ā i ԀԄ˭üӘԏԧӲҾҮҶʠŸŲӃӝԤӼԟӱӠԤӾԀԄϯԦƷƢпʌåŮˤ×ԀԄ љљѧ ӃϾʫпљљѧ ӃϾʫӁΥʁпʭϱԀԄ˭üӘԏԧӲҾҮҶ ª˖ʠŸŧĠʌåŮˤ͢uāiʠŸʌåŮˤ×ԀԄ љљѧ Ӄ ŲӃӝԤӼԟӱӠԤӾԀԄϯԦcƷƢпϾʫпљљѧ ӃϾʫӁΥʁп
͢ º i ǵ ԟԓӶԧԖӘԏԧӲҾҮҶ̼ ̼ʧʌåŮˤŲӃӝԤāiϯԦc ʧʌåŮˤŲԀԄ љљѧ ӃϾ ӼԟӱӠԤӾԀԄ љљѧ ӃƷƢпʫпϾʫӁΥʁп
˽̱ʎɽſǼʢŧĠʌåŮˤŲſǼʢԘ ӽԠӁңҩӔԀԄāiϯԦƷӝԤӼԟӱӠԤӾԀԄ љљѧљљѧ ӃȤ̲Ų΋?пƢпӃȤ̲Ų΋?ӁΥʁп̼ʧԦ̳̬˿̗ŧ Ġʌ̈́ ň ͢ ā ̼ʧңӑӆ̳̬˿̗Ӂңҩ åŮˤŲӝԤӼԟӱӠԤiϯԦƷƢп ӔԀԄ љљѧ ӃȤ̲Ų΋?пӾԀԄ љљѧ ӃȤ̲Ų΋
?ӁΥʁп
ʎ
āi
ª˖ӝԤӼԟӱӠԤӾԀԄԀԄ љљѧ Ӄ˽̱^Ɵ΁ǵпϯԦ}Ʒпљљѧ Ӄ˽̱^Ɓ΁ǵԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ӁΥʁпĠʑп ʺЉп

îʾп ǓŔпɲп Ϗпîʼп Ϗп

ԨŨĳîāîāЅԩпĠǛп KðǥпԨ˝·Эîāԩпǯп 9пŧʎɽԦſſǼʢԘ ӽԠӁңҩӔԀԄ ſǼʢŧĠʌåӃźàǼqťāљљѧ ӃȤ̲Ų΋?пАҾ΁ǵӁΥʁпiϯԦƷƢпɕ ÇʠŸԦɶʢ ˣªͭʎā ԀԄ љљѧ Ӄª˖ʠŸԘӽԠ ˖ʠŸԘӽԠӁңҩӔiϯԦ}Ʒп ӁңҩӔȤ̲Ų΋?пӝԤӼԟӱӠԤӾԀԄ љљѧӃȤ̲Ų΋?ӁΥʁп͢ºɽʈ̳̬˿̗ŧĠʌåӃźāiϯԦ ̫ɧʡƁŧĠʌåӃ΁ǵпàАҾ΁ǵӁΥʁпΜĿп͢ʈāiɶʢŧĠʌåӃźàɶʢǒӃʎ7ŮӃ΁ǵпϯԦƷƢпАҾ΁ǵӁΥʁпԎԠӲԆӝӣӮӝӡԤ ԟԓӶԧԖӘԏԧӲҾҮҶª ª˖ʠŸŧĠʌåŮˤӲ ʿ ˚ ϥ ˖ʠŸʌåŮˤŲԀԄ љљѧ ŲӃӝԤӼԟӱӠԤӾԀԄͭ ʎ ͢ ā ӃϾʫпљљѧ ӃϾʫӁΥʁпiϯԦƷƢп͢āϥԦ͢΁ǵˑā éŲ̸ʠŸˣӃɶʢŧĠʌ ɶʢŧĠʌåӃźàʿ ˚ Ċ Ԧ Ʒ åӃ΁ǵпАҾ΁ǵӁΥʁп
Ƣп

ԎԠӲԆӝ
ӣӮӝӡԤ
ԨŨĳîāîāЅԩпӲʿ˚ϥʾʑп ˞Ŕп
͢ɽƁ
qťāi
ϯԦƷƢп
͢āʿ˚
Ԩ®¤ĨĻ˝îāî
ˑ͢ɽχ
āЅԩп
ϕāiϯԦ
ĤЀп ½пƷƢп̼ʧˣŧĠʌåŮˤŲ̼ʧˣӃŧĠʌåӁŮˤŲӃӝԤӼԟӱӠԤӾԀԄӃԀԄ љљѧ ӃϾʫпљљѧ ӃϾʫӁΥʁпª˖ʠŸŧĠʌåŮˤª˖ʠŸŧĠʌåӁŮˤŲŲӃӝԤӼԟӱӠԤӾԀԄӃԀԄ љљѧ ӃϾʫпљљѧ ӃϾʫӁΥʁппԻʿ˚̣ӃéǜɿɄԨʿ˚'̣ͯӘ°ӍԩԼпǇп
ʿ˚'̣ͯ®пƊĪϥĦ®п

̧®пĠǛп Kðǥп͢ºɽʈ āiϯпƷƢпԨéǜӃǒǧԺŃƆп щяп ńп шп ǡп шп ǆԩп
п
п
ǁп

п

ʿ˚'̣ͯ®пƊĪϥĦ®п̧®п|ͥп 1п͢ɽɂʨāiϯпƷƢпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®п

ʭϱԀԄ˭üӘԏԧӲϧ͢ˑîā͢ҾҮҶʠŸʌåŮˤ×ͺп ͏ȩпuāiϯԦ}ƷпԀԄ љљѧ ӃϾʫпԨéǜӃǒǧԺŃƆп щьп ńп юп ǡп шп ǆԩпппǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®пʿ˚̣ȶ®п ϧ ͢ˑ îā ͢u ϧ͢ˑîā͢uāiϯԦ͒ȓɒλпāiϯԦ}Ʒп}ƷпԍԢӱӠӨӾҽӃŞxпª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄљљѧ ӃϾʫӁΥʁпԍԢӱӠӨӾҽӃŞxпª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁ
Υʁп

п
Ǉп
ՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®п

ϧ͢ˑîāʎā i ϯ Ԧ c Ʒ Ĭıп 1ͫпƢпԨéǜӃǒǧԺŃƆп щьп ńп юп ǡп шп ǆԩпппǁпԀԄ љљѧ Ӄ˽̱^Ɵ΁ǵпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®п ϧ ͢ˑ îā ʎāiϯԦ}Ʒпϧ͢ˑîāʎ}ƷпāiϯԦԍԢӱӠӨӾҽӃŞxпª˖ӝԤӼԟӱӠԤӾԀԄљљѧ Ӄ˽̱^Ɓ΁ǵӁΥʁпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпмͥп ɋŃпª˖ӝԤӼԟӱ ӠԤӾԀԄ љљѧ Ӄ˽̱^Ɓ΁ǵӁΥʁпп
ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®п

ԟԓӶԧԖӘԏԧӲҾҮ ϧ͢ˑîā͢Ҷ̼ʧʌåŮˤŲԀԄ º i ǵ ā i ϯ Ԧ Ȫп ͐Śпљљѧ ӃϾʫпcƷƢпԨéǜӃǒǧԺŃƆп щэп ńп ып ǡп щьп ǆԩпппǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®пʿ˚̣ȶ®п ϧ ͢ˑ îā ͢º ϧ͢ˑîā͢ºiǵāĠͷп ƹüпiǵāiϯԦ}ƌпiϯԦ}ƌп

ԍԢӱӠӨӾҽӃŞxпӁ̼ʧʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧӃϾʫӁΥʁпԍԢӱӠӨӾҽӃŞxпӁ̼ʧʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄљљѧ ӃϾʫӁΥʁпп
ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨ϧ͢ˑîā͢ɶʢǒӃʎ7ŮӃʈ ā i ϯ Ԧ c Ʒ óϞп Kп΁ǵпƢпԨéǜӃǒǧԺŃƆп щэп ńп ьп ǡп шп ǆԩпппǁпéǜsӃƊĪԦ̧®пé ǜ Ԩ ģ + ԩ š Ӄ Ɗ ʿ˚̣ȶ®пĪԦ̧®п ϧ ͢ˑ îā ͢ʈ ϧ͢ ˑî ā͢ʈîʼп Ϗп
āiϯԦƷƢпāiϯԦƷƢп

261006
S1311035ɶʢŧĠʌåӃźàАҾ΁ǵӁΥʁпԍԢӱӠӨӾҽӃŞxпɶʢŧĠʌåӃźàАҾ΁ǵӁΥʁпп
ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®п

ϧ͢ˑîāʡéŲ̸ʠŸˣӃɶʢƁ ʎ ʈ ā i ϯ Ԧ ǯп 9пŧĠʌåӃ΁ǵпcƷƢпԨéǜӃǒǧԺŃƆп щюп ńп ып ǡп шп ǆԩпппǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®пԍԢӱӠӨӾҽӃŞxпɶʢŧĠʌåӃźàАҾ΁ǵӁΥʁпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxп ϧ ͢ˑ îā ʡƁ ˝·Эîā͢āϥԦ͢΁ǯп 9пʎʈāiϯԦcƷƢп ǵˑāʿ˚ĊԦƷƢпɶʢŧĠʌåӃźàАҾ΁ǵӁΥʁпп
ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®п

ԟԓӶԧԖӘԏԧӲҾҮ ϧ͢ˑîā͢Ҷ̼ʧʌåŮˤŲԀԄ º i ǵ ā i ϯ Ԧ Ġͷп ƹüпљљѧ ӃϾʫп}ƌпԨéǜӃǒǧԺŃƆп щюп ńп ып ǡп шчп ǆԩпппǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®пԍԢӱӠӨӾҽӃŞxп̼ʧʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁΥʁпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxп̼ʧʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧӃϾʫӁΥʁп ϧ ͢ˑ îā ͢º ϧ͢ˑîā͢ºiǵāȪп ͐ŚпiǵāiϯԦcƷƢп iϯԦcƷƢпп
ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХппƊĪԦ̧®п

пԨéǜӃǒǧԺŃƆп щюп ńп эп ǡп щщп ǆԩпппʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпппԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®п ϧ ͢ˑ îā ͢u ϧ͢ˑîā͢uāiϯԦāiϯԦƷƢпƷƢпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпĬǪп ǋп

ª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁ
Υʁп

п
Ǉп
ՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®п

ԟԓӶԧԖӘԏԧӲҾҮ ϧ͢ˑîā͢Ҷª˖ʠŸʌåŮˤŲºɽʈ āiԀԄ љљѧ ӃϾʫпϯԦƷƢпԨéǜӃǒǧԺŃƆп щяп ńп шп ǡп шп ǆԩпппǁпéǜsӃƊĪԦ̧®пʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпĠǛп Kðǥпª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄљљѧ ӃϾʫӁΥʁпéǜԨģ+ԩšӃƊĪԦ̧®пŨĳîāԎԠӲԆӝӣӮӝ ϧ ͢ˑ îā ͢ºӡԤӲʿ˚ϥͭʎ͢āiɽʈ āiϯԦƷƢпϯԦƷƢпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпĠǛп Kðǥпª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁ
Υʁп

п
п
Ǉп
ՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®п

ʭϱԀԄ˭üӘԏԧӲϧ͢ˑîā͢ҾҮҶʠŸʌåŮˤ×uāiϯԦ}ƷпԀԄ љљѧ ӃϾʫпԨéǜӃǒǧԺŃƆп щяп ńп ып ǡп шп ǆԩпппǁпéǜsӃƊĪԦ̧®пʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxп͒ȓɒλпª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄљљѧ ӃϾʫӁΥʁпéǜԨģ+ԩšӃƊĪԦ̧®п ϧ ͢ˑ îā ͢u ϧ͢ˑîā͢uāiϯԦāiϯԦ}ƷпcƷƢпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпͺп ͏ȩпª˖ʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁ
Υʁп

п
Ǉп
ՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®п

ϧ͢ˑîāŧ
ʎɽԦſǼqť
āiϯԦƷƢпԨéǜӃǒǧԺŃƆп щяп ńп шчп ǡп шп ǆԩпՇՌпſǼʢԘӽԠӁңҩӔԀԄ љљѧ ӃȤ̲Ų΋?пʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпšͥп ʶȩпſǼʢŧĠʌåӃźàАҾ΁ǵӁΥʁпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035пǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®пǁɭîāԦȬāϥԦϧ͢ˑîāŧʎɽԦſǼŧ ʎ ɽſ Ǽʢ āiqťāiϯԦƷƢпϯԦcƷƢпʿ˚̣ȶ®п

ԍԢӱӠӨӾҽӃŞxпĠʑп ʺЉп

ſǼʢŧĠʌåӃźàАҾ΁ǵӁΥʁпп
ǇпՓՖՔՑՕՏՐՒҽӃʿ˚ΕХпƊĪԦ̧®пʿ˚̣ȶ®пԀԄ љљѧ Ӄª˖ʠŸԘӽ ϧ͢ˑîāͭʎͷʑп KðǥпԠӁңҩӔȤ̲Ų΋?пāiϯԦΜĿпԍԢӱӠӨӾҽӃŞxпɕ ÇʠŸԦɶʢˣª˖ʠŸԘӽԠӁңҩӔӝԤӼԟӱӠԤӾԀԄ љљѧ ӃȤ̲Ų΋?ӁΥʁпԨéǜӃǒǧԺŃƆп щяп ńп шшп ǡп шп ǆԩпппǁпéǜsӃƊĪԦ̧®пéǜԨģ+ԩšӃƊĪԦ̧®пʿ˚̣ȶ®п

ϧ͢ˑîāͭʎāiϯԦ}Ʒпϧ͢ˑîāͭʎ}Ʒпîʾп ǓŔпāiϯԦԍԢӱӠӨӾҽӃŞxпɕ ÇʠŸԦɶʢˣª˖ʠŸԘӽԠӁңҩӔӝԤӼԟӱӠԤӾԀԄ љљѧӃȤ̲Ų΋?ӁΥʁппԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ԱԱп ʿ˚Ӄș͸ԨҎп ПʵV7ӘԱ԰Ƿ(^ҽ8ƆԩпԨԱԩʿ˚ԍԢӱӠӨӾӃʵʮԦŽ̞ӆ΄ʖӃș͸пп ̼ʧӀҿϮ˩ӀʠŸɂʨӃҶӎӁӄҚԔӨԢʮͼɷҽӄǌӒҤӁҽҦӀҤҹҶԕӨԢӀʌåԨŧĠʌåԩӃɾʜŲӘ΁ǌҰӔҫҾӁӑӓţǱ љљѧ ҽ¥̲ҽҟҹҶʠŸϥ3ɾʜʮӀ͢ɽχϕӃϾʫҥŬ͸ҽҟӔқ$ǂҚѷѼп҄ѷ҂Ҁѽ ʿ˚Ҿ ѷѼп҄ѷ҄ѽ ʿ˚ϿӃîҦӀӧԙӻԍҥ¿ХҾӀҹҼҠӔҥҚҫӕӄʎ7ӘҝÖέӀӏӃҞҾҮҼƠҢӔҫҾҥîҦӀÊҾ̢ҢӒӕӔқҴӃҶӎҚʎ7ӃԎӼԢŲԨɾʜӀŧĠʌåԩӘȩ˃ӁҾӒҢҚҴӕӁÜһҠҶ љљѧ ƈʚӃ˝̶ҥϮ͸ҽҟӔқǪʿ˚ҽӄҚʠŸŧĠʌåźàӘƤ˻ҮҚҴӃɾʜŲӁŮˤ¥̲ӀКǁʮӝԤӼԟӱӠԤӾԀԄ љљѧ ӃyƆӘʵʮҾҮҶʿ˚ƘɷřƆӘʵƞҰқϾʫӘʵƞҰӝԤӼԟӱӠԤӾԀԄ љљѧ ӄҚ̼ʧԦԗӸԒԟӻӨӰԤӿԢԧԖԦſǼʢˣӃíțӀʡƁԦʠŸӁϚʐ¥̲ӀǁҮҠɂʨɇӃƩȈӁҺӀҥӓҚƇҥÎӃKŏԦˍˈӈӃîҦӀΥʁҥǧŠҭӕӔқǪʿ˚ԍԢӱӠӨӾӄҚъ ҺӃʿ˚ʅӘ·ҩҚªҜҥώƯҮҼʿ˚ӘƦϏҮКǁʮӝԤӼԟӱӠԤӾԀԄ љљѧ ӃyƆӘʵƞҮҼҠӔқʿ˚΄ʖҾҮҼҚш ʅҥʠŸŧĠʌåźàӘƤ˻Қщ ʅҥӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫҚъ ʅҥȤ̲Ų΋?ӘͫҡҫҾҽҚҠӃƆǸӘԋӜԧӿԆӻӨҰӔҫҾӁӑӓʠŸӁėŮҮҶӝԤӼԟӱӠԤӾԀԄ љљѧ ӃĄƆӘʵƞҰқпԨԲԩʿ˚˿̗пп Ǫʿ˚˿̗ӄҚԱʅԩʠŸŧĠʌåӃɾʜʮɾŲӃƤ˻ԨʅϼԺ|ͥԩҚԲʅԩŧĠʌåŮˤŲӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫԨʅϼԺĬǪԩҚԳʅԩʠŸŧĠʌåӁңҩӔԀԄ љљѧ ӃȤ̲Ų΋?ԨʅϼԺͥĊԩҚӃ ъ ʅҤӒȚƆҭӕӔқп
пш ʅԩ|ͥҚîʼѬóϞѭҚĠʑѬšͥѭҚɳҚǯԨ˝·ЭîԩҥƕŘқŤӒӕҶźàӘ щ ʅӁƩ=ҰӔқпщ ʅԩĬǪҚĠǛԨŨĳîԩҚȪѬĠͷѭҚͺѬ͒ȓѭҥƕŘқш ʅҽŤӒӕҶźàӘÜӁǁҶӀԀԄљљѧ ӃϾʫӘʵƞҰқҭӒӁ$îāҤӒԀԄ љљѧ ϾʫӃĚϽʿ˚̣ҽҟӔʾʑԨŨĳîԩңӑӆĤЀԨ®¤ĨĻ˝îԩҥ|ӗӔҫҾҽҚ˃ĈӁʿ˚ӘƦϏҰӔқпъ ʅԩͥĊҚͷ£ҚмͥѬĬıѭҚîʾѬͷʑѭҥƕŘҮҚԀԄ љљѧ Ӄ¿ХɷӘ щ ʅӁԋӜԧӿԆӻӨҰӔқп
пп źàƪӃҶӎӁćǧʮӁʅ.Οңӑӆʅϼ.ΟҚʿ˚ƆǸà´.ӘͫҠҚʖ̣ҥV7ɿɄҾͅӒӃ3̚ӘƎƫҽҦӔӑҡӁҰӔқӋҶҚ͍ƌʿ˚̣Ԩ}ƷԦ}ƌԦîāЅʎԦѥљԩӃ˙ȘʮʖӘ
BҰԨîāЅʎ щч ®Қѥљщ ®ҚѦіщч ®ԩҾҾӏӁҚşӒӃʫͯȤ.Ә·ҩҼҠӔқӀңҚǪʿ˚Ӄ̍ƚӄҚsʿ˚'̣ͯӃĠǛҥŨĳîӈηhҮҶҫҾҤӒҚʠŸŧĠʌåҽíҨӃʿ˚Ĉ̕ӘǢҰӔ|ͥҥͫҡқпԨԳԩʿ˚ǃ·Ԧ·LˣпԻǃ·ԼпƷ¼Ԧʿ˚̣ӃƊĪҰӔǃ·ҚӆîāЅʎҾāϥʎӘ°Ӎ;ʐ̣ƺӄ(ҽҟӔқпшхп žāЭԺЙ˙ԨшыььхыэпѻщԩҚʿ˚ĊˣƺԨъьԩҚԍԢӱӠӨӾӁЀAҰӔ;ʐ̣ƺԨѐю ԩқпщхп εͫЭԺЙ˙ԨяыыхэюпѻщԩҚʿ˚ĊˣƺԨщыԩҚԍԢӱӠӨӾӁЀAҰӔ;ʐ̣ƺԨюя ԩқпъхпѧ ȒԺЙ˙ԨшччюхшпѻщԩҚʿ˚ĊˣƺԨъъԩҚԍԢӱӠӨӾӁЀAҰӔ;ʐ̣ƺԨщю ԩқппԻӀͲ̚Қ·LԼпǪԍԢӱӠӨӾӁңҠҼҚӁ;ʐҭӕҶͲ̚Қ·LӃҡҸҚˏā}ƆӘ¡ҩҶӏӃҽY­oʐȤÇҾҮҼíҨӃʿ˚̣ҥ;ʐҮҶͲ̚ҾoʐǒϿԨŃƆ щьՎщѐ ńŌԩӄ(ҽҟӔқп
шхп YɸɷԡԧӯԧЦŧϻӰӲӼԖԨішѦтԩԺԨŃƆ щь ńŌӁğUҚъыщы ǒϿԩқпщхп ͅ˽̱΁ǵiВͲ̚ ћіјѧԾՅՉՈՆՍՋԨŃƆ шщ ńŌӁğUҚщюъч ǒϿԩқпъхп ˽̱ӝԗԧӱԤөӰӲӼԖԨŃƆ щь ńŌӁğUҚэюъю ǒϿԩқпыхпѡјфўјѥфѢѧ ӰӲӼԖԺԨŃƆ щы ńŌӁğUҚъячь ǒϿԩқпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ьхп ʎ7Ϝ/üʫʆ΁ǵӰӲӼԖԺԨŃƆ шэ ŌӁğUҚьэъя ǒϿԩқпэхп ԡԧӯԧӲӦԙԤЦŧϻԺԨŃƆ шя ŌӁğUҚээьч ǒϿԩқпюхп гόɖ7ӨԢԔӾөԞԋέϰiǵͲ̚ԨŃƆ щь ńŌӁğUҚшуѐъч ǒϿԩқпяхп ԅӝԓӦӰӛԨ4ϫ˹ԩԣԧӨӲӼԧӰԝԤԨŃƆ щь ńŌӁğUҚщѐэ ǒϿԩқпԨԴԩʿ˚ƆǸӃș͸п ҎΆҚԱԳӆԱԴӁėŮҰӔƆǸӁӄ̐ӆԪӘ%ҰҫҾқп
ӼԧԔ®ңӑӆƕṚ̌п ӼԧԔ 1ԺʠŸŧĠʌåӃɾʜŲӃƤ˻пп п п |ͥ1Қîʼп Ϗ[óϞп K]ҚĠʑʺЉ[šͥʶȩ]Қɲп ϏҚǯ9
п ӼԧԔ 2ԺŧĠʌåŮˤŲӝԤӼԟӱӠԤӾԀԄ DDS ӃϾʫп п п ĬǪп ǋҚĠǛKðǥҚȪ͐Ś[Ġͷƹü]Қͺ͏ȩ[͒ȓɒλ]Қʾʑ˞ŔҚĤЀ½
п ӼԧԔ 3ԺʠŸŧĠʌåӁңҩӔԀԄ љљѧ ӃȤ̲Ų΋?
п п п ͥĊЏŔҚͷ£Ĺ©ҚмͥɋŃ[Ĭı1ͫ]ҚîʾǓŔ[ͷʑKðǥ]ппӼԧԔԱґ ɶʢŲ̽ʠŸңӑӆî̽ҥәӃʡƁЀώiüӃƤ˻ҾҴӕӒӃʫʆϥ3Ӄ­ćӘͫҹҶқҫӕ
ӋҽӁҚͪ˦^ʱӁʫʆҰӔ Transient receptor potential vanilloid 4ԨTRPV4ԩҥͪ˦ωϓŲӐͪ˦ǁʎӁЀҰӔҫҾҚ̽˦ԔӨԢԋӚԧӱӐ T ˽̱ӀҿӃɶʢԦTʟ˽̱ӁʫʆҰӔ
Neurokin 1ԨNK1ԩ¡Ď7ҚNADPH ӣӦӰӹԧӵ NOX1 ңӑӆ K2P5.1 K+ӺԙԤԃԠӀҿҥɶ
ʢԦTʟŮˤӃΖ˧ӁЀҮҼҠӔҫҾҚҭӒӁɕ ˦˯́ʱӁʫʆҰӔ G ӸԤԇӨέYŞ×̳̬ϫ¡Ď7 GPR35 ӃɍŲ ҥî̽ɶӃɂʪBϏiüҾҮҼǢʐҽҟӔҫҾӘǌӒҤӁҮҶқҒ ƑҥәuӁӑӔҥә āʨɇӘͫҡҽ¿ХҾӀҹҼҠӔɱҮҠʥӘ0ҡ̽ɶӃʡƁЀώiüӃ­ćӘͫҠҚӛԓӾԧӰӲҚ̽^˽͗ҚɶʢŲӮӝӾӤӝԤӃЀӁҺҠҼȖ΅ҮҶқғ ̼ʧ^4ϫʌåӁңҩӔ4ϫ˹ŮˤÊüӘƤ˻ҮҚLipocalin2 ӐԟԇԧӵӀҿӃЀӘǌӒҤӁҮҶқҭӒӁҚҥә˽̱ӁңҩӔ Ca2+ɍŲ Cl-ӺԙԃԠԽnoctamin1ԨANO1ԩӐ Ca2+ɍŲ
K+ӺԙԃԠ KCa1.1/KCa3.1 ӃŞxӘ΁ǵҮҶқҔ ҳәŴӃʡƁЀώiüӃƤ˻ӘͫҠҚM2 ԔӨԢԋӚԧӱңӑӆȢɿ˽̱ҤӒʏʎҭӕӔInterleukin-33ԨIL-33ԩӃЀӘǌӒҤӁҮҶқҕ ̎͂͗ӃӾԞԤӲԢӪԧӰԝԤӁңҩӔʱ˽̱ҾӃʷ8ʐӐ˯ɖԖӺԤīωϓӁЀώҰӔiüңӑӆȤŉӃ΁ǌӘͫҠҚIV ×̐ȵԋӜԞԗԤӾӃ̔Ӑ III ×iɆͲ̚ӃÉηϒӃŞxӘ
ǌӒҤӁҮҶқӋҶҚî̽ʱҤӒʏʎҭӕӔӪԘӤӝԤҽҟӔ Growth-related Oncogene alphaԨGRO-αԩӃЀӘǌӒҤӁҮҶқҖ éŲ̸ʠŸǒӃӿԇԕԤˊ̀aʎӁЀӗӔŧĠʌå΁ǵӃҶӎҚԍԞԀԟӛӘʐҠҼ΁ǵҮҚɾӁ DJ-1 ӃŞxӘǌӒҤӁҮҶқҗ ̳̬˿̗ŧĠʌåӁңҩӔԡӱӲӺԤʏʎҾ̳̬˿̗ʡƁ ӁҺҠҼȖ΅ҮҶқӋҶƑԡӱӲӺԤƑ7ƐӁӑӔ̳̬̩ʡƁӈӃŝНӘȖ΅ҮҚʡƁƳÁӃ¥̲ŲӘͺhҮҶқп ɶʢŲ̽ʠŸҚª˖ҥәҚҳәŴҚ̎͂͗ſǼʢҚéŲ̸ʠŸҚ̳̬̩ˣӃțҜӀʠŸӃʠŸŧĠʌåӘΎ˽Ӂ΁ǵҮҚíҨӃʡƁЀώiüңӑӆҴӕӒӃʫʆϥ3Ә­ćҮҶқʠŸŧĠʌåӃ΁ǵӁҺҠҼӄҚŘlӃćӘșӂϕƆҽҦҶҾ̢ҢӒӕӔқӼԧԔԲпґ ̼ʧŧĠʌåԨŧŖ4 Ѿѝ ңӑӆͯЙϪ˹ԩӁſŮҰӔȤ̲Ų˹üӘ·΄ҮҚͯЙFЫҮҶԀԄљљѧ ӃȚ˨Ӂ ӓ˿әҷқпҒ ˽̱ϿӸӝӾӱԙԤӨӰԝԤӘϾͱҭҲӔӽԆӝӲӘʐҠҼ̼ʧ^Ӌҽɔω¥̲ӀӝԤӼԟӱӠԤӾԀԄ˭üӘ8͵ҮҚҭӒӁȆϫ͢ęUԀԄ љљѧ ӃϾʫӘϏӎҶқпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ғ ŧŖДɎӁӑӔ˿̗ŧĠʌåӃé Ҿ˽̱ӁӑӔɽέ ςӌȤȚҽҟӔӡԤӿӮӝӾԧӰӲӃЀώӘǌӒҤӁҮҚԀԄ љљѧ Ӑгiü͢ɽˣӃ˽̱ӈӃ ςӌӘ΋?ҮҶқӋҶҚŧŖДɎӁӑӔӡԤӿӮӝӾԧӰӲӃɾŲӘΖӉҚ˽̱^ҽ ҁѶѦѣі Әʏʎ¥̲ӀTʟŲӘȦƭҭҲҶǁͻȆϫ͢ºҽҟӔ ѷѦѳѲ ӃχϕӘΌӌҶқҭӒӁҚ̳̬˿̗ҽӃ̳̬͟˙ӁЀҰӔԡӱӲӺԤӁėҰӔ ѷѦѳѲ Ә8͵ҮҚŧŖДɎӁӑӔ̳̬˽̱ӈӃχϕӘΌӌҶқпҔ ԕӾӬԤӿԟӛʒǱýӸԤԇӨέӘʐҠҶӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӘΌӌҶқпҕ ̳έԀԄӽӜӲӨԨԆӝӴԠԩӘŮʐҮҚш ǷӃ̳έ́ҽӃͰ͹ƍͬӘϾʫҮҚǁҶӀӝԤӼԟӱӠԤӾԀԄ љљѧ ӘȚ˨ҮҶқпҖ ʭϱԀԄ˭ü ѥ҂фѣѥҁ Ӄ8͵ǂɇӘƤ˻ҮҚҭӒӁʠŸŧĠʌåӁңҩӔɍŲϫ˹˖ӁėҰӔǸӘȖ΅ҮҶқӋҶҚѥ҂фѣѥҁ ӃɾŲӘŮʐҮҼ̩ЍČӁėҰӔǸӁҺҠҼӏȖ΅ҮҶқпҗ ͢ɽӃбӸԧӫӻӼӜԤөɇӘƩȈҮҚƑҥәuӘƮκҭҲҶԀԄ˭üӐӸԤԇӨŲ͢ºӁӑӔбη˓ƏqǸӁҺҠҼȖ΅ҮҶқпҘ ӝӣԤɖ7ԀԄ˭üӘʐҠҶǁҶӀ љљѧ Ә̢ȈҮҚҴӃȚύӐɾŲӘ΁ǵҮҶқпҙ ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRԀԄ˭üӘϾʫҮҚҴӃɾũӘ΁ǵҮҶқпп ҥәӘӄүӎҾҰӔțҜӀʠŸŧĠʌåӁŮˤҰӔԀԄ љљѧҚȆϫ͢ºӀҿӃгiü͢ɽӘƮκ¥̲ӀԀԄ љљѧ ӃϾʫӁƆ{ҮҶқӋҶҚбӸԧӫӻӼӜԤөɇӐ љљѧ ӁŮʐ¥̲ӀǁҶӀԀԄ˭üӃϾʫңӑӆʈΙȚ˨ӁƆ{ҮҶқʠŸŧĠʌåŮˤŲӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫҾҮҼӄŘlӃćϋӓϏͫҮҚíҨӃƆǸӘƟҪӔҫҾҥҽҦҶҾ̢ҢӒӕӔқппӼԧԔԳпґ ƇҜҥϾʫҮҶ̼ʧŧĠʌåŮˤŲԀԄ љљѧ Ӄ7^ƁӘȺʐ љљѧ ҾȴιҰӔҾҾӏӁҚǁͻԀԄ љљѧ Ӂɂʨ͢ӘęUҮҚƑҥәǸӘȖ΅ҮҶқпҒ Ӥԓӱ̨̼ЀώԎԠԐӲӟӝԠӲԨѠѧѝѪԩſǼӁӑӓҥә ҮҶʫŲ7̻ɖŲԟԤԇ̼Ԩѥњѡԩ
ӘTʟVԔӟӲӁ˓ȕҮҶ ѥњѡ ԘӽԠԔӟӲӘ˃˝ҮҚԘӽԠԀԄ˭ü јэч ԋԞԧԡԤӐ њѦӲӾԡӲΒğuˣӘʐҠҼ љљѧ Ӄ΋?ԘӽԠҾҮҼӃǢʐŲӘȖ΅ҮҶқпғ ƑҥәȤ̲Ų΋?ԇԞԗԧӸҾҮҼҚ̼ʧ˿̗ҽгʫʆҰӔɺӰԝӻӨӸԤԇӨέ Hsp105 ңӑӆ
Hsp70 ӁʻʵҮҚ ӸԤԇӨέӃʫʆԗӤԁӳԖӘ΁ǵҮҶқӋҶҚҥәŧĠʌåԨ4ϫ˹ǰ*ԩҽӃʫʆϏӘ΋?ҰӔҶӎҚԠӰԋӠԞԧӵԡԓԧӸԧʫʆ˽̱ӐԄӻӨӹӟԤ˽̱Ә8͵Ү΁ǵҮҶқҥәŹŲ ԘӽԠҾҮҼ v-Src Βğʫʆ˽̱ӁӑӔ΋?˲ӘȚ˨Ү΁ǵҮҶқҔ ̈́ňԟԓӶԧԖ͵uԨDoxil®ԩӃv8ʐҽҟӔƌγʢJ̝ΒʫŲӁҺҠҼҚ2 ʅӃʾʑӒҥϾʫӃӣӦӮԟԍԞӺԤęUԀԄ DDS ͵uҾȴιȖ΅ҮҶқҕ ԀԄ DDS ӣӦӮԟԍԞӺԤ͵uӃ¶ͽЍČΒʫŲӁҺҠҼҚИԀԄ DDS ӣӦӮԟԍԞӺԤ͵uҾȴιȖ΅ҮҶқп Ǫʿ˚ҽϾʫҭӕҶԀԄ љљѧ Ӄ΋?Ӑ7^ƁӘ΁ǵҮҚ̼ʧϥ3ӈӃ˓ͫŲӁЀҰӔźàӘŤҶқӋҶҚԀԄ љљѧ ӃǁҶӀ΋?˲Ӄ˃˝ҚҭӒӁԀԄ љљѧ ӣӦӮԟԍԞӺԤӃv8ʐʫʆȤŉӃ΁ǵӁӑӓҚԀԄ љљѧ ͵uӃv8ʐӃɣʈΙӘȚ˨ҮҶқԀԄ љљѧ ӃȤ̲Ų΋?ӁҺҠҼӄҚșӂŘlӃćӘϕƆҽҦҶҾ̢ҢӒӕӔқп
п
ԻOӕҶƆǸҥҥҹҶɷԼпӼԧԔ шп пґ ͪ˦^ʱӃ TRPV4 ҥɶʢŲ̽ʠŸӃʡƁӃϏĩҚҭӒӁӄî̽ҥәӁңҩӔͪ˦ǁʎӁЀҮҼҠӔҫҾӘǌӒҤӁҮҶ*3қɶʢŲ̽ʠŸӃʡƁӁңҠҼ̽˦ԔӨԢԋӚԧӱӐ T ԟԤԇʇӀҿӃɶʢԦTʟ˽̱ӁʫʆҰӔ
NK1 ¡Ď7ҚNOX1 ңӑӆ K2P5.1 K+ӺԙԃԠҥɶʢԦTʟŮˤӃBϏӁЀҮҼҠӔҫҾӘˆҮԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

Ҷ*2,13,15,16,18,19,20,31,33қ
GPR35 ӃɍŲ ӄî̽ʱ˽̱ӃϑίӃBϏҰӔҫҾҽNČFŦӘBϏҰӔҫҾӘˆҮҶ*6қҒ ƑҥәuӁӑӔ̽ɶӃʫʢӁӄҚ̽ʱ˽̱Ӄ TNF-α >þŲӛԓӾԧӰӲΒğӁӑӔ̽^˽͗ӁėҰӔԆԟӛȤ̲Ӄˀ̋ҚҭӒӁҴӃ́ǸʎүӔȧʮɶʢŮҥϊȧʮӁЀҰӔҫҾӘΊǌҮҶ*4,5,17қғ ̼ʧ^4ϫ˹ʌåӘǢҰӔԔӟӲӃͪɬ ӁҚ4ϫ˹ΒğÊüăć ӁĐҰӔҶӎɂʨȞʮҾҮҼǢǦҽҟӔ Lipocalin2 ϰҥæîҰӔҫҾӘͺhҰҾҾӏӁҚԟԇԧӵˣ$ӃÊüӃЀӏǁҶӁǌӒҤӁҮҶ*26қʩ˽̱ӁңҠҼҚCa2+ɍŲ Cl-ӺԙԃԠ ANO1 Ӑ Ca2+ɍŲ K+ӺԙԃԠ KCa1.1/KCa3.1 Ӄʫʆҥ HDAC ЃČuӐԉӸԕԤ D ӁӑӓqťҭӕӔҫҾӘǌӒҤӁҮҶ*8,11,12,15,24қҔ ԔӟӲҳәŴԘӽԠӁңҠҼŮżΰŦӁӑӔ IL-33 ʫʆӃϏҚŦżΰšӁȷ˦Ʋʱ˽̱Ӂ|Ң M2 ԔӨԢԋӚԧӱңӑӆӬԤԏԤӰԝԀԠȢɿ˽̱ӁңҩӔ IL-33 ʏʎӘǌӒҤӁҮҶ*22,25қҕ ̎͂͗ӁӑӔʱ˽̱^ӈӃ ExoS ɉUӁ IV ×̐ȵԋӜԞԗԤӾӃ̔ҥŬ͸ҽҟӔҫҾӘͺhҮҶ*9,10қ̎͂͗Ӄ III ×iɆͲ̚ӃÉηϒҥӡԋӠӨӸԧӃ˽̱^ɉUӁϮ͸ӀҫҾӘ ʗҽlӎҼǌӒҤӁҮҚ̽˦ʱ˯́īҥÉηӘƏqҰӔҫҾҽʱ˽̱pϕsȯЊҽӡԋӠӨӸԧiɆӘqťҮҼҠӔ¥̲ŲӘͺhҮҶ*29қ̎͂͗ӁӑӔЛȵϒ>þŲӃԖӺԤīωϓӄҚî̽ʱҤӒʏʎҭӕӔӪԘӤӝԤӃҺҽҟӔ GRO-α ӁӑӓBϏҰӔҫҾӘͺhҮҶ*23қҖ ̸ӃӿԇԕԤˊ̀NČʌåҽ DJ-1 ҥDΠʮӁȤ̲ҰӔҫҾҚӋҶ DJ-1 ́« «ɽҥԇԧӦԤӶԤʡӃiüȞʮ͢ӁӀӔ¥̲ŲӘͺhҮҶ*28қҗ ̳̬˿̗ŧĠʌåҚԡӱӲӺԤҥ̳̬˿̗ʡʮ ÊüҽҟӔ¥̲ŲӘͺhҮҶ*27,30қпӼԧԔԲпґ ̼ʧŧĠʌåӃŧŖ4 Ѿѝ ҽͯЙД͔ҥԭҤӒԫӁηƪҮҚгҠͪ ɪʙŲҾҥә˽̱;¸ŲӘǢҰӔǁҮҠԀԄ љљѧԨԟԓӶԧԖԩӘϾʫҮҶ*50қпҥә˽̱ͯЙӃϪ˹Ӂӑӓ́ɽŲҥɾʜʮӁé Ү˽̱^Ӂ͢ɽӘχϕ¥̲ӀǁҮҠԀԄ љљѧӃϾʫӁƆ{ҮҶ*57қпҒ ˽̱ϿӸӝӾӱԙԤӨӰԝԤӘϾͱҭҲӔӽԆӝӲҾҮҼʫͺҭӕҶԐԍӺӿ іѨшччщ ӘǽζȚύӘǢҰӔԀԄ љљѧ ͯЙӁƮκҰӔҫҾҽҚ̼ʧŧĠʌåӃ˽̱ϿЋӘͅʫʮӁϾͱҮҚҴӃǽζŲӁӑҹҼ̼ʧ^ôӋҽɔω¥̲ӀӝԤӼԟӱӠԤӾԀԄ˭üӃϾʫӁƆ{ҮҶ*37қпΆӃʌåŮˤŲӽԆӝӲӘʐҠӔҫҾҽҚ̼ʧ˽̱^ӃʌåԨѾѝԩӁŮˤҮҼȆϫ͢ ҁѷѦѣі
ӘƴhҽҦӔӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁƆ{ҮҶ*42қпғ ŧŖДɎӁӑҹҼ˿̗ŧĠʌåҥé ҰӔҾҾӏӁҚ˽̱ӁӑӔɽέ ςӌȤȚҽҟӔӡԤӿӮӝӾԧӰӲҥΒΰҭӕҚԀԄ љљѧ Ӑгiü͢ɽˣҥ˽̱ӁʃӑҨ ӓςӋӕӔҫҾӘͺhҮҶ*43қпŧŖДɎӁӑӔӡԤӿӮӝӾԧӰӲӁiüϰqЄҥҟӔҫҾӘͺhҮҚӡԤӿӶԧԖ̷hӽԆӝӲҾӃ˿«ҲҽʃӑҨ˽̱έӁ ѷѦѳѲ ӘχϕҰӔҫҾӁƆ{ҮҶқҭӒӁҚ̳̬˿̗ҽӃ̳̬͟˙ӁЀҰӔԡӱӲӺԤӁėҰӔ ѷѦѳѲ Ә8͵ҮҚŧŖДɎӁӑӓ̳̬͟˙ӃqťӁƆ{ҮҶ*41қпҔ ԕӾӬԤӿԟӛʒǱýӸԤԇӨέӘʐҠҚ˭üìϥӃ Ѿѝ é ӁŮˤҮҼ͢ɽӘƴh¥̲ӀӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁƆ{ҮҶ*44қпҕ ̳έԀԄӽӜӲӨԨԆӝӴԠԩӃȚύҾɾŲӁʻʵҮҚҫӕӘʐҠӔҫҾҽ ш ǷӃ̳έ́ҽӃͰ͹ƍͬӘϾʫҮҶқҭӒӁҚљљѧ ƈʚӁŮүҼʜӀӔ̳έ́ӁӑҹҼͰ͹ҰӔƍͬӘϾʫҮҚҫӕӋҽ

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ӁӀҠӝԤӼԟӱӠԤӾԀԄ љљѧ ӃȚ˨ӁƆ{ҮҶ*45қпҖ ѥ҂фѣѥҁ 8͵ǂɇӘ˃˝ҮҚțҜӀӮӝӳӃ ѥ҂фѣѥҁ Ӄ8͵ӁƆ{ҮҚʠŸŧĠʌåҽʫʎҰӔí˖ɍŲϫ˹˖ӁėҮ ѥ҂фѣѥҁ ҥгҠɕɍŲӘǢҰӔҫҾӘǌӒҤӁҮҶ*58қп
ѥ҂фѣѥҁ Ӄ̩̓А˙ɾŲӘoʐҮҼɍŲϫ˹˖ҥЀҰӔ̩ЍČӘƏqҰӔҫҾӘǌӒҤӁҮҶ
*39қпҗ бӃŧĠʌåӘȞʮҾҰӔбӸԧӫӻӼӜԤө˹üӃ·΄Ԧ͢ɽχϕɇӃϾʫӁƆ{ҮҶ*54,39қпƑʩuӘƮκҮҶбӸԧӫӼӜԤө×ԀԄ˭üҥбη˓ӁǢҽҟӔҫҾӘǌӒҤӁҮҶ*35,36қпҘ ӝӣԤɖ7ӘiƸέҾҰӔǁҮҠ љљѧ ҾҮҼӝӣԤɖ7ԀԄ˭üӘϾʫҮҚшѝфҚшѐћфҚъшѥфѣѢѦ ӘʐҠҼҚӝӣԤɖ7ԀԄ˭üҥӝӣԤɖ7цȸ×ӡԔԠӰԝԤӘřƆҮҼҠӔҫҾӘΊǌҮҶ*34қпҙ ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRԀԄ˭üӘϾʫҮҚԟӿӤӝԤӀҿӃäÜŲ͢ɽӘ ѼѢ ԡԏԠҽȖh¥̲ҽҟӔҫҾӘ˝ΊҮҶ*49қппӼԧԔԳпґ ƇҜҥϾʫҮҶ̼ʧŧĠʌåŮˤŲԀԄ љљѧ ҥҚ˭üͯЙӁFЫҮҶ̼ʧŧĠʌåŮˤԐԍӺӿӁӑӓ˽̱ìԔӾԟӻӨӲӘ#ҮҶ̼ʧ˽̱ϿӃ̖ҥӓӘɠŖҭҲӔҾҾӏӁ̼ʧ˽̱ӃӛӨӺԤ̷Ϯ«ӘΒΰҰӔҫҾҽҚ̼ʧ˿̗^ôӁɔωҽҦӔҫҾӘͺhҮҶ*40қпҒ ѠѧѝѪ ſǼӁӑӓҥә ҮҶʫŲ7̻ɖŲԟԤԇ̼ԨѥњѡԩӘTʟVԔӟӲӈ˓ȕҮҚԀԄљљѧ Ӄ΋?ɽԘӽԠԨѥњѡ ԘӽԠԔӟӲԩӃ8͵ӁƆ{ҮҚǪԘӽԠӘʐҠҚљѷѯѺѺ҇Ѻп ҂Ҁѷҁ҃ѺѴѷѲѳҥ ѥњѡ ӁėҮҼƑ̼ʧɍŲӘǢҮҼҠӔҫҾӘǌӒҤӁҮҶ*73қпԘӽԠԀԄ˭ü јэч ԋԞԧԡԤӐ њѦ ӲӾԡӲΒğuˣӃƑ ѥњѡ ɍŲӘ΋?ҮҚҴӕӒӃ8ʐȤŉӘͺhҮҶ*63,65,72,82қпғ ҥә˽̱ӁңҠҼҚɺӲӾԡӲʌåҽ Hsp105 ҥ Stat3 ́«ӸԤԇӨέҽҟӔ Nmi Ҿʷ8ʐҮҚStat3 ԟԤϫ Ә#ҮҼ Hsp70 ʫʆӘϏҭҲӔҫҾӘǌӒҤӁҮҶ*84қ
HSP105 ӄ HIF-1α Ҿʷ8ʐҮҚHIF-1α Ӄ͟˙Ҿ HIF-1 ηbɍŲ ϏӁĐҰӔҫҾӘǌӒҤӁҮҶ*67қǁͻ Hsp70 ʫʆqťÊüҾҮҼҚAF9 ңӑӆ SNRPE ӀҿӘ­ćҮҚҫӕӒҥҚҥә˽̱ӁңҩӔ Hsp70 ʫʆϏӃÊҾӀӔ¥̲ŲӁҺҠҼà´ҮҶ*76қҥәŹŲ ԘӽԠҾҮҼ v-Src Βğʫʆ˽̱Ә8͵ҮҚ˽̱^ӺԢӰԤԟԤϫ ӃϏӁӑӓҚǼ͈7iϩʜŁӐ DNA ӹԗԧӱҥΰҫӔҫҾҚӋҶҥәŹŲ ӃƞȞҽҟӔíȘ˺Ϸ7řƆӐǼ͈7ʜƺŲҥæ|ҰӔҫҾӘǌӒҤӁҮҶ*68,74қҔ ̈́ňԟԓӶԧԖ͵uԨDoxil®ԩӃv8ʐԨƌγʢJ̝ΒʫŲԩӁʻʵҮҚǁͻԀԄ DDS ӣӦӮԟԍԞӺԤ͵uӄҚDoxil®ҾȴιҮҼƌγʢJ̝țʱ̀˿̗ЍČӘˆҭӀҠҫҾӘǌӒҤӁҮҚƌγʢJ̝ҥԟԓӶԧԖ͵uӁYϋҮҶv8ʐҽӄӀҨҚ^ҭӕӔ͢ɽӃΰɶŲӁΰÊҰӔҫҾӘ
ˆҮҶ*70қҕ ԀԄ DDS ӣӦӮԟԍԞӺԤ͵uӃ¶ͽЍČΒʫŲӁҺҠҼ DELICIOUS ӘʐҠҼ΁ǵҮҚҴӃԞӻӾӁңҩӔʍ¶ſ¡ŲӃ48ʐӄҴӃИԀԄ DDS ӣӦӮԟԍԞӺԤӑӓӏŗҨҚҴӕӄġӀҨҾӏʍ¶¡Ď7ӃʫʆéӁėҰӔŝНӃ˔ŌӘǏҮҶӏӃҽҟӔҫҾӘͺhҮҶ*71қпԻΕХҾӀҹҶɷԼӼԧԔ 1ґ íҨӃʡƁЀώiüңӑӆҴӕӒӃʫʆϥ3ҥǌӒҤӁӀҹҶҥҚҫӕӒʡƁЀώiüӁėҮҼɾʜʮӁ8ʐҰӔ͢ɽӃϾʫҥʆǒɷҽӄiҽҟӔқҒ ʡéϥ3ӋҽӃ͢ɽӃχϕӄӼԧԔ 2 Ӄʿ˚ˣҤӒ¥̲ӁӀҹҼҦҶҥҚɶʢŲ˽̱Қͪ˦^ʱ˽̱Қʱ˽̱Қ̳̬˽̱ӀҿӃҭӒӁđӀϥ3ӁϛƒʮӁ͢ɽ8ʐҭҲӔҶӎӁӄҚҴ

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ӕҵӕӃ˽̱Ӂʶƥ ӓςӋҲӔӀҿӁӑӓχϕ¥̲ӀӝԤӼԟӱӠԤӾԀԄ DDS ҟӔҠӄӑӓ
ɾʜʮӁȞʮiüӁ8ʐҰӔ͢ɽӃϾʫҥŬ͸ҽҟӔқғ Ǫʿ˚ҽ­ćҮҶʡƁЀώiüӃϥӄӮӝӾӤӝԤӀҿӃӸԤԇӨέҽҟӓҚҫӕӒӘȞʮҾҰӔá«ӁӄҚshRNA ӐƑ7͵uӀҿӘƮκ¥̲ӀӝԤӼԟӱӠԤӾԀԄ DDS ҥŬ͸ҽҟӔқҔ ʆǒɷҽӄ in vitro ǰ*ҽӃȖ΅ӁʙӋҹҼҠӔȞʮiüӏҟӓҚҫӕӒӁҺҠҼӄI7ԡԏԠҽӃΊǌҥŬ͸ҽҟӔқӼԧԔ 2ґ ̼ʧŧĠʌåӁŮˤҰӔțҜӀǁҮҠԀԄ DDS ӃϾʫӁƆ{ҮҶҥҚʆÒӃҾҫӖҚʎ7^ҽӃΎ˽Ӏ͢ɽƁӁЀҰӔźàҥγҮҼҠӔқŮʐӘϏӎҼͫҨҶӎӁӄҚȞʮϥ3(ìӃϥ3ӈӃА˙Ӑ'Ν̀δӀҿӃ͢ɽƁӁЀҰӔǜӀӔȖ΅ҥŬ͸ҽҟӔқҒ Pt-NPs ӁҺҠҼӄҚ̩̓ңӑӆ̻̾(ìӈӃχϕҥʆɿҽӄГҮҠҶӎҚ7^ƁqťӘʵʮҾҮҶ Pt-NPs Ӄ āFЫɇӃϾʫҥŬ͸ҽҟӔқбӸԧӫӼӜԤө×ԀԄ˭üӁҺҠҼӄҚƮκ¥̲Ӏ͢ɽӃɽŲҥЄӒӕӔҶӎҚȺʐŲӁOӕҶԀԄ˭üӘ8͵ҰӔҫҾҥΕХҽҟӔқғ ӝӣԤɖ7ԀԄ˭üҽӄҚʎ7^ҽӃăćŲӘˆҰȇƘҾӀӔ in vitro ҽӃ́ǸӘŤӔҫҾҥҽҦ
ұҚin vivo ҽӃ7^ƁӘΖӉӔӋҽӁӄ͆ӒӀҤҹҶқҔ ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRԀԄ˭üӁҺҠҼӄҚγ-өԠӸԕԠӾԞԤӲԋӠԞԧӵӁӄėҮŮˤҮҶӏӃӃҚćϰŲӘ˃˝ҰӔӋҽӁӄ͆ӒӀҤҹҶқҕ ɢŌŮˤŲ̳έԀԄ˭üӃŮˤɢŌӄʆǒɷҽӄ 42ҾʠŸϥ3ӃɢŌӑӓгҨҚ38-40ŮˤӘˆҰɢŌŮˤŲ̳έԀԄ˭üӃϾʫҥŬ͸ҽҟӔқӼԧԔ 3

ґ ϾʫҮҶ̼ʧŧĠʌåŮˤŲԀԄ DDS ӃɾŲӐ̼ʧ˿̗ӈӃɔωŲӁҺҠҼӄȖΊҽҦҶҥҚƑ PEL «ɽӃԀԄ DDS ҥʆǒɷҽӄ˃˝ҭӕҼңӒұҚȖΊӄӋҷϏәҽҠӀҠқ
Ғ HIF-1҉ΒğuҽҟӔä ӬԆԠӾӃg̚Ӂӑӓ Hsp105 ӃʜŁʫʆҥʎүӔҫҾӘ˃ΑҮҶҥҚ4ϫ˹ÛЬҽӄ Hsp105 ӃʜŁʫʆӘͺhҰҫҾҥҽҦӀҤҹҶқ̼ʧŧĠʌåӁңҩӔ
Hsp105 ʜŁʫʆӃ¥̲ŲӁҺҠҼȖ΅ҥŬ͸ҽҟӔқғ ¶ͽЍČӁЀҰӔȖ΅ҽӄҚӁԞӻӾӘʐҠҼȖ΅ӘͫҹҼҦҶҥҚ¶ͽ¡Ď7ӁėҰӔƑԞӻӾƑ7ӃŮŲҥҮҨҚʍ¶¡Ď7ӮԌԜԁӻӾӃΎ˽Ӏ΁ǵҥҽҦӀҤҹҶқ"šӄԔӟӲĈа˲Ӄ˃˝ӘҰҰӎӔŬ͸ҥҟӔқпԻͅĺ΋?ӃĈǃ́ǸҾėŮɿɄԼпп ͅĺ΋?ӁЀҮҼӄҚªʅϼԨ|ͥҚĬǪҚͥĊԩҥćǧʮӁϏơŌ«ҠӘ˃ΑҮҚʅ^ҽΟΙҮʿ˚ӘϏӎҼҦҶқªʅϿӃώƯӁҺҠҼӄҚʅϼӘ ūӁªʅ¼Ͽҽώ̂Ү«ҡ7qӘȚ˨ҮҼң
ӓҚV7Ӄʿ˚Ӄ̄ƚӄʿ˚'̣ͯӃ|ͥҥͫҹҼҦҶқӋҶҚªńŌӁV7ԕԧӼӜԤөӘͫҹҼҦҶқпп ªńŌӁңҩӔϏơҾƆǸӁҺҠҼӄҚXϾӲӸӝԠӃƆǸʫͯ.ӘϾMҮҚʿ˚ƆǸӘXͯҰӔҾҾYӁҚńŌȲӃʿ˚ȗ̕Ә°ӎҼņ.ԨāϼҚvāϼҚʿ˚ˑϼҚªϥϼ̧ӃƷƢІҽȚƆԩӁӑӓ΋?ԨӬԗԤӾңӑӆԋӜԧӿԆӻӨԩӘ¡ҩҚҴӕӒӁҺҠҼӄʅϼңӑӆʅ¼.ΟˣҽΟΙҮҚʿ˚Ӄǂ¯ŲӃFȩˣӘͫҹҼҦҶқп
пԻìϥԨˢ̣ԩ΋?ӃĈǃ́ǸҾėŮɿɄԼпп ʿ˚ϏơŌˣӘĉͿʮӁ΋?ҰӔҶӎҚìϥ΋?̣ҾҮҼЗĮʸ˝îāîāЅ͢āʿ˚Ѕ͢ʎ· āƷĊƷƢӃôп ʶ QʎңӑӆîЂîāîāЅ͢āʿ˚ˑ͵uāiϯƷƢӃ ĸǔ8Q

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ʎӁʿ˚ӃϏơӐʿ˚ƆǸӁҺҠҼ΋?ҮҼОҠҶқ̍«ƊͺҾҮҼӄҚҠұӕӃìϥ΋?̣ҤӒӏԍԢӱӠӨӾӃϏơӄРΖҽiӀƆǸҥŤӒӕҼҠӔҾӃ΋?ӘОҠҼҠӔқппԻʿ˚ǧϿ˾šӃĩǦԼпп Ǫʿ˚ҽӄҚQφӃҾңӓҚíҨӃʿ˚ƆǸҥƟҥҹҼңӓҚҭӒӁʠŸŧĠʌåӃ΁ǵӐҴӕӒӁŮˤҰӔӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁ̖ҥӔʈΙȚ˨Ә ūҾҰӔʿ˚ÜʴӘřƆҰӔҫҾҥҽҦҶқ"šҚҫӕӒӃʿ˚ÜʴӘœҦ̈Ҧ̉ƝҭӒӁӄʫĩҭҲӔҫҾҽҚĜǱӃǪāʫӃӝԤӼԟӱӠԤӾԀԄ љљѧ ӃϾʫӁ̖ҪҼҠҦҶҠҾ̢ҢҼҠӔқ(ӁҚIҜӃӼԧԔӁЀҰӔ"šӃĩǦӁҺҠҼφӉӔқппӼԧԔ шпґ ɶʢŲ̽ʠŸӐƑҥәuΰÊŲ̽ɶӀҿӃɕ ÇʠŸҚª˖̼ʧҚҳәŴҚſǼʢҚԇԧӦԤӶԤʡӀҿӃ ǺʠŸҚ̫ɧˣӃ'ΝŲʠŸˣӃíҨӃʡƁԘӽԠӘ˃˝ҮҼңӓҚǁͻԀԄљљѧ Ӄ΋?ӃӌӀӒұҚǁͻ͢ɽӃ΋?ӐǁͻʡƁЀώiüӃƤ˻ӀҿӁӏŮʐҥǧŠҭӕӔқпҒ íҨӃʡƁЀώiüңӑӆɂʨȞʮiüӘ­ćҮҚҴӕӒӃiüʡƁȤŉӘǌӒҤӁҮҼңӓҚ
ҫӕӒӃźàӄțҜӀʠŸɂʨӁӏŮʐҽҦӔҫҾҥǧŠҭӕӔқпғ íҨӃʡƁЀώiüңӑӆɂʨȞʮiüӁʫʆϥ3ӘɾćҮҼңӓҚ"šӃ љљѧ Ȟʮϥ3ӁЀ
ҰӔźàҾҮҼǢʐҽҟӔқп
пӼԧԔ щпґ ϾʫҮҶ̼ʧ4 Ѿѝ ŮˤŲԀԄ љљѧ ӃŧĠʌåŮˤŲȤȚӄҚɶʢϥ3ӐŹŲ̳̬˿̗ӃŧĠʌåӁӏϚʐҽҦӔҾǧŠҭӕӔҶӎҚǪʿ˚ҽŤӒӕҶª˿̗ӃɾŲӘ̢ƄҮҶӽԆӝӲ·΄ӘͫҡҫҾҽҚ̼ʧ(ìӃʠŸԦ˿̗ӈӃĩϾӘ΄ʖҮҼҠӔқпҒ Ǫʿ˚ӁӑҹҼϾʫҮҶԀԄ љљѧ ӁҚ$ӃԀԄ љљѧ ӃɾŲӘͩ«ԦƮκҰӔҫҾҽҚӑӓгȧӀȤ̲ӘǢҰӔԀԄ љљѧ ӈҾĩϾҰӔҫҾӏ΄ʖҮҼҠӔқп
ғ Pt-NPs Ӄ āFЫɇӘϾʫҰӔҫҾӁӑӓҚPt-NPs ӃđӀ7^Ɓqťҥ¥̲ҾӀӓҚ̩̓ʠŸҚ̾́Ʊ˖(ìӃʠŸɂʨӈӃŮʐҥ¥̲ӀӔӏӃҾ̢ҢӒӕӔқҔ ϾʫҮҶбӸԧӫӼӜԤө×ԀԄ˭üӃƆiӐ˿ƆӘƳ͇ҰӔҫҾҽҚԀԄ˭üӈӃțҜӀɽŲӃ͢ɽӃƮκҥ¥̲ҾӀӓҚȺʐŲӁOӕӔбȞʮ DDS ҥȚ˨ҽҦӔҾ̢ҢӒӕӔҕ ӝӣԤɖ7ԀԄ˭üӃăćŲӘ¯ҭҲҚԔӟӲҽӃ7^ƁӘΖӉҚгҠͪ ɪʙŲҾгҠʩ˽̱;¸ŲӘǢҰӔӝӣԤɖ7ԀԄ˭üӘy͵ҽҦӔ¥̲ŲҥǧŠҭӕӔқҖ ȞʮҾҰӔϪ˹ӐӸԤԇӨέӃÜέӘԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRԀԄ˭üӃ́ͯЙӁF
ЫҰӔҫҾӁӑӓҚγ-өԠӸԕԠӾԞԤӲԋӠԞԧӵӀҿʩӁЀώҰӔϪ˹ӐӸԤԇӨέӃгſŌiǵɇӘ˃˝ҽҦӔ¥̲ŲҥҟӔқҗ I7̳έԀԄ˭üҥҚMRI ӁҼȩŁϥ3ҾгɢŌʠŸϥ3ӃmnӘ¥̲ҾҰӔҚɢŌŮˤŲ
DDS ӃϾʫӁ̖ҥӔҫҾҥǧŠҭӕӔқӼԧԔ 3

ґ ʫŲ7̻ɖŲԟԤԇ̼ԨPELԩӃ˓ȕԔӟӲӄƑ̼ʧ͢ɽӃ DDS ΋?ԘӽԠҾҮҼǢʐҽҟӓҚ"šҚƑ PEL «ɽӐƑ PEL ԀԄ DDS ˣӃ΋?˲ҾҮҼӃɍʐҥǧŠҭӕӔқҒ ̼ʧ˿̗ӁңҩӔ Hsp105 ӄҚHIF-1҉Ӑ Stat ӃɍŲ Ә#ҮҼҥәŹŲ ӁĐҰӔ¥̲ŲҥҟӓҚҥәŧĠʌåӁңҩӔ Hsp105 ӃʫʆӐȤ̲ЃČӘȞʮҾҮҶԀԄ DDS ӃϾʫҥǧŠҭӕӔқԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ғ ҥәɢɺɂʨҽӃoʐӘŻćҮҚHsp ʫʆЃČ͢ӘƮκҮҶɢŌſ¡ŲԀԄ DDS Әˢ 2 ʅҾY­ҮҼ8͵ ҽҟӔқ­ćҮҶ AF9 ӀҿӃǁͻ Hsp70 ʫʆqťÊüӐ Hsp105-Nmi-Stat3 ̀δӘȞʮҾҮҶ siRNA ӐЃČ͢ӘoʐҰӔҫҾҽҚǁҶӀiüӘȞʮҾҮҶԀԄ DDS ӃϾʫҥǧŠҭӕӔқҔ ԀԄ DDS ӣӦӮԟԍԞӺԤӁӑӔ¶ͽЍČӁėҮҼҚ̈́ňҽ:ʐƐҭӕӔ¥̲ŲӃгҠ S-1 Ӏ
ҿӃ$ӃƑҥәuӃŝНӘ΋?ҰӔҫҾҽҚӑӓăVӀԀԄ DDS ӁϾʫӁ̖ҪӔҫҾҥǧŠҭӕӔқԻʿ˚ƆǸӃvȧʮǸԼӼԧԔ 1ґ ʆÒ̈́ňŮʐҭӕҼҠӔҚҟӔҠӄϾʫ ӃʡƁЀώiüңӑӆɂʨȞʮiüӁėҰӔ͢uӁҺҠҼǁҶӀϚŮʠŸӈҾĩϾҽҦӔ¥̲ŲҥҟӔқҒ ɶʢŲӮӝӾӤӝԤʏʎӘƏqҰӔӋҶӄƑɶʢŲӮӝӾӤӝԤʏʎӘæîҭҲӔӝӣԤӺԙԃԠ
8ʐ͢ӘӲӨԟԧԁԤөҮҚͅĺTʟʠŸԘӽԠɽӘʐҠҶʡƁ΁ǵĈаӁӑӓҴӃǢŲҥĈΊҭӕӕӅҚɾΈʓΗӁ̖ҥӔ¥̲ŲҥҟӔқғ ӝӣԤӺԙԃԠʫʆΖ˧ȤȚӁʻʵҮҼǁͻӝӣԤӺԙԃԠȤ̲FЫiüӃ­ćҥҽҦӕӅҭӒӀӔʿ˚ӃʫĩҥǧŠҽҦҚǠ˾ʮӁӄɾΈʓΗӃėΣӁӀӓҡӔқӋҶҚʩŧĠʌåӁңҩӔӝӣԤӺԙԃԠӃiüƟӘiüӝԗԧӱԤө΁ǵҰӔҫҾӁӑӓҚTʟӰԀԍӲřƆӁңҩӔӝӣԤӺԙԃԠӃǒ˛ϿʮӁʈ΁ҰӔҫҾӁӑӓҚTʟ˲ӁңҩӔӝӣԤӺԙԃԠʿ˚ҥϏĩҰӔқҔ 4ϫ˹̼ʧԔԧӤԧLipocalin2 ӁЀҮҚԈӾҥәỴ̈ͪɬӘėΣӁɾʜʮƑ7ӁӑӔ4ϫ˹̼ʧ˪ǍȖhɇϾʫӁ̖ҥӔҾǧŠҭӕҚĈʐ ӐɾΈʓΗҥͺςӋӕӔқӼԧԔ 2ґ ϾʫҮҶ̼ʧ4 pH ŮˤŲԀԄ DDS ӘɾΈhЧҮҶԨʫǌ̣ԺĠǛKðǥҚɲп ϏҚҝŖϫŲՊՀŮˤŲԐԍӺӿӆ΍ԐԍӺӿӘ°ӍԟԓӶԧԖҞPCT/JP2013/078497ԩқҒ ʠŸŧĠʌåҽʫʎҰӔɍŲϫ˹Әɕ¥̲Ӏ Pt-NPs ӄҚɍŲϫ˹ҥʡƁӁЀҰӔҥәң
ӑӆɶʢӀҿӃțҜӀʠŸɂʨӈŮʐ¥̲ӁӀӔӏӃҾǧŠҭӕӔқғ ϾʫҮҶбӸԧӫӼӜԤө×ԀԄ˭üӁƑʩuӐбˮеʢɂʨ͢ӀҿӘƮκҰӔҫҾҽҚțҜӀбʠŸɂʨӃʃ ҥ¥̲ӁӀӔӏӃҾǧŠҭӕӔқҔ ӝӣԤɖ7ӄȸɨŲ͢ɽӏʞȸŲ͢ɽӏɨ΁ҰӔҾҠҡԜԁԧӨӀɨúҽҟӔҫҾҥɉʵҭӕҼңӓҚҴӕӘԀԄ˭ü ҮҶӝӣԤɖ7ԀԄ˭üӄҚҫӕӋҽӁӀҠǁҮҠ DDS ҾҮҼɾΈʓΗӁ̖ҥӔ¥̲ŲҥҟӔқҕ ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRԀԄ˭üӄҚỴ̈ŧĠʌåӃȘŧϰʎ7ΌƿӘ˪@ԦσόҤҺαгſŌӁȖh¥̲Ӏ̈́ňȖǿӦӻӾҾҮҼĈʐ ҭӕӔҫҾҥǧŠҭӕӔқҖ ɢŌŮˤŲ̳έԀԄ˭üӄҚгɢŌʠŸϥ3ӘгſŌȖh¥̲ӀԀԄ˭üҽҟӓҚ̈́ňˣӁңҩӔʎ7ԍԢԧԌҾҮҼӃŮʐҥǧŠҭӕҚɾΈʓΗӁ̖ҥӔ¥̲ŲӘǢҰӔқ
ӼԧԔ 3

ґ ԘӽԠԀԄ˭üԊԢԟӱԁԛӟԖ× C60 ԋԞԧԡԤӄƑ PEL ɍŲҷҩҽӀҨӟӝԠӲͶ͵ЃČ8ʐӏͺhҭӕҚƑ̼ʧ͢ҾҾӏӁƑӟӝԠӲ͢ҾҮҼӃĈʐ ӐɾΈʓΗҥǧŠҭӕӔқҒ 8͵ҮҶª˖ԄӻӨӹӟԤ˽̱ӐԠӰԋӠԞԧӵԡԓԧӸԧ˽̱Қv-Src Βğʫʆ˽̱ӄҚDDS Ӄ΋?˲ӃӌҽӀҨҚHsp ʫʆqťuӐ v-Src ÜέӸԤԇӨέӃӲӨԟԧԁԤө˲ҾҮҼŮʐ¥̲ҽҟӔқԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ғ ǁͻ Hsp70 ʫʆqťÊüҾҮҼ­ćҮҶ AF9 ӄҚʭͪʡÊϜ/üӃηōԇԧӾԀԧϜ/üҽҟӔқAF9 ӁӑӔ Hsp70 ʫʆԗӤԁӳԖӃ΁ǵӄҚHsp70 ʫʆƏqӁӑӔ͢uſ¡ŲϏӘʵʮҾҮҶʭͪʡɂʨɇӃϾʫӁ̖ҥӔ¥̲ŲҥҟӔқҔ ǪԍԢӱӠӨӾӁңҠҼҚԟԓӶԧԖ͵uӃv8ʐʫʆҥҚԟԓӶԧԖӃ˿̗˓ͫŲҾ^͢ɽӃɾŲӁӑҹҼɣҽҦӔ¥̲Ųҥˆ¾ҭӕҚ"šӑӓΎ˽ӀȖ΅ӘϏӎӔҫҾӁӑӓҚԀԄ DDS
͵uӃӑӓăVӀ;ʐɇӃƩȈӁ̖ҥӔҫҾҥǧŠҭӕӔқпԱԲп ӦԧԣԧӿԨŘ΍ʿ˚^ĎӘӑҨͯҮҼҠӔҾŰӗӕӔӏӃӘԸПʵ(^ҽΆκҮҼҨҷҭ
ҠқԩпԨԱԩп п ʠŸŧĠʌåп п п п п п п п ԨԲԩп п љљѧп п п п п п п п п п п п п п ԨԳԩп п ʌåŮˤŲп п п п п п п пԨԴԩп п ̼ʧԨҥәԩп п п п п п п п п п ԨԵԩп п ɕ ÇʠŸп п п п п п п п п п ԨԶԩп п ſǼʢп п п п п п п п пԨԷԩп п ҳәŴп п п п п п п п п п п п п ԨԸԩп п ǺʠŸп п п п п п п п п п п ппԱԳп ʿ˚ʫͯӃɿɄԨʿ˚ΙƼˣXͯɿɄқr ӏ°ӍқԩпΆҚԱԱрԴсӁΆκҮҶʿ˚ƆǸӁėŮҰӔӏӃӁӄԪӘ%ҰҫҾқп
пԻБΐΙƼԼп
ӼԧԔԱ

1.

2.

3.

4.

5.

6.

7.

Fujii M, Ohyanagi C, Kawaguchi N, Matsuda H, Miyamoto Y, Ohya S, Takeshi Nabe T.
Eicosapentaenoic acid ethyl ester ameliorates atopic dermatitis-like symptoms in special
diet-fed hairless mice, partly by restoring covalently bound ceramides in the stratum
corneum. Exp Dermatol, in press. ԨǿΔǢԩ
UtsumiD , Matsumoto K, Tsukahara T, Amagase K, Tominaga M, Kato S. Transient receptor
potential vanilloid 1 and transient receptor potential ankyrin 1 contribute to the progressionof colonic inflammation in dextran sulfate sodium-induced colitis in mice: Links to calcitonin
gene-related peptide and substance P. J Pharmacol Sci. 136, 121-132 (2018)ԨǿΔǢԩ*
Matsumoto K, Yamaba R, Inoue K, Utsumi D, Tsukahara T, Amagase K, Tominaga M, Kato
S. Transient receptor potential vanilloid 4 channel regulates vascular endothelial
permeability during colonic inflammation in dextran sulphate sodium-induced murine colitis.
Br J Pharmacol. 175, 84-99 (2018)ԨĕǿǢԩ*
Hamoudaп Ղ, Sanoп Ճ, Oikawaп Մ, Ozakiп T, Shimakawa M, Matsumoto M, Amagase K,
Higuchi K, Kato S. Apoptosis, dysbiosis and expression of inflammatory cytokines aresequential events in the development of 5- fluorouracil - induced intestinal mucositis inmice. Basic Clinical Pharmacol Toxicol. 121, 159-168 (2017) ԨǿΔǢԩ*
Kato S, Hamouda N, Kano Y, Oikawa Y, Tanaka Y, Matsumoto K, Amagase K, Shimakawa
M. Probiotic Bifidobacterium bifidum G9-1 attenuates 5- fluorouracil- induced intestinal
mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.
Clin Exp Pharmacol Physiol. 44, 1017-1025 (2017) ԨǿΔǢԩ*
Tsukahara T, Hamouda N, Utsumi D, Matsumoto K, Amagase K, Kato S. G protein-coupled
receptor 35 contributes to mucosal repair in mice via migration of colonic epithelial cells.
Pharmacol Res, 123, 27-39 (2017) ԨǿΔǢԩ*
Yokota H, Tsuzuki A, Shimada Y, Imai A, Utsumi D, Tsukahara T, Matsumoto M, Amagase
K, Iwata K, Nakamura A, Yabe-Nishimura C, Kato S. NOX1/NADPH oxidase expressed incolonic macrophages contributes to the pathogenesis of colonic inflammation inԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

trinitrobenzene sulfonic acid-Induced murine colitis. J Pharmacol Exp Ther, 360, 192-200(2017) ԨǿΔǢԩ
8. Fujimoto M, Inoue T, Kito H, Niwa S, Suzuki T, Muraki K, Ohya D. Transcriptional repressionof HER2 by ANO1 Cl- channel inhibition in human breast cancer cells with resistance totrastuzumab. Biochem Biophys Res Commun, 482, 188-194 (2017). ԨǿΔǢԩ*
9. Hayashi N, Yokotani A, Yamamoto M, Kososhi M, Morita M, Fukunishi C, Nishizawa N, andGotoh N. Extracellular signals of a human epithelial colorectal adenocarcinoma (Caco-2)cell line facilitate the penetration of Pseudomonas aeruginosa PAO1 strain through the
mucin layer. Front. Cell. Infect. Microbiol. 7, 415 (2017)ԨǿΔǢԩ*
10. Shikata M, Hayashi N, Fujimoto A, Nakamura T, Matsui T, Ishiyama A, Maekawa Y, Gotoh
N. The pilT gene contributes to type III ExoS effector injection into epithelial cells in
Pseudomonas aeruginosa. J Infect Chemother. 22, 216-220 (2016)(ǿΔǢ)*
11. Anowara K, Fujimoto M, Kito H, Niwa S, Suzuki T, Ohya S. Down-regulation of
Ca2+-activated K+ channel KCa1.1 in human breast cancer cells treated with the vitamin D
receptor agonists. Int J Mol Sci, 17, pii: E2083 (2016). ԨǿΔǢԩ*
12. Ohya S, Kito H, Hatano N, Muraki K. Recent advances in therapeutic strategies that focus
on the regulation of ion channel expression. Pharmacol Ther, 160, 11-43 (2016). (ǿΔǢ)*
13. Tagishi K, Shimizu A, Endo K, Kito H, Niwa S, Fujii M, Ohya S. Defective splicing of the
background K+ channel K2P5.1 by the pre-mRNA splicing inhibitor, pladienolide B in
lectin-activated mouse splenic CD4+ T cells. J Pharmacol Sci, 132, 205-209 (2016). ԨǿΔǢԩ*
14. Fujii M, Endo-Okuno F, Iwai A, Doi K, Tomozawa J, Kohno S, Inagaki N, Nabe T, Ohya S.
Hypomorphic mutation in the hairless gene accelerates pruritic atopic skin caused byfeeding a special diet to mice. Exp Dermatol, 25, 565-567 (2016). ԨǿΔǢԩ*
15. Ohya S, Kanatsuka S, Hatano N, Kito H, Matsui A, Fujimoto M, Matsuba S, Niwa S, Zhan P,
Suzuki T, Muraki K. Downregulation of the Ca2+-activated K+ channel KCa3.1 by histone
deacetylase inhibition in human breast cancer cells. Pharmacol Res Perspect, 4, e00228(2016). ԨǿΔǢԩ*
16. Utsumi D, Matsumoto K, Amagase K, Horie S, Kato S. 5-HT3 receptors promote colonicinflammation via activation of substance P/neurokinin-1 receptors in dextran sulphate
sodium-induced murine colitis. Br J Pharmacol 173, 1835-1849 (2016) ԨǿΔǢԩ*
17. Kato S, Hayashi S, Kitahara Y, Nagasawa K, Aono H, Shibata J, Utsumi D, Amagase K,
Kadowaki M. Saireito (TJ-114), a Japanese traditional herbal medicine, reduces
5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis
in intestinal crypt cells. PLoS One. 10, e0116213, 1-15 (2015) ԨǿΔǢԩ*
18. Matsumoto K, Hosoya TY, Ishikawa E, Tashima K, Amagase K, Kato S, Murayama T, Horie
S. Distribution of transient receptor potential cation channel subfamily V member
1-expressing nerve fibers in mouse esophagus. Histochem Cell Biol. 142, 635-644 (2014)ԨǿΔǢԩ*
19. Endo K, Kurokawa N, Kito H, Nakakura S, Fujii M, Ohya S. Identification of thedominant-negative, splicing isoform of the two-pore domain K+ channel K2P5.1 in lymphoidcells and enhancement of their expression by splicing inhibition. Biochem Pharmacol, 98,
440-452 (2015). ԨǿΔǢԩ*
20. Nakakura S, Matsui M, Sato A, Ishii M, Endo K, Muragishi S, Murase M, Kito H, Niguma H,Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

Kurokawa N, Fujii M, Araki M, Araki K, Ohya S. Pathophysiological significance of thetwo-pore domain K+ channel K2P5.1 in splenic CD4+CD25- T cell subset from achemically-induced murine inflammatory bowel disease mode. Front Physiol, 6, 299 (2015).
ԨǿΔǢԩ*
21. Fujii M, Shimazaki Y, Muto Y, Kohno S, Ohya S, Nabe T. Dietary deficiencies of unsaturated
fatty acids and starch cause atopic dermatitis-like pruritus in hairless mice. Exp Dermatol,
24, 108-113 (2015). ԨǿΔǢԩ
22. Nabe T, Wakamori H, Yano C, Nishiguchi A, Yuasa R, Kido H, Tomiyama Y, Tomoda A, Kida
H, Takiguchi A, Matsuda M, Ishihara K, Akiba S, Ohya S, Fukui H, Mizutani N, Yoshino S.
Production of interleukin (IL)-33 in the lungs during multiple antigen challenge-induced
airway inflammation in mice, and its modulation by a glucocorticoid. Eur J Pharmacol 757,
34-41 (2015). ԨǿΔǢԩ*
23. Hayashi N, Nishizawa H, Kitao S, Deguchi S, Nakamura T, Fujimoto A, Shikata M, Gotoh N.
Pseudomonas aeruginosa injects type III effector ExoS into epithelial cells through thefunction of type IV pili. FEBS Lett 589, 890-896 (2015)ԨǿΔǢԩ*
24. Matsuba S, Niwa S, Muraki K, Kanatsuka S, Nakazuno Y, Hatano N, Fujii M, Zhan P. Suzuki
T, Ohya S. Downregulation of Ca2+-activated Cl- channel TMEM16A by the inhibition ofhistone deacetylase in TMEM16A-expressing cancer cells. J Pharmacol Exp Ther 351,
510-518 (2014) ԨǿΔǢԩ*
25. Nabe T. Interleikin (IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci 126,
85-91 (2014).ԨǿΔǢԩ*
26. Nakamura I, Hama S, Itakura S, Takasaki I, Nishi T, Tabuchi Y, Kogure K. Lipocalin2 as aplasma marker for tumors with hypoxic regions. Sci Rep. 4, 7235 (2014) ԨǿΔǢԩ*
27. Ikeda Y, Tsuchiya H, Hama S, Kajimoto K, Kogure K. Resistin regulates the expression ofplasminogen activator inhibitor-1 in 3T3-L1 adipocytes. Biochem Biophys Res Commun.
448, 129-133 (2014)ԨǿΔǢԩ*
28. Tashiro N, Nishimura K, Daido K, Oka T, Todo M, Toshikawa A, Tsushima J, Takata K,
Ashihara E, Yoshimoto K, Agata K, Kitamura Y. Pharmacological assessment ofmethamphetamine-induced behavioral hyperactivity mediated by dopaminergictransmission in planarian Dugesia japonica. Biochem Biophys Res Commun, 449, 412-418(2014)ԨǿΔǢԩ*
29. Ohgita T, Hayashi N, Gotoh N, Kogure K. Suppression of type III effector secretion bypolymers. Open Biol. 3, 130133 (2013)ԨǿΔǢԩ*
30. IkedaY, Tsuchiya H, Hama S, Kajimoto K, Kogure K. Resistin affects lipid metabolism during
adipocyte maturation of 3T3-L1 cells. FEBS J. 280, 5884-5895 (2013)ԨǿΔǢԩ*
31. Yasuda M, Kato S, Yamanaka N, Iimori M, Matsumoto K, Utsumi D, Kitahara Y, Amagase K,
Horie S, Takeuchi K. 5-HT receptor antagonists ameliorate 5-fluorouracil-induced intestinal
mucositis by suppression of apoptosis in murine intestinal crypt cells. Br J Pharmacol.
168, 1388-1400 (2013) ԨǿΔǢԩ*
32. Nabe T, Kijitani Y, Kitagawa Y, Sakane E, Ueno T, Fujii M, Nakao S, Sakai M, Takai S.
Involvement of chymase in allergic conjunctivitis of guinea pigs. Exp Eye Res 113, 74-79(2013).ԨǿΔǢԩ
33. Nabe T, Matsuya K, Akamizu K, Fujita M, Nakagawa T, Shioe M, Kida H, Takiguchi A,
Wakamori H, Fujii M, Ishihara K, Akiba S, Mizutani N, Yoshino S, Chaplin DD. Roles ofԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

basophils and mast cells infiltrating the lung by multiple antigen challenges in asthmatic
responses of mice. Br J Pharmacol 169, 462-476 (2013) ԨǿΔǢԩ*ӼԧԔԲ

34. Takegami S, Watanabe K, Konishi A, Kitade T. Formation of ionic liquid submicron particles.
1
H and 19F nuclear magnetic resonance spectroscopic studies. J. Dispersion Sci. Technol.
In press ԨǿΔǢԩ*
35. Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Tanaka Y, Yamada S, Naito C,
Yamamoto A. Development of PEGylated aspartic acid-modified liposome as abone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.
Biomaterials, 154, 74-85 (2018)ԨǿΔǢԩ*
36. Yamashita S, Katsumi H, Sakane T, Yamamoto A. Bone-targeting dendrimer for the deliveryof methotrexate and treatment of bone metastasis. Journal of Drug Targeting, in press(2018)ԨǿΔǢԩ*
37. Jung H, Shimatani Y, Hasan M, Uno K, Hama S, Kogure K. Development of flexible
nanocarriers for siRNA delivery into tumor tissue. Int J Pharm, 516, 258-265 (2017)ԨǿΔ
Ǣԩ*
38. Katsumi H, Tanaka Y, Hitomi K, Liu S, Quan YQ, Kamiyama F, Sakane T, Yamamoto A:
Efficient transdermal delivery of alendronate, a nitrogen-containing bisphosphonate, using
tip-loaded self-dissolving microneedle arrays for the treatment of osteoporosis.
Pharmaceutics, 9, E29 (2017)ԨǿΔǢԩ
39. Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Kusamori K, Sakane T, Yamamoto A:
Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers asbone-targeting carriers for the treatment of bone diseases. J. Control. Release, 262,
10-17(2017)ԨǿΔǢԩ*40. Suzuki S, Itakura S, Matsui R, Nakayama K, Nishi T, Nishimoto A, Hama S, Kogure K.
Tumor Microenvironment-Sensitive Liposomes Penetrate Tumor Tissue via AttenuatedInteraction of the Extracellular Matrix and Tumor Cells and Accompanying Actin
Depolymerization. Biomacromolecules, 18, 535-543 (2017)ԨǿΔǢԩ*
41. Hasan M, Tarashima N, Fujikawa K, Ohgita T, Hama S, Tanaka T, Saito H, Minakawa N,
Kogure K. The novel functional nucleic acid iRed effectively regulates target genes
following cytoplasmic delivery by faint electric treatment, Sci. Technol. Adv. Mater, 17,554-562 (2016) ԨǿΔǢԩ
42. Itakura S, Hama S, Matsui R, Kogure K. Effective cytoplasmic release of siRNA fromliposomal carriers by controlling the electrostatic interaction of siRNA with acharge-invertible peptide, in response to cytoplasmic pH, Nanoscale, 8, 10649-10658(2016)ԨǿΔǢԩ*
43. Hasan M, Nishimoto A, Ohgita T, Hama S, Kashida H, Asanuma H, Kogure K. Faint electric
treatment-induced rapid and efficient delivery of extraneous hydrophilic molecules into thecytoplasm, J. Control. Release, 228, 20-25 (2016)ԨǿΔǢԩ*
44. Takagi K, Ohgita T, Yamamoto T, Shinohara Y, Kogure K. Transmission of External
Environmental pH Information to the Inside of Liposomes via Pore-Forming Proteins
Embedded within the Liposomal Membrane, Chem. Pharm. Bull, 64, 432-438 (2016)ԨǿΔ
Ǣԩ*Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

45. Yamada A, Mitsueda A, Hasan M, Ueda M, Hama S, Warashina S, Nakamura T, Harashima
H, Kogure K. Tri-membrane nanoparticles produced by combining liposome fusion and anovel patchwork of bicelles to overcome endosomal and nuclear membrane barriers tocargo delivery. Biomater Sci. 4, 439-447 (2016) (ǿΔǢ)*
46. Katsumi H, Nishikawaп M, Hirosaki R, Okuda T, Kawakami S, Yamashita F, Hashida M,
Sakane T, Yamamoto A. Development of PEGylated cysteine-modified lysine dendrimers
with multiple reduced thiols to prevent hepatic ischemia/reperfusion injury. Mol. Pharm.,
13 (8), 2867-2873 (2016)ԨǿΔǢԩ
47. Katsumi H, Mozume T, Yanagi S, Hasei T, Watanabe T, Sakane T, Yamamoto A.
Pharmacokinetic and therapeutic efficacy of intrapulmonary administration of zoledronate
for the prevention of bone destruction in rheumatoid arthritis. J. Drug Target., 24 (6),530-536 (2016)ԨǿΔǢԩ
48. Takegami S, Kitamura K, Ohsugi M, Konishi A, Kitade T. 19F nuclear magnetic resonancespectrometric determination of the partition coefficients of flutamide and nilutamide(antiprostate cancer drugs) in a lipid nano-emulsion and prediction of its encapsulation
efficiency for the drugs. AAPS Pharm. Sci. Tech. 17, 1500-1506 (2016)ԨǿΔǢԩ
49. Yamamoto R, Takegami S, Konishi A, Horikawa H, Yonezawa S, Kitade T. Polydiacetylene
liposomal aequorin bioluminescent device for detection of hydrophobic compounds. Anal.
Chem. 88, 5704-5709 (2016)ԨǿΔǢԩ*50. Hama S, Itakura S, Nakai M, Nakayama K, Morimoto S, Suzuki S, Kogure K. Overcoming
the polyethylene glycol dilemma via pathological environment-sensitive change of thesurface property of nanoparticles for cellular entry. J Control Release. 206, 67-74 (2015)ԨǿΔǢԩ*
51. Itakura S, Hama S, Ikeda H, Mitsuhashi N, Majima E, Kogure K. Effective capture ofproteins inside living cells by antibodies indirectly linked to a novel cell-penetrating
polymer-modified protein A derivative. FEBS J. 282, 142-152 (2015)ԨǿΔǢԩ
52. Toyoda M, Hama S, Ikeda Y, Nagasaki Y, Kogure K. Anti-cancer vaccination by transdermaldelivery of antigen peptide-loaded nanogels via iontophoresis. Int J Pharm. 483, 110-114(2015) ԨǿΔǢԩ
53. Wu D, Quan Y. S, Kamiyama F, Kusamori K, Katsumi H, Sakane T, Yamamoto A.
Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving
microneedle array fabricated from sodium hyaluronate in rats. Biol. Pharm. Bull., 38,
365-373 (2015)ԨǿΔǢԩ
54. Katsumi H, Sano S, Nishikawa M, Hanzawa K, Sakane T, Yamamoto A. Molecular design ofbisphosphonate-modified proteins for efficient bone targeting in vivo. PLoS One, 10,e1305966 (2015)ԨǿΔǢԩ*
55. Takegami S, Kitamura K, Ohsugi M, Ito A, Kitade T. Partitioning of organophosphorus
pesticides into phosphatidylcholine small unilamellar vesicles studied by second-derivative
spectrophotometry. Spectrochim Acta Part A. 145, 198-202 (2015)ԨǿΔǢԩ
56. Takegami S, Katsumi H, Asai K, Fujii D, Fujimoto T, Kawakami H, Tokuyama T, Konishi A,
Yamamoto A, Kitade T. Application of 19F NMR spectroscopy using a novel α-tocopherol
derivative as a 19F NMR probe for a pharmacokinetic study of lipid nano-emulsions in mice.
Pharm Anal. Acta. 6, 339 (2015)ԨǿΔǢԩ
57. Itakura S, Hama S, Ohgita T, Kogure K. Development of nanoparticles incorporating a novelԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

liposomal membrane destabilization peptide for efficient release of cargos into cancer cells.
PLoS One, 9, e111181 (2014)ԨǿΔǢԩ*
58. Katsumi H, Fukui K, Sato K, Maruyama S, Yamashita S, Mizumoto E, Kusamori K, Oyama
M, Sano M, Sakane T, Yamamoto A. Pharmacokinetics and preventive effects of platinum
nanoparticles as reactive oxygen species scavengers on hepatic ischemia/reperfusion
injury in mice. Metallomics 6,1050-1056 (2014)ԨǿΔǢԩ*
59. Wu D, Tanaka Y, Jin Y. R, Yoneto K, Alama T, Quan Y. S, Kamiyama F, Kusamori K,
Katsumi H, Sakane T, Yamamoto A. Development of a novel transdermal patch containing
sumatriptan succinate for the treatment of migraine: in vitro and in vivo characterization. J.
Drug Del. Sci. Technol. 24, 695-701 (2014)ԨǿΔǢԩ
60. Katsumi H, Nishikawa M, Nishiyama K, Hirosaki R, Nagamine N, Okamoto H, Mizuguchi H,
Kusamori K, Yasui H, Yamashita F, Hashida M, Sakane T, Yamamoto A. Development of
PEGylated serum albumin with multiple reduced thiols as a long-circulating scavenger ofreactive oxygen species for the treatment of fulminant hepatic failure in mice. Free Radic
Biol Med, 69, 318-23 (2014)ԨǿΔǢԩ
61. Liu S, Jin M. N, Quan Y. S, Kamiyama F, Kusamori K, Katsumi H, Sakane T, Yamamoto A.
Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving
microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after
application to the skin. Eur J Pharm Biopharm, 86, 267-276 (2014)ԨǿΔǢԩ
ӼԧԔ 3

62. Campbell M, Watanabe T, Nakano K, Davis RR, Lyu Y, Tepper CG, Durbin-Johnson B,
Fujimuro M, Izumiya Y. KSHV episomes reveal dynamic chromatin loop formation withdomain specific gene regulation. Nat. Commun., 9, 49 (2018) ԨǿΔǢԩ
63. Baba Y, Shigemi Z, Hara N, Moriguchi M, Ikeda M, Watanabe T, Fujimuro M. Arctigenin
induces apoptosis in primary effusion lymphoma cells under glucose deprivation. Int J
Oncol., 52, 505-517 (2018) ԨǿΔǢԩ*
64. Nishimura M, Watanabe T, Yagi S, Yamanaka T, Fujimuro M. Kaposi's sarcoma-associatedherpesvirus ORF34 is essential for late gene expression and virus production. Sci. Rep., 7,329 (2017) ԨǿΔǢԩ
65. Shigemi Z, Manabe K, Hara N, Baba Y, Hosokawa K, Kagawa H, Watanabe T, Fujimuro M.п
Methylseleninic acid and sodium selenite induce severe ER stress and subsequent
apoptosis through UPR activation in PEL cells. Chemico-Biological Interactions, 266, 28–37(2017) ԨǿΔǢԩ*
66. Ifuji A, Kuga T, Kaibori Y, Saito Y, Nakayama Y. A novel immunofluorescence method tovisualize microtubules in the antiparallel overlaps of microtubule-plus ends in the anaphaseand telophase midzone. Exp. Cell Res., 360, 347-357 (2017)ԨǿΔǢԩ
67. Mikami H, Saito Y, Okamoto N, Kakihana A, Kuga T, Nakayama Y. Requirement of Hsp105
in CoCl2-induced HIF-1҉ accumulation and transcriptional activation. Exp. Cell Res. 352
225-233 (2017)ԨǿΔǢԩ*
68. Kakae K, Ikeuchi M, Kuga T, Saito Y, Yamaguchi N, Nakayama Y. v-Src-induced nuclear
localization of YAP is involved in multipolar spindle formation in tetraploid cells. Cell.
Signal., 30, 19-29 (2017)ԨǿΔǢԩ*
69. Nakata S, Watanabe T, Nakagawa K, Takeda H, Ito A, Fujimuro M. The dynamics ofԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

histone H2A ubiquitination in HeLa cells exposed to rapamycin, ethanol, hydroxyurea, ER
stress, heat shock and DNA damage. Biochem. Biophys. Res. Commun., 472, 46-52 (2016)
ԨǿΔǢԩ
70. Nishida K, Kashiwagi M, Shiba S, Muroki K, Ohishi A, Doi Y, Ando H, Ishida T, Nagasawa K.
Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Toxicol. Appl. Pharmacol., 337, 76-84 (2017)ԨǿΔǢԩ*
71. Ohishi A, Nishida K, Miyamoto K, Imai M, Nakanishi R, Kobayashi K, Hayashi A, Nagasawa
K. Bortezomib alters sour taste sensitivity in mice. Toxicol. Rep., 4, 172-180 (2017)ԨǿΔ
Ǣԩ*
72. Shigemi Z, Baba Y, Hara N, Matsuhiro J, Kagawa H, Watanabe T, Fujimuro M. Effects of
ER stress on unfolded protein responses, cell survival, and viral replication in primaryeffusion lymphoma. Biochem. Biophys. Res. Commun., 469, 565-572 (2016) ԨǿΔǢԩ*73. Shigemi Z, Furukawa Y, Hosokawa K, Minami S, Matsuhiro J, Nakata S, Watanabe T,
Kagawa H, Nakagawa K, Takeda H, Fujimuro M. Diallyl trisulfide induces apoptosis by
suppressing NF-kappa B signaling through destabilization of TRAF6 in primary effusion
lymphoma. Int J Oncol., 48, 293-304 (2016) ԨǿΔǢԩ*74. Ikeuchi M, Fukumoto Y, Honda T, Kuga T, Saito Y, Yamaguchi N, Nakayama Y. v-Src
causes chromosome bridges in a caffeine-sensitive manner by generating DNA damage.
Int. J. Mol. Sci., 17: 871, (2016)ԨǿΔǢԩ*
75. Kuga T, Sasaki M, Mikami T, Miake Y, Adachi J, Shimizu M, Saito Y, Koura M, Takeda Y,
Matsuda J, Tomonaga T, Nakayama Y. FAM83H and casein kinase I regulate theorganization of the keratin cytoskeleton and formation of desmosomes. Sci. Rep, 6:26557(2016)ԨǿΔǢԩ
76. Saito Y, Nakagawa T, Kakihana A, Nakamura Y, Nabika T, Kasai M, Takamori M,
Yamagishi N, Kuga T, Hatayama T, Nakayama Y. Yeast two-hybrid and one-hybrid
screenings identify regulators of hsp70 gene expression. J. Cell. Biochem., 117:
2109-2117 (2016)ԨǿΔǢԩ*
77. Iwamoto E, Ueta N, Matsui Y, Kamijo K, Kuga T, Saito Y, Yamaguchi N, Nakayama Y. ERK
plays a role in chromosome alignment and participates in M-phase progression. J. Cell.
Biochem., 117: 1340-1351 (2016)ԨǿΔǢԩ
78. Ohishi A, Nishida K, Yamanaka Y, Miyata A, Ikukawa A, Yabu M, Miyamoto K, Bansho S,
Nagasawa K. Oxaliplatin alters expression of T1R2 receptor and sensitivity to sweet taste
in rats. Biol. Pharm. Bull., 39, 578-586 (2016)ԨǿΔǢԩ
79. Ohishi A, Keno Y, Marumiya A, Sudo Y, Uda Y, Matsuda K, Morita Y, Furuta T, Nishida K,
Kazuki Nagasawa. Expression level of P2X7 receptor is a determinant of ATP-induced
death of mouse cultured neurons. Neuroscience, 319, 35-45 (2016)ԨǿΔǢԩ
80. Nishida K, Kubota T, Matsumoto S, Kato J, Watanabe Y, Yamamoto A, Furui M, Ohishi A,
Nagasawa K. Expression of prostatic acid phosphatase in rat circumvallate papillae.
PLoS One, 11, e0158401 (2016)ԨǿΔǢԩ
81. Wakao K, Watanabe T, Takadama T, Uia S, Shigemi Z, Kagawa H, Higashi C, Ohga R,
Taira T, Fujimuro M. Sangivamycin induces apoptosis by suppressing Erk signaling inprimary effusion lymphoma cells. Biochem. Biophys. Res. Commun., 444, 135-140 (2014)
ԨǿΔǢԩ
82. Watanabe T, Nakamura S, Ono T, Ui S, Yagi S, Kagawa H, Watanabe H, Ohe T, Mashino T,Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

Fujimuro M. Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via
suppression of Akt in primary effusion lymphoma. Biochem. Biophys. Res. Commun., 451,
93-100 (2014) ԨǿΔǢԩ*
83. Wakabayashi N, Skoko JJ, Chartoumpekis DV, Kimura S, Slocum SL, Noda K, Palliyaguru
DL, Fujimuro M, Boley PA, Tanaka Y, Shigemura N, Biswal S, Yamamoto M, Kensler TW.
Notch-Nrf2 axis: Regulation of Nrf2 gene expression and cytoprotection by Notch signaling.
Mol. Cell. Biol., 34, 653-663 (2014) ԨǿΔǢԩ
84. Saito Y, Yukawa A, Matozaki M, Mikami H, Yamagami T, Yamagishi N, Kuga T, Hatayama T,
Nakayama Y. Nmi interacts with Hsp105Ҋ and enhances the Hsp105 -mediated Hsp70
expression. Exp. Cell Res. 327, 163-170 (2014)ԨǿΔǢԩ*85. Nishida K, Dohi Y, Yamanaka Y, Miyata A, Tsukamoto K, Yabu M, Ohishi A, Nagasawa K.
Expression of adenosine A2b receptor in rat type II and III taste cells. Histochem. Cell
Biol., 141, 499-506 (2014)ԨǿΔǢԩ
86. Nishida K, Nomura Y, Kawamori K, Moriyama Y, Nagasawa K. Expression profile ofvesicular nucleotide transporter (VNUT, SLC17A9) in subpopulations of rat dorsal root
ganglion neurons. Neurosci. Lett., 579, 75-79 (2014)ԨǿΔǢԩ
87. Nishida K, Kitada T, Kato J, Dohi Y, Nagasawa K. Expression of equilibrative nucleosidetransporter 1 in rat circumvallate papillae. Neurosci. Lett., 533, 104-108 (2013)ԨǿΔǢԩ
88. Okuda H, Nishida K, Higashi Y, Nagasawa K. NAD⁺ influx through connexin hemichannels
prevents poly(ADP-ribose) polymerase-mediated astrocyte death. Life Sci., 92, 808-814(2013)ԨǿΔǢԩ

ԻÌǝԼп
1.

2.
3.

4.

5.

6.

7.
8.

Saito Y, Nakayama Y. Mammalian heat shock protein Hsp105: The hsp70 inducer and apotent target for cancer therapy. Heat shock proteins, Vol. 14, Asea AAA and Kaur P (Eds)
HSP70 in Human Diseases and Disorders Springer, in pressɲ ϏҚǴHˋüҚĠǛKðǥԮˢ 5 ˟ 4 ˧ҥәŧĠʌåӘӸԧӫӻӾҾҮҶ DDS ƍͬϾʫԮ
DDS QˠƍͬӃ͵uӈӃŮʐϾʫԮpp.283-291Ԯƍͬźà.(2017)ͺ͏ȩҚĬǪ ǋ: ˢ 6 ˟ ʡéϥ3Ԧ̓ÇӘӸԧӫӻӾҾҮҶ DDS Ӄ[7ʮŮʐ< 2 ˧ бӘӸԧӫӻӾҾҮҶ DDS. DDS QˠƍͬӃ͵uӈӃŮʐϾʫ, ƍͬźà.̑, pp. 331-336,ƍͬźà. (2017)ͺ͏ȩҚȟ ͏əҚˊĬƼʔҚĬǪ ǋ: ˢ 3 ˟ ʨԦ͢ºӈӃĩϾ 3 ԈӛԠԢԤϫӘ˹ǮҾҰӔɨ΁×ԔӝӨԢԁԧӿԠӘoʐҮҶ˱ĥʡɂʨ͢Ӄ̀ʱӽԟԆԟԧ, ԔӝӨԢԁԧӿԠӃ͵ύҾŮʐĩϾ,
ĸǔ8ʳF, pp. 129-134, ӰԧӡԖӰԧhɻ (2016)ͺ͏ȩҚĬǪп ǋ. ˢ 2 ˟ 2 ԔӝӨԢԁԧӿԠӘʐҠҶԐԍӺӿԦӸԤԇӨŲ͢ºӃȧ '×̀ʱ±͵uӃϾʫ. ȧ 'ԐԍӺӿ͢y͵, ήδK̑, pp. 73-79, ԗӽӜӤԠӿӞ
(2014)ͺ͏ȩҚĬǪп ǋ. ˢ 1 ˟ ˢ 3 ˧ ԔӝӨԢԁԧӿԠҾ͵uϾʫ [1] ɨ΁×ԔӝӨԢԁԧӿԠӘʐҠҶГ±Ų͢ɽӃ̀ʱ±ƳÁ. ɉě͢Ԧ̀£͵uӁ'ӗӔǁҮҠ͢uƐӽԆӝӲӃϾʫ, pp. 37-40, ƍͬźà. (2014)
Abu Lila A.S, Ishida T, Allen T.M, Liposomal nanomedicine, in Frontiers of Nanobiomedical
Research. Torchilin V.(Ed.) World Scientific, 1, pp.1-53 (2014)ͺ͏ȩҚĬǪп ǋ. ͵uāʮӛԍԢԧӺӁӑӔƶͪʢɂʨӃʿ˚ϾʫՎƑϫ uӃ DDS ϾʫҾƶͪʢɂʨӈӃŮʐՎ. ƶͪʢӃΉǀ/ɂʨӃĈɿҾƈʚ ʡƁԦԗӤԁӳԖӘӇӋҢҶϾʫƈʚ, ăDX#,ʖ̑А, pp.101-104 ƍͬźà. (2013)Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S13110359.

ͺ͏ȩҚĬǪп ǋ. бˮеʢɂʨ͢ԉӲԑӲԑԃԧӾӃ̮̀Ɛ× DDS ӃϾʫ. Ѝ£Ɛ͵uӃϾʫҾŮʐ―ȧ '×͢ºӃǁͻƐřƁӃϾƖӘʵƞҮҼ―, ĬǪп ǋʳF,
pp91-69, ӰԧӡԖӰԧhɻ (2013)10. ͺ͏ȩҚĬǪп ǋ. бˮеʢɂʨ͢ԉӲԑӲԑԃԧӾӃȧ '×̀ʱ±͵uӃϾʫ―ǁͻ;ȸŲԇӻӺӆԔӝӨԢԁԧӿԠӘʐҠҶ̀ʱ±ӰӲӼԖӃϾʫ―. Ѝ£Ɛ͵uӃϾʫҾŮʐ―ȧ '×͢ºӃǁͻƐřƁӃϾƖӘʵƞҮҼ―, ĬǪп ǋʳF, pp166-171,ӰԧӡԖӰԧhɻ (2013)11. ͺ͏ȩҚȟп ͏əҚˊĬƼʔҚĬǪп ǋ. ԈӛԠԢԤϫԔӝӨԢԁԧӿԠӘʐҠҶԐԍӺӿԦӸԤԇӨŲ͢ºӃ̀ʱ±͵uӃϾʫ. ŮʐҥƙҥӔ DDSՎ 7ʌåҤӒοȗԦčДӋҽՎ,Ėʑп ŔҚ ĸǔ8Қρп ÿҚɼϯXüҚ̆ʑ˰ϺҚͷϯп ƹ̑͜, pp. 389-394, NTS (2013).
12. ɲп ϏҚĠǛKðǥ. pH ŮˤŲӃ͢ɽӦԙԟӛԮϜ/üā MOOK n`ҝҫҫӋҽŇҥӔӿԞӻө Ţ ƴƍ ͬӃ Ǡs ̐Ԯ¤ ҨҼǁ ҮҠӿ Ԟӻ ө ӽԟԆ ԟ ԧ ӰӲӼԖ Ԩ DDSԩ Ҟ, ʑʘ ɊŚ ̑А ,pp.357-362, ȅő.ˇԗӽӜӤԠӿӞ(2013)Իā.ʫͯԼпӼԧԔԱ
1. ǳǪKȧϤҚÞп ȩƵҚ^ɓîʽҚïԥɴ˳üҚĤĵп Қ|ͥ1: ԔӟӲͬšйʦŲӝԡӟӲԘӽԠӃʡƁӁңҩӔ TRPM2 ӃŞx. ˢ 14 ÉǆǪɕ ˦ā.̍.āͬА. (ǲ)2018.2.
2. |ͥ1ҚԅԘӟӹп ԀԅԞҚ5ϯϕŭҚķĸʺǨҚǳǪKȧϤïԥɴ˳üҚȝ£¸ˎ: 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӃʡƁӁңҩӔӛԓӾԧӰӲҚ̽^˽͗¢ӃʜŁңӑӆɶʢŲӮӝӾӤӝԤӃŞx. ˢ 14 ÉǆǪɕ ˦ā.̍.āͬА. (ǲ) 2018.2.
3. ^ɓîʽҚãʼҚǳǪKȧϤҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: ԔӟӲ DDS Βΰî̽ɶԘӽԠӃʡƁӁңҩӔ TRPV1 ңӑӆ TRPA1 ӃŞx. ˢ 14 ÉǆǪɕ ˦ā.̍.ā
ͬА. (ǲ) 2018.2.
4. Nahla Hamouda, Tatsushi Sano, Masaki Shimakawa, Kenjiro Matsumoto, Kikuko
Amagase, Kazuhide Higuchi, Shinichi Kato: Pathogenic role of dysbiosis in thedevelopment of 5-fluorouracil-induced intestinal mucositis in mice. ˢ 14 ÉǆǪɕ ˦ā.̍.āͬА. (ǲ) 2018.2.
5. ^ɓîʽҚãʼҚǳǪKȧϤҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶԘӽԠӃʡƁӁңҩӔ TRPV1ҚTRPA1 ңӑӆʽͽˊ̀ӃŞxԺCGPR ңӑӆӮԌӲӸԤӲ P ҾӃЀώ. ǆǪ͢ā.ˢ 138 ń. (ϱɀ) 2018.3.
6. ǳΡǢľüҚ˄Ĭ|óҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: GPR40 ӃɍŲӁӑӔԔӟӲӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʫʎƏqңӑӆɂʪBϏǸ. ǆǪ͢ā.ˢ 138 ń. (ϱɀ), 2018.3.
7. sȣҡӒӒҚǳǪKȧϤҚ^ɓîʽҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: ԔӟӲî̽ɶЀώҥәӃʡƁӁңҩӔ Transient receptor potential vanilloid 4 (TRPV4)ӃЀ. ǆǪ͢ā.
ˢ 138 ń. (ϱɀ) 2018.3.
8. Anowara Khatun, ɰ ÜԬжУąŜԬĸ£ʺʒԬͥǪʒԬ ̟ϭĈԬͥȩŨԬîʼ ϏԺ
Antiandrogen-induced protein degradation of Ca2+-activated K+ channel KCa1.1 in humanbreast cancer cellԮǆǪ͢ā. 138 ń.Ԩϱɀԩ 2018.3.
9. ĠǶµŃԬжУąŜԬîʼ ϏԬͥȩŨԺӛӾԊԧŲʱ̀ɶԘӽԠԔӟӲʒǱͯʱ˽̱ӁңҩӔ TSLP ϓwʏʎȤȚӃ΁ǵԮǆǪ͢ā. 138 ń.Ԩϱɀԩ 2018.3
10. ăŷʺԬɡπDŭԬȥɒԬ ķЏŅԬîʼ ϏԬͥȩŨԺC57BL/6 ԔӟӲӘʐҠҶƂŲƨʣԘӽԠӃ˃˝ԮǆǪ͢ā. 138 ń.Ԩϱɀԩ 2018.3

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

11. ǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԔӟӲî̽ɶңӑӆî̽ɶЀώʫҥәӁңҩӔͪ˦^ʱ˽̱ʫʆ TRPV4 ӃЀ. ˢ 35 ÉӮӝӾԍԢӼӨӰԝԤʿ˚. (ϧ) 2017.3.
12. ǳǪKȧϤҚ^ɓîʽҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: î̽ɶңӑӆî̽ɶЀώʫʩӁңҩӔͪ˦^ʱ TRPV4 ӃЀ. ˢ 90 ÉǆǪ͢ʈā.ń. (ϼĵ) 2017.3.
13. ^ɓîʽҚãʼҚǳǪKȧϤҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: î̽ɶӃʡƁӁңҩӔ TRPV1 ңӑӆ TRPA1 ӃŞx. ˢ 90 ÉǆǪ͢ʈā.ń. (ϼĵ) 2017.3.
14. ɚͺăľҚǳǪKȧϤҚ^ɓîʽҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: î̽ɶңӑӆî̽ɶЀώҥәӃʡƁӁңҩӔ TRPV4 ӺԙԃԠӃЀ. ǆǪ͢ā.ˢ 137 ń. (&¦) 2017.3.
15. |˵ÆðϤҚħЮ͘üҚĆǪĢüҚ ːҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1:Helicobacter pylori Βΰ̯˯́ʡéӁėҰӔөԠӸԕԤϫӃDΠǸ. ǆǪ͢ā.ˢ 137 ń. (&¦) 2017.3.
16. |ͥèʺҚ^ɓîʽҚãʼҚǳǪKȧϤҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: î̽ɶӃʡƁӁңҩӔ TRPV1 ңӑӆ TRPA1 ӺԙԃԠӃŞx. ǆǪ͢ā.ˢ 137 ń. (&¦)
2017.3.
17. ĠĸɢüҚǳǪKȧϤҚïԥɴ˳üҚÞп ȩƵҚĤĵп Қ|ͥ1: ͬšйʦŲӝԡӟӲӃʡƁӁңҩӔ TRPM2 ӺԙԃԠӃȤ̲΁ǵ. ǆǪ͢ā.ˢ 137 ń. (&¦) 2017.3.
18. ȣǪóʎüҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: GPR35 ӰөԀԠӘ#ҮҶî̽ʱFŦBϏңӑӆî̽ɶƏq8ʐ. ǆǪ͢ā.ˢ 137 ń. (&¦) 2017.3.
19. ˄Ĭ|óҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: GPR40 ɍŲ ӁӑӔԔӟӲӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӁėҰӔDΠʮŞx. ǆǪ͢ā.ˢ 137 ń. (&¦)
2017.3.
20. Shinichi Kato, Nahla Hamouda, Daichi Utsumi, Takuya Tsukahara, Kenjiro Matsumoto,
Kikuko Amagase: Sequential Role of Apoptosis, Gram-negative Enterobacteria, andInflammatory Cytokines in the Pathogenesis of 5-Fluorouracil-induced Intestinal Mucositis
in Mice. Experimental Biology (Chicago, USA), 2017.4.
21. Kenjiro Matsumoto, Daichi Utsumi, Kikuko Amagase, Makoto Tominaga, Shinichi Kato:Transient receptor potential vanilloid 4 (TRPV4) regulates vascular endothelial
permeability during colonic inflammation in dextran sulfate sodium-induced murine colitis.
Experimental Biology (Chicago, USA) 2017.4.
22. Takuya Tsukahara, Nahla Hamouda, Daichi Utsumi, Kenjiro Matsumoto, Kikuko Amagase,
Shinichi Kato: G Protein- Coupled Receptor 35 Signaling Promotes Mucosal Repair via
Migration of Colonic Epithelial Cells in Mice. Experimental Biology (Chicago, USA)2017.4.
23. Daichi Utsumi, Kenjiro Matsumoto, Takuya Tsukahara, Kikuko Amagase, Makoto
Tominaga, Shinichi Kato: Potential Role of Transient Receptor Potential Vanilloid 1 andAnkyrin 1 in Colonic Inflammation in Dextran Sulfate Sodium (DSS)- induced Murine
Colitis. Experimental Biology (Chicago, USA) 2017.4.
24.
ϯƖ»ҚǳǪKȧϤҚïԥɴ˳üҚÞп ȩƵҚĤĵп Қ|ͥ1: ͬšйʦŲӝԡӟӲӃʡƁӁңҩӔ TRPՁ2 ӃŞx. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2017 (ϧ) 2017.8.
25. ǳÔϭȿüҚĮʑȿʽҚķĸʺǨҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔԉԋӜӳӲ͗ G9-1 ȅӃǸ. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2017 (ϧ)2017.8.
26. Ɔɴп ÓҚǳǪKȧϤҚ^ɓîʽҚïԥɴ˳üҚĒȹʺʉҚ|ͥ1: ԔӟӲͪ˦^ʱ
TRPV4 ӄӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӃϏͫӁЀҰӔ. ʎ7Ȥ̲Ҿy͢Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

27.
28.

29.
30.

31.

32.

33.

34.

35.
36.

37.

38.

39.
40.

41.

42.

261006
S1311035ӰԤԓӱӟԖ 2017 (ϧ) 2017.8.
Ʌп îÔҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: GPR35 ɍŲ ӄî̽ʱϑίBϏ8ʐӘ#ҮҼî̽ɶӘƏqҰӔ. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2017 (ϧ) 2017.8.
^ɓîʽҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԔӟӲ DDS Βΰî̽ɶԘӽԠ
ӃʡƁӁңҩӔ TRPV1 ңӑӆ TRPA1 ӃŞx. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ
2017 (ϧ) 2017.8.
ɚͺăľҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: î̽ɶЀώҥәӃͪ˦ǁʎqťӁңҩӔ
TRPV4 ӃЀ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2017 (ϧ) 2017.8.
ċÑ9ȫҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: GPR40 ɍŲ ӁӑӔԔӟӲî̽ʱ˽̱ӃNČFŦBϏ8ʐ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2017 (ϧ)2017.8.
ãʼҚ^ɓîʽҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: GPR40 ɍŲ ӁӑӔԔӟӲӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӁėҰӔDΠʮŞx. ˢ 45 ÉǆǪɯʧā. (ϧ)2017.11.
^ɓîʽҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԔӟӲӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶԘӽԠӃʡƁӁңҩӔ TRPV1 ңӑӆ TRPA1 ӃŞx. ˢ 45 ÉǆǪɯʧā.
(ϧ) 2017.11.
Hamouda NahlaҚ5ϯϕŭҚķĸʺǨҚǳǪKȧϤҚïԥɴ˳üҚȝ£¸ˎҚ|ͥ1:Apoptosis, dysbiosis, and expression of inflammatory cytokines are sequential events inthe occurrence of 5- fluorouracil-induced intestinal mucositis in mice. ˢ 45 ÉǆǪɯʧā. (ϧ) 2017.11.
Miki Matsui, Susumu OhyaԺThe role of Ca2+-activated K+ channel KCa3.1 in mesentericlymph node CD4+ T cells of chemically-induced murine inflammatory bowel diseasemodelԮǆǪTʟā.Ԩ&¦ԩ2017.12.
îʼ ϏԬͥǪʒԬжУąŜԬϘͥüԬǳǩǱԬ ̟ϭĈԺʩ˽̱ӁңҩӔӨԢԞӝӿӺԙԃԠЃČӁӑӔԈӾʱƆϼÊü¡Ď7 HER2 ηbƏqԮConBio 2017ԨˊƉԩ 2017.12.
ϘͥüԬлĸӀҺ̜ԬҶҧҮ¸ЉԬɝȸśêԬжУąŜԬ ̟ϭĈԬͥȩŨԬîʼ ϏԺ
two-pore ×ӤԟӟԖӺԙԃԠ K2P5.1 ӲԍԞӝӲԆԟӛԤӾӃ­ćҾɍŲ T ԟԤԇʇӁңҩӔ
pre-mRNA ӲԍԞӝӰԤөЃČuӁӑӔ K2P5.1 ɍŲƏqԮConBio 2017ԨˊƉԩ 2017.12.
Anowara KhatunԬɰ ÜԬжУąŜԬĸ£ʺʒԬͥǪʒԬ ̟ϭĈԬͥȩŨԬîʼ ϏԺ
Protein degradation of KCa1.1 K+ channel by androgen receptor inhibition in breast cancer
cellsԮˢ 132 ÉǆǪ͢ʈā.τʝϥ.ԨîЂԩ 2017.11.
ͥȩŨԬɏϯ̅ϭЮԬîˊś9Ԭ̜ɘϧüԬɡπDŭԬîʼ ϏԺӛӾԊԧŲʱ̀ɶԘӽԠԔ
ӟӲӃƨʣțͫӁңҩӔ allopregnanolone (ALLO) ӃЀԮˢ 132 ÉǆǪ͢ʈā.τʝϥ.ԨîЂԩ 2017.11.
ͥȩŨԬȌˉóԬˡ^Џ§Ԭîʼ ϏԺӛӾԊԧŲʱ̀ɶԔӟӲӃ phenobarbital ΒʫƨʣͫӁңҩӔ̸^ AMPA ¡Ď7ӃЀԮˢ 27 ÉÎЌʣӌӰԤԓӱӟԖԨǲԩ 2017.11.
ĸ£ʺʒԬAnowara KhatunԬɰ ÜԬͥǪʒԬжУąŜԬ ̟ϭĈԬîʼ ϏԺʩ˽̱ӁңҩӔƑӛԤӿԢӫԤuӁӑӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa1.1 ɍŲƏqȤȚӃ΁ǌԮˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.ԨZŎԩ 2017.10.
ϼΡĸȢԬǳǩǱԬжУąŜԬîʼ ϏԺԈӾ T ԟԤԇʇʒǱ HUT-78 ˽̱ӁңҩӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa3.1 ɍŲ uӁӑӔƑɶʢŲӮӝӾӤӝԤ IL-10 ʫʆԦʏʎƏqԮˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.ԨZŎԩ 2017.10.
îʼ ϏԬͥǪʒԬжУąŜԺʩ˽̱ӁңҩӔƑӛԤӿԢӫԤuӁӑӔӤԠӰӟԖɍŲ ӤԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

43.
44.

45.

46.

47.
48.

49.
50.

51.

52.

53.

54.

55.

56.

57.

58.

261006
S1311035ԟӟԖӺԙԃԠ KCa1.1 ʫʆƏqԮˢ 76 ÉǆǪʩā.āͬА.ԨȠɐԩ 2017.9.
ͥǪʒԬжУąŜԬîʼ ϏԺԈӾʩ˽̱æȮӁңҩӔ HER2 ηbqťӁėҰӔӨԢԞӝӿӺԙԃԠӃĐԮˢ 76 ÉǆǪʩā.āͬА.ԨȠɐԩ 2017.9.
ǳǩǱԬĖɰǭüԬжУąŜԬ ̟ϭĈԬϳǨÿˌԬîʼϏԺԈӲӾԤ̷ӛӴӺԠ Ϫ˹Ӂӑ
Ӕ CD4 ЈŲ T ˽̱ӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠηbԦɍŲqťԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2017Ԩϧԩ 2017.8.
ĸ£ʺʒԬAnowara KhatunԬɰ ÜԬͥǪʒԬжУąŜԬ ̟ϭĈԬîʼ ϏԺʩ˽̱ӁңҩӔӛԤӿԢӫԤ¡Ď7Ә#ҮҶӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa1.1 ӃʫʆԦɍŲqťԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2017Ԩϧԩ 2017.8.
ĠǶµŃԬĬʑʒ͊ЮԬǳoȻüԬîʼ ϏԬͥȩŨԺӛӾԊԧŲʱ̀ɶԔӟӲʒǱͯʱ˽
̱ӁңҩӔ TSLP ϓwʏʎȤȚӃ΁ǵԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2017Ԩ
ϧԩ 2017.8.
ăŷʺԬɡπDŭԬîʼ ϏԬͥȩŨԺC57BL/6 ԔӟӲӘʐҠҶƂŲƨʣԘӽԠӃ˃˝Ԯ
ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2017Ԩϧԩ 2017.8.
ϘͥüԬĸʑľĽԬî¸O#Ԭ5ͥĘ§ԬжУąŜԬîʼ ϏԮpH ſ¡ŲӤԟӟԖӺԙԃԠ
K2P5.1 ́«ӸԤԇӨ CD81 Ӄ­ćҾ CD81 ӁӑӔ K2P5.1 Ȥ̲qťԮ ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2017Ԩϧԩ 2017.8.
îʼ ϏԺɶʢŲʠŸӃy͢ȞʮҾҮҼӃӤԟӟԖӺԙԃԠԮʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ
2017Ԩϧԩ 2017.8.
ͥǪʒԬЉɒԬжУąŜԬ ̟ϭĈԬǯǨSŚԬîʼ ϏԺԈӾʩ˽̱æȮӁңҩӔӨ
ԢԞӝӿӺԙԃԠӃŞxҾӨԢԞӝӿӺԙԃԠЃČӁӑӔ HER2 ηbƏqԮˢ 131 ÉǆǪ͢ʈā.τʝϥ.Ԩ®¤Ĩԩ 2017.6.
ǳǩǱԬĖɰǭüԬǯıȿ|ԬǯɴĈľԬжУąŜԬ ̟ϭĈԬͥȩŨԬϳǨÿˌԬîʼ ϏԺԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČuӁӑӔ CD4 ЈŲ T ˽̱ӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠӃηbԦɍŲƏqԮˢ 131 ÉǆǪ͢ʈā.τʝϥ.Ԩ®¤Ĩԩ 2017.6.
îʼ ϏԬAnowara KhatunԬͥǪʒԬ ̟ϭĈԬжУąŜԬϳǨÿˌԺʩ˽̱ӁңҩӔԉ
ӸԕԤ D ¡Ď7ӛӭԁӲӾӁӑӔ Ca2+ɍŲ K+ӺԙԃԠ KCa1.1 ʫʆԦɍŲqťȤȚӃ΁ǌԮˢ
94 ÉǆǪʎʈā.î.Ԩɐǳԩ 2017.3.
Anowara KhatunԬͥǪʒԬ ̟ϭĈԬжУąŜԬϳǨÿˌԬîʼ ϏԺʩ˽̱ӁңҩӔԉ
ӸԕԤ D ¡Ď7Ә#ҮҶӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa1.1 ʫʆԦɍŲqťԮǆǪ͢ā.ˢ 137 ń.Ԩ&¦ԩ 2017.3.
ɰ ÜԬAnowara KhatunԬжУąŜԬ ̟ϭĈԬϯˉϭԬ ÏʹȎ͙Ԭîʼ ϏԺԈӾʩ˽̱ӁңҩӔƑӛԤӿԢӫԤuӁӑӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa1.1 ɍŲqťԮǆǪ͢ā.ˢ 137 ń.Ԩ&¦ԩ 2017.3.
ĖɰǭüԬǳǩǱԬǯıȿ|ԬǯɴĈľԬжУąŜԬ ̟ϭĈԬϳǨÿˌԬîʼ ϏԺԔӟ
Ӳ T ˽̱ӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČӁӑӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ
KCa3.1 ηbƏqԮǆǪ͢ā.ˢ 137 ń.Ԩ&¦ԩ 2017.3.
ʑ ɗԬҶҧҮ¸ЉԬɝȸśêԬϘͥüԬжУąŜԬ ̟ϭĈԬͥȩŨԬîʼ ϏԺɍŲT ˽̱ӁңҩӔ pre-mRNA ӲԍԞӝӰԤөЃČuӁӑӔӤԟӟԖӺԙԃԠ K2P5.1 ʫʆԦɍŲqťԮǆǪ͢ā.ˢ 137 ń.Ԩ&¦ԩ 2017.3.
Anowara KhatunԬɰ ÜԬϯˉϭԬ ÏʹȎ͙Ԭ ̟ϭĈԬжУąŜԬͥǪʒԬîʼϏԺԈӾʩ˽̱ӁңҩӔƑӛԤӿԢӫԤuӁӑӔ Ca2+ɍŲ K+ӺԙԃԠ KCa1.1 ʫʆԦɍŲqťԮˢ 90 ÉǆǪ͢ʈā.ń.Ԩϼĵԩ 2017.3.
ͥǪʒԬЉɒԬжУąŜԬ ̟ϭĈԬϳǨÿˌԬǯǨSŚԬîʼ ϏԺԈӾʩ˽̱ӁңԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

59.
60.

61.

62.
63.
64.
65.
66.

67.

68.
69.

70.

71.
72.
73.

74.

75.

261006
S1311035

ҩӔ Ca2+ɍŲ Cl-ӺԙԃԠ ANO1 ЃČӁӑӔ HER2 ηbƏqԮˢ 90 ÉǆǪ͢ʈā.ń.
Ԩϼĵԩ 2017.3.
îʼ ϏԺɶʢŲ̽ʠŸԘӽԠӃ T ˽̱Ȥ̲ӁңҩӔӤԟӟԖӺԙԃԠӃʡƁʎʈāʮŞxԮˢ 90 ÉǆǪ͢ʈā.ń.Ԩϼĵԩ 2017.3.
ǳǩǱԬĖɰǭüԬǯıȿ|ԬǯɴĈľԬжУąŜԬ ̟ϭĈԬϳǨÿˌԬîʼ ϏԺԔӟ
Ӳ CD4 ЈŲ T ˽̱ӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČӁӑӔ Ca2+ɍŲ
K+ӺԙԃԠ
KCa3.1 ηbƏqԮˢ 90 ÉǆǪ͢ʈā.ń.Ԩϼĵԩ 2017.3.
ϘͥüԬҶҧҮ¸ЉԬɝȸśêԬжУąŜԬ ̟ϭĈԬîʼ ϏԺԔӟӲɍŲ
CD4 ЈŲ˽̱ӁңҩӔ pre-mRNA ӲԍԞӝӰԤөЃČu pladienolide B ӁӑӔ two-pore × K+ӺԙԃԠ
K2P5.1 ʫʆԦɍŲqťԮˢ 90 ÉǆǪ͢ʈā.ń.Ԩϼĵԩ 2017.3.
ȠΡ˩ҚǶʶȢҚšͥʶȩҚĠʑʺЉ. ̎͂͗ӁӑӔԖӺԤīωϓӁҢӔӮӝӾӤӝԤӃŝ
Н. ˢ 29 ÉŧʎɽӰԤԓӱӟԖ (Ňĳ) 2017. 8
ǶʶȢҚšͥʶȩҚĠʑʺЉ. ̽˦ʱ˽̱ҥ̎͂͗ӁӑӔԖӺԤīωϓӘϏҰӔԗӤԁӳԖӃ΁ǵ. ŃƆ 29 ńŌτʝ̽˦ŧʎɽʿ˚.̍.Ԧʿ˚ʫͯ. (îЂ) 2017. 6
ǶʶȢҚšͥʶȩ. Pseudomonas aeruginosa injects type III effector ExoS into host cells
through the retraction of type IV pili. ˢ 90 ÉǆǪ˽͗ā.̍. (&¦) 2017. 3
ǶʶȢҚšͥʶȩ. ̎͂͗ PAO1 ȅҥÛЬʱ˽̱ӘſʽҰӔԗӤԁӳԖӃ΁ǵ. ˢ 51 É̎͂͗ſǼʢʿ˚. (îi) 2017.2
Ʌп ЎǥҚĒȹп ͤҚ͓ĸʺ͚ҚċǪǌǆЮҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԉԋӜӳӲ͗Ӄ 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔƏqǸ. ˢ 89 ÉǆǪ͢ʈā.ń. (Ƞɐ)
2016.3.
ϯǯPȢҚǬɑп ̦Қĸǯп ˂ҚɁśüҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠңӑӆӝԟԄӼӤԤΒΰ̽ɶӃʡƁӁңҩӔӛԓӾԧӰӲΒğȤȚӃʷϖ. ˢ 89 ÉǆǪ͢ʈā.ń. (Ƞɐ) 2016.3.
ǐĬʒ÷Қͷп CǌҚρ¥͘üҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ƑҥәuΒΰ̽ɶӃʡƁӁңҩӔ̽^˽͗ӃЀ. ˢ 89 ÉǆǪ͢ʈā.ń. (Ƞɐ) 2016.3.
п KҚǳǪKȧϤҚ^ɓîʽҚ^ʑϢƵҚĒȹʺʉҚïԥɴ˳üҚ|ͥ1: ͪ˦^ʱ˽̱ӁʫʆҰӔ TRPV4 ԔӟӲӽӦӲӾԞԤˁϫΒʫî̽ɶӃϏͫӁЀҰӔ. ˢ 89 ÉǆǪ͢ʈā.ń. (Ƞɐ) 2016.3.
îΡп śҚǳǪKȧϤҚʑķX Қïԥɴ˳üҚÞȻCɂҚ|ͥ1: ԞӻӾɕ ˦ӁңҩӔ
TRPM2 ӺԙԃԠӃʫʆҾ TNBS Βΰ^̓ʤͽϓƵҾӃЀ. ˢ 89 ÉǆǪ͢ʈā.ń.
(Ƞɐ) 2016.3.
|ͥ1ҚǶп µ8ҚǳǪKȧϤҚïԥɴ˳üҚϽ̴п ʺ: Ƒҥәu 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔǾ͋ɦӃǸ. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
^ɓîʽҚǳǪKȧϤҚïԥɴ˳üҚÞȻCɂҚ|ͥ1: ӴԢӾԁԤ/5-HT3 ¡Ď7ӘȞʮҾҮҶɕ ˦ɶʢqťӈӃŮʐ. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
ρҟҤӓҚ5ϯϕŭҚǯ ŷȢҚ˒п ǣüҚǳǪKȧϤҚïԥɴ˳üҚȝ£¸ˎҚ|ͥ1:5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔԞԋӺӱԤӃʽͽˊ̀Ә#ҮҶƏqǸ. ǆǪ͢ā.
ˢ 136 ń. (Ƞɐ) 2016.3.
ħЮ͘üҚċǪǌǆЮҚʑǯʽɮҚ|˵ÆðϤҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԉԋӜӳӲ͗Ӄ 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔǢʐŲ. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ)
2016.3.
Daichi Utsumi, Kenjiro Matsumoto, Kikuko Amagase, Makoto Tominaga, Shinichi Kato:
Potential role of transient receptor potential ankyrin 1 (TRPA1) in colonic inflammation inԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

76.

77.

78.

79.

80.

81.

82.
83.

84.
85.

86.
87.
88.

89.

261006
S1311035

dextran sulfate sodium (DSS) – induced murine colitis. American Gastroenterological
Association (SanDiego, USA) 2016.5.
Takuya Tsukahara, Nahla Hamouda, Daichi Utsumi, Kenjiro Matsumoto, Kikuko Amagase,
Shinichi Kato: G protein-coupled receptor 35(GPR35) contributes to mucosal healing inmouse colonic epithelial cells.
American Gastroenterological Association (San Diego,
USA) 2016.5.
Kenjiro Matsumoto, Daichi Utsumi, Kikuko Amagase, Makoto Tominaga, Shinichi Kato:Transient receptor potential vanilloid 4(TRPV4) regulates vascular endothelial permeability
during colonic inflammation in dextran sulfate sodium(DSS)- induced murine colitis.
American Gastroenterological Association (San Diego, USA) 2016.5.
Shinichi Kato, Nahla Hamouda, Tatsushi Sano, Kikuko Amagase, Kazuhide Higuchi:
Sequential role of apoptosis, gram-negative enterobacteria, and inflammatory cytokines in
the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. American
Gastroenterological Association (San Diego, USA) 2016.5.
ĬĵҭӐҤҚãʼҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: G ӸԤԇӨYŞ×¡Ď7
GPR35 Ӄî̽ʱ˽̱ӁңҩӔNČFŦӘBϏҰӔ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2016 (ċÙ) 2016.8.
ǯ ŷȢҚǐĬʒ÷ҚϯǯPȢҚρп ҟҤӓҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӃʡƁӁңҩӔӛԓӾԧӰӲҚ̽^˽͗ңӑӆɶʢŲӮӝӾӤӝԤӃŞx.
ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2016 (ċÙ) 2016.8.
ĸ ½ľҚǳǪKȧϤҚ^ɓîʽҚĒȹʺʉҚïԥɴ˳üҚ|ͥ1: ԔӟӲӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔͪ˦^ʱ TRPV4 ӃŞx. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2016 (ċÙ) 2016.8.
ãʼҚ^ɓîʽҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: G ӸԤԇӨYŞ×¡Ď7 GPR35Ӄî̽ʱ˽̱ӃϑίӁңҩӔŞx. ˢ 44 ÉǆǪɯʧā. (ɓϔ), 2016.9.
|ͥ1Қ^ɓîʽҚǳǪKȧϤҚïԥɴ˳ü: ӴԢӾԁԤ/5-HT3 ¡Ď7ңӑӆӮԌӲӸԤӲ P/NK1 ¡Ď7ӘȞʮҾҮҶɕ ˦ɶʢqťӈӃŮʐ. ˢ 44 ÉǆǪɯʧā. (ɓϔ)
2016.9.
ǳǪKȧϤҚîΡп śҚïԥɴ˳üҚÞп ȩƵҚĤĵп Қ|ͥ1: ͬšйʦŲӝԡӟӲ
ԨPOԩӃʡƁӁңҩӔ TRPM2 ӃȤ̲. ˢ 18 ÉǆǪˊ̀ɕ Çʡā. (ɓϔ) 2016.9.
ԅԘӟӹп ԀԅԞԨNahla HamoudaԩҚǐĬʒ÷ҚϯǯPȢҚĸɋˉҚĤĵп ŪҚķĸʺǨҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: Pathogenic Role of Apoptosis, Enterobacteria, andCytokines in 5-FU-induced Intestinal Mucositis. ˢ 130 ÉǆǪ͢ʈā.τʝϥ. (ϧ)
2016.11.
Ohgita T, Fukuda K, Momiyama K, Hayashi N, Gotoh N, Saito H. ˽͗×iɆͲ̚ӃÉη
ϒӁӑӔӡԋӠӨӸԧνχӃqť. ˢ 54 ÉǆǪʎɽɽʈā.î.(ҺҨӅ) 2016.11
ȹĬ͏ɂҚͷǪǌ{ҚĠǛKðǥҚƾͥŅҚɲ ϏԮ4ϫ˹ʌåӃҥә˽̱ӁңҩӔ^ʱԟԇԧӵϜ/üӃʫʆæî. ˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.(îЂ) 2016.10
ƋʑЉ©ҚǶ ʶȢҚˍʑǉŃҚˬĬüҚšͥʶȩҚƾͥŅԮ˽͗×iɆͲ̚ӃӡԋӠӨ
ӸԧνχȤȚ΁ǌӃҶӎӃÉηԭiɆʷЀӃȖ΅. ˢ 14 Éȧ 'Әƕҡ͍ƌӃҶӎӃԋӜӱ
ӤԠԦԋӚԧԔԋӢԧԞԖ PPF2016(îЂ) 2016.8
ƋʑЉ©ҚǶ ʶȢҚĸ ̡ҚˬĬüҚˍʑǉŃҚĠǛKðǥҚšͥʶȩҚƾͥŅԮ˽͗
×iɆȤȚӃ΁ǌӘʵƞҮҶiɆͲ̚ӃÉηԭiɆʷЀӃȖ΅. ˢ 11 ÉӾԞԤӲԓԧӸԧʿ˚.ń.(ϧ) 2016.7

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

90. ƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥҚƾͥŅ:ԮӸԤԇӨέiɆӃǁͻԟӛԠӸӝԖ΋?˲ӘʐҠҶ˽͗×iɆԗӤԁӳԖӃȖ΅. ǆǪ́ā.ˢ 38 ń.(ǲ) 2016.5
91. ƋʑЉ©Қĸ ̡ҚˬĬüҚǶ ʶȢҚšͥʶȩҚĠǛKðǥԮ˽̱×iɆȤȚӃ΁ǌӘʵƞҮҶӡԋӠӨӸԧiɆӃćϰ΋?. ǆǪ͢ā.ˢ 136 ń.(Ƞɐ) 2016.3
92. ƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥԮ×iɆȤȚӃ΁ǌӘʵƞҮҶiɆͲ̚ӃӡԋӠӨӸԧiɆόŌӃćϰ΋?. ˢ 89 ÉǆǪ˽͗ā.̍.ԨîЂԩ2016.3
93. ĸ ̡ҚƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥԮ̎͂͗ҾԟԓӶԧԖӃɽʈʮƥ΂ҥ
×iɆӰӲӼԖӁӊҰŝНӃȖ΅. ˢ 89 ÉǆǪ˽͗ā.̍.ԨîЂԩ 2016.3
94. ͷǪǌ{Қɲ ϏҚ ǯ-²ҚȊ̞¸ҚˍǪ āҚĠǛKðǥ. 4ϫ˹ʌåӃ̈́ňʮƴě̤̐Ųʩ˽̱ӁңҩӔԕӾӬԤӿԟӛӃӸԧԤӣԧԆԧӃɍŲ ԮǆǪ͢ā.ˢ 136 ń.ԨȠɐԩ 2016.3
95. Anowara Khatun Ԭ ̟ ϭ Ĉ Ԭ ͥ Ǫ  ʒ Ԭ ж У ą Ŝ Ԭ î ʼ Ϗ Ժ Downregulation of
Ca2+-activated K+ channel KCa1.1 by vitamin D in human breast cancer cellsԮˢ 130 ÉǆǪ͢ʈā.τʝϥ.Ԩϧԩ 2016.11.
96. ͥǪʒԬЉɒԬжУąŜԬ ̟ϭĈԬîʼ ϏԺԈӾʩ˽̱ӁңҩӔӨԢԞӝӿӺԙԃԠЃČӁӑӔʱƆϼÊü¡Ď7 HER2 ηbƏqԮˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.ԨîЂԩ 2016.10.
97. ɰ ÜԬϯˉϭԬ Ïʹo͙ԬжУąŜԬAnowara KhatunԬ ̟ϭĈԬîʼ ϏԺӛԤӿԢӫԤ¡Ď7ЈŲԈӾʩ˽̱ӁңҩӔƑӛԤӿԢӫԤuӁӑӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa1.1 ηbƏqԮˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.ԨîЂԩ 2016.10.
98. îʼ ϏԬͥǪʒԬжУąŜԺԈӾʩ˽̱ȅӁңҩӔ Cl-ӺԙԃԠӁӑӔʱƆϼÊü¡Ď
7 HER2 ηbqťԮˢ 75 ÉǆǪʩā.āͬ̍.ԨȠɐԩ 2016.10.
99. Anowara KhatunԬϯˉϭԬ ÏʹȎ͙Ԭ ̟ϭĈԬжУąŜԬîʼ ϏԺInvolvement of
KCa1.1 K+ channel in vitamin D-induced prevention of breast cancer cell proliferationԮʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2016Ԩ&¦ԩ 2016.8.
100. ǳǩǱԬ!ɹąȢԬǾĮϭóԬĬʑЉŔԬɡπ̃МԬжУąŜԬͥȩŨԬîʼ ϏԺɶʢŲ̽ʠŸԘӽԠԔӟӲqťŲ T ˽̱ӁңҩӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠ KCa3.1 ЃČuƐӁӑӔ IL-10 ηbBϏԮˢ 129 ÉǆǪ͢ʈā.τʝϥ.ԨŇĳԩ2016.6.
101. ǯɴĈľԬ H5¸Ԭǯıȿ|Ԭ5ͥп ̌ԬϘͥüԬжУąŜԬͥȩŨԬîʼ ϏԺӽӦӲӾԞԤˁϫԀӾԟӟԖΒʫŲɶʢŲ̽ʠŸԘӽԠԔӟӲӃ CD4 ЈŲ T ˽̱ӁңҩӔ̰ǕӤԟӟԖӺԙԃԠ K2P5.1 ӃʫʆԦɍŲæîҾ K2P5.1 ԄӻӨӛӟӾӁӑӔʢɿӃθɠԮǆǪ͢ā.ˢ
136 ń.ԨȠɐԩ2016.3.
102. ͥǪʒԬǳ͛˷'ԬЉɒԬжУąŜԬîʼ ϏԺʱæȮÊü¡Ď7 HER2 ЈŲԈӾʩ˽̱ӁңҩӔӤԠӰӟԖɍŲ ӨԢԞӝӿӺԙԃԠ ANO1 ЃČӁӑӔ HER2 ηbƏqԮǆǪ͢ā.ˢ 136 ń.ԨȠɐԩ2016.3.
103. ҶҧҮ¸ЉԬɝȸśêԬϘͥüԬжУąŜԬͥȩŨԬîʼ ϏԺɍŲ CD4 ЈŲ T ˽̱ӁңҩӔӲԍԞӝӰԤөЃČuӁӑӔ̰Ǖ K+ӺԙԃԠ K2P5.1 ɍŲqťԮǆǪ͢ā.ˢ 136 ń.
ԨȠɐԩ2016.3.
104. îʼ ϏԬǳ͛˷'ԬЉɒԬ Ïʹo͙ԬͥǪʒԺʱæȮÊü¡Ď7 HER2 ЈŲʩ˽̱ӁңҩӔӤԠӰӟԖɍŲ ӨԢԞӝӿӺԙԃԠ ANO1 ЃČӁӑӔ HER2 ηbƏqԮˢ 89ÉǆǪ͢ʈā.ń.ԨȠɐԩ 2016.3.
105. ϘͥüԬҶҧҮ¸ЉԬɝȸśêԬжУąŜԬͥȩŨԬîʼ ϏԺT ˽̱ӁңҩӔ pre-mRNAӲԍԞӝӰԤөЃČuӁӑӔ̰ǕӤԟӟԖӺԙԃԠ K2P5.1 ɍŲƏqԮˢ 89 ÉǆǪ͢ʈā.ń
.ԨȠɐԩ 2016.3.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

106. ʬ5ǐ͘ҚǳǪKȧϤҚïԥɴ˳üҚÞп ȩƵҚĤĵп Қ|ͥ1: ͬšйʦŲӝԡӟӲӃʡƁӁңҩӔ TRPM2 ӃȤ̲΁ǵ. ˢ 130 ÉǆǪ͢ʈā.τʝϥ. (ϧ) 2016.11.
107. ȠΡ˩ҚǶʶȢҚͷɰɟҚˍͷǗҚĬǪǋ̜Қšͥʶȩ. ʱ˽̱ҥ̎͂͗ӁӑӔԖӺԤīωϓӘϏҰӔȤȚӃ΁ǵ. ˢ 6 É 4 îāώƯԋӢԧԞԖ (ϧ) 2016. 12.
108. ǶʶȢҚšͥʶȩ. ʱ˽̱ӘſʽҮҶ̎͂͗ҥԖӺԤīӘωϓҰӔȤȚӃ΁ǵ. ˢ 64 ÉǆǪ āʨɇā.ͷǆǪƲϥ̍. ˢ 59 ÉǆǪſǼʢā. ǆǪÔǂ.āͬА. ˢ 86 ÉǆǪſǼʢͷǆǪÔǂ.āͬА. «­ā. (Ⱦ̓) 2016. 11.
109. ǶʶȢҚšͥʶȩ. ̎͂͗ҥ̽˦ʱ˽̱ӘſʽҰӔԗӤԁӳԖӃ΁ǵ. ŃƆ 28 ńŌ τʝ̽˦ŧʎɽʿ˚.̍.Ԧʿ˚ʫͯ. (îЂ) 2016. 6.
110. Hayashi N and Gotoh N. Translocation of Pseudomonas aeruginosa through the epithelial
cell layer. The 13th Korea - Japan International Symposium on Microbiology. (Korea)
2016. 5.
111. ǶʶȢҚšͥʶȩ. Pseudomonas aeruginosa ҥʱ˽̱ӘſʽҰӔȤȚӃ΁ǵ. ˢ 90 ÉǆǪſǼʢā.āͬΜɫ. (&¦) 2016. 4.
112. ȠΡ˩Қ¤ǞŭӋӓüҚˍͷǗҚĬǪǋ̜ҚǶʶȢҚšͥʶȩ. ̽˦ʱ˽̱ҥ̎͂͗ӁӑӔԖӺԤīωϓӘϏҰӔȤȚӃ΁ǵ. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
113. ǳʶҚÈǂÜÅҚʾĬśóҚsĸ́ҚǶʶȢҚšͥʶȩ. ̎͂͗ҥ III ×ӡԋӠӨӸԧExoSӘʱ˽̱^ӁɉUҰӔҶӎӁŬ͸Ӏ IV ×̐ȵӃȤ̲΁ǵ. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ)
2016.3.
114. ˍͷǗҚĬǪǋ̜Қ¤ǞŭӋӓüҚȓʑʹʒҚȠΡ˩ҚǶʶȢҚšͥʶȩ. ̽˦ʱ˽̱ӃiɆɽέӄ̎͂͗ӁӑӔԖӺԤīωϓӘϏҰӔ. ˢ 89 ÉǆǪ˽͗ā.̍. (îЂ)
2016.3.
115. ǯ̜ЮҚƽͥĞҚͥɰŜɒҚϳǨĴҚĮóòüҚǶʶȢҚšͥʶȩ. ̎͂͗ҥiɆҰӔďԖӺԤi΁ԍԢӼӛԧӵӃƤ˻. ˢ 89 ÉǆǪ˽͗ā.̍. (îЂ) 2016.3.
116. ǶʶȢҚÈǂÜÅҚͥǪˋ'Қ ǯΧҚǳʶҚʾĬśóҚsĸ́Қšͥʶȩ. III ×ӡԋӠӨӸԧExoS Ӄď˽̱^ɉUӁңҩӔ̎͂͗Ӄ IV ×̐ȵ pilT Ҿ pilU Ϝ/üӃŬ͸Ų. ˢ
89 ÉǆǪ˽͗ā.̍. (îЂ) 2016.3.
117. ǶʶȢҚšͥʶȩ. ̎͂͗ӁӑӔďʱӾԞԤӲԢӪԧӰԝԤԗӤԁӳԖӃ΁ǵ. ˢ 50 É̎͂͗ſǼʢʿ˚. (ǲ) 2016.2.
118. ĳʑʹͻҚ^ɓîʽҚΚУɢóҚĬʑйϭҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔӴԢӾԁԤ/5-ՀՃ3 ¡Ď7ңӑӆӮԌӲӸԤӲ
P/NK1 ¡Ď7ӃЀ. ˢ 11 ÉǆǪɕ ˦ā.̍.āͬА. (ǲ) 2015.2.
119. |ͥ1ҚȠʑп ϙҚ"ȍĶҚ̘ǨśЮҚĳʑʹͻҚïԥɴ˳üҚįʑ¸ĈҚʼϥĞ:ɶʢŲ̽ʠŸӃʡƁӁңҩӔ NADPH oxidase1 (NOX1)ӃŞx. ˢ 88 ÉǆǪ͢ʈā.ń.
(®¤Ĩ) 2015.3.
120. ǳǪKȧϤҚĬ̟ϭȫҚ^ɓîʽҚïԥɴ˳üҚ|ͥ1: ԔӟӲӽӦӲӾԞԤˁϫΒʫî̽ɶԘӽԠӁңҩӔͪ˦^ʱ˽̱ʫʆ TRPV4 ӃЀ. ˢ 88 ÉǆǪ͢ʈā.ń. (®¤Ĩ)
2015.3.
121. ^ɓîʽҚΚУɢóҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔӴԢӾԁԤ/5-HT3 ¡Ď7ңӑӆӮԌӲӸԤӲ P/NK1 ¡Ď7ӃЀ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
122. ĸǯп ˂ҚǬɑп ̦ҚɁśüҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠңӑӆӝԟԄӼӤԤӁӑӓΒΰҭӕӔ̽ɶӃʡƁӃȴι. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
123. ϡ С _ЮҚ Ă5 ͺ нϐҚ ǳǪ Kȧ ϤҚ ïԥ ɴ˳ üҚ ʑķ X ҚÞ ȻC ɂҚ |ͥ 1 :Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

Transient Receptor Potential Melastatin 2 ӺԙԃԠӃʫʆҾԞӻӾî̽ɶԘӽԠӁңҩӔ^̓ʤͽϓƵӈӃЀ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
124. ϱȿʒʈҚċ̴п žҚĠʑØʺͮҚǳǪKȧϤҚïԥɴ˳üҚăʹҚ|ͥ1: ԉӲԑӲԑԃԧӾ˲͢uӁӑӓΒΰҭӕӔ̯˯́NČŲӁңҩӔʎ7^ŧϰϱĪҾӃӦԡԧӾřƆҾӃЀώ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
125. Kenjiro Matsumoto, Riho Yamaba, Daichi Utsumi, Kikuko Amagase, Makoto Tominaga,
Shinichi Kato: Vascular endothelial transient receptor potential vanilloid 4 links colonicinflammation in dextran sulfate sodium-induced colitis model mice. American
Gastroenterological Association (Washington, USA) 2015.5.
126. Daichi Utsumi, Kenjiro Matsumoto, Kikuko Amagase, Shinichi Kato: Serotonin/5-HT3
receptor and substance P/NK1 receptor pathways contribute to the pathogenesis ofcolonic inflammation in mice. American Gastroenterological Association (Washington,
USA) 2015.5.
127. ǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ͪ˦^ʱ˽̱ӁʫʆҰӔ TRPV4 ӄҚԔӟӲӽӦӲӾԞԤˁϫΒʫî̽ɶӃϏͫӁЀҰӔ. ˢ 43 ÉǆǪɯʧā. (Ⱦ̓) 2015.6.
128. ãʼҚɡπCЎҚͥЖŔҚ|ͥ1Қ͓ĸ½ʔ: ӨԢԧԤʡỴ̈Ġ̽˯́ӁңҩӔ
TNF-α ӁӑӔ GPR120 ʫʆǊӘ#ҮҶ GLP-2 iɆƏq8ʐ. ˢ 127 ÉǆǪ͢ʈā.τʝ
ϥ. (ĭЁ) 2015.6.
129. |ͥ1: ɕ ˦ɶʢӁңҩӔӴԢӾԁԤ/5-HT3 ¡Ď7ӃŞx. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟ
Ԗ 2015 (͛) 2015.8.
130. Ǫ¬п ͞ҚĬ̟ϭȫҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ͪ˦^ʱ˽̱ӁʫʆҰӔ
TRPV4 ӺԙԤԃԠӄԔӟӲӽӦӲӾԞԤˁϫΒʫî̽ɶӃϏͫӁЀҰӔ. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2015 (͛) 2015.8.
131. ĮϥǢ˳üҚšͥΰȻҚΚУɢóҚǳǪKȧϤҚïԥɴ˳üҚǶп µ8ҚϽ̴п ʺҚ|ͥ1
: ԔӨԢԋӚԧӱңӑӆî̽ʱӁңҩӔǾ͋ɦӃӮӝӾӤӝԤʫʆƏqӃȤŉ. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2015 (͛) 2015.8.
132. ͓ĸʺ͚ҚĒȹп ͤҚĠʑØʺͮҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԍԢԆӝӣӼӜӨӲ
Ӄ 5-ԋԠӣԢӟԞӰԠΒΰŲ̽ɶӁңҩӔǢʐŲ. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2015 (͛)2015.8.
133. Ĭĵ͙ȫҚ͓ĸʺ͚ҚĒȹп ͤҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ԉԋӜӳӲ͗ӁӑӔ 5ԋԠӣԢӟԞӰԠΒΰŲ̽ɶӃƏqǸ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2015 (ǲ) 2015.8.
134. Ǭɑп ̦Қͷп CǌҚρ¥͘üҚïԥɴ˳üҚǳǪKȧϤҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔƑʎɽέӃǸ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2015 (ǲ)
2015.8.
135. ɁśüҚĸǯп ˂ҚǬɑп ̦Қïԥɴ˳üҚǳǪKȧϤҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠңӑӆӝԟԄӼӤԤӁӑӓΒΰҭӕӔ̽ɶӃʡƁӃȴι. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟ
Ԗ 2015 (ǲ) 2015.8.
136. ̘ǨśЮҚĳʑʹͻҚ"ȍĶҚįʑ¸̜ҚʼϥĞҚ|ͥ1: ɶʢŲ̽ʠŸӃʡƁӁңҩӔ NOX1/NADPH oxidase ӃŞx. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2015 (ǲ)
2015.8.
137. šͥΰȻҚΚУɢóҚǳǪKȧϤҚǶп µ8ҚϽ̴п ʺҚ|ͥ1: ԔӨԢԋӚԧӱңӑӆî̽ʱ˽̱ӁңҩӔǾ͋ɦӃӮӝӾӤӝԤʫʆƏqȤŉӃ΁ǵ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2015 (ǲ) 2015.8.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

138. ċǪǌǆЮҚǳǪKȧϤҚïԥɴ˳üҚÞȻCɂҚ|ͥ1: TRPM2 ӺԙԃԠӃʫʆҾ
TNBS ΒΰԞӻӾ^̓ʤͽϓƵҾӃЀ. ˢ 65 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ)
2015.10.
139. ƆĸйͮҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ͪ˦^ʱʫʆ TRPV4 ӺԙԤԃԠӃæîӄԔӟӲӽӦӲӾԞԤˁϫΒʫî̽ɶӃϏͫӁЀҰӔ. ˢ 65 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ) 2015.10.
140. Hama S, Nakamura I, Nishimoto A, Nishi T, Itakura S, Kogure K. Lipocalin2 stabilizes
hypoxia inducible factor-in through the iron delivery into normoxic cancer cells Ԯ
AACR-NCI-EORTC INTERNATIONAL CONFERENCE MOLECULAR TARGETS AND
CANCER THERAPEUTICS (Boston,USA) 2015.11.
141. ƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥ. ×ӡԋӠӨӸԧӃiɆƏqӘʵƞҮҶiɆͲ̚ӃÉη-iɆʷЀӃ΁ǵ. ˢ 88 ÉǆǪ˽͗ā.̍. ԨĭЁԩ 2015. 3
142. ϱãǈľԬɈíϯ˳ͫԬǳ ȍԬǳ͛˷'ԬAnowara KhatunԬγϯǔŃԬжУąŜԬ ̟ϭĈԬͥȩŨԬϳǨÿˌԬǯǨSŚԬîʼ ϏԺҥә˽̱ӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ӁӑӔӤԠӰӟԖɍŲ ӤԟӟԖӺԙԃԠηbqťԮˢ 128 ÉǆǪ͢ʈā.τʝϥ.ԨîЂԩ
2015.11.
143. ǳʑĜԬǨƉ!̜ԬʾʑǢľԬρǪóǢԬȸΡǚǌԬ¬ϯ 1ԬˍʹͫԬîʼ ϏԬóϞKԺſ8ԔӟӲȷϔʱ˽̱ҤӒӃƑΒʫ IL-33 ʏʎӁңҩӔ IgE ӃЀӃ¥̲ŲԮˢ 128
ÉǆǪ͢ʈā.τʝϥ.ԨîЂԩ 2015.11.
144. ͥȩŨԬϘͥ§üԬįăĘЮԬÑŵ#Ԭįĵ˸üԬǳʑˉЮԬ˗ØʶȢԬóϞ KԬîʼϏԺӈӛԡӲԔӟӲӁңҩӔЪƿΒʫӛӾԊԧŲʱ̀ɶӃʫʢ͸ÊӃ΁ǌԮˢ 65 ÉǆǪ͢ā.τʝƲϥî.ԨîЂԩ 2015.10.
145. ǳ ȍԬϱãǈľԬɈíϯ˳ͫԬAnowara KhatunԬǳ͛˷'Ԭ ̟ϭĈԬжУąŜԬͥȩŨԬǯǨSŚԬϳǨÿˌԬîʼ ϏԺԈӾʩ˽̱ȅ YMB-1 ӁңҩӔ HDAC ЃČuӆɍŲԉӸԕԤ D3 ӁӑӔӝӣԤӺԙԃԠηbqťԮˢ 65 ÉǆǪ͢ā.τʝƲϥî.ԨîЂԩ 2015.10.
146. ɡπ̃МԬ!ɹąȢԬǳǩǱԬĬʑЉŔԬжУąŜԬͥȩŨԬîʼ ϏԺԔӟӲqťŲ T ԟԤԇʇӁңҩӔ Ca2+ɍŲ K+ӺԙԃԠ KCa3.1 ЃČu in vivo ƐӁӑӔ IL-10 ηbBϏԮˢ
65 ÉǆǪ͢ā.τʝƲϥî.ԨîЂԩ 2015.10.
147. ɝȸśêԬϘͥüԬӸӧӰ¸ЉԬî¸O#ԬлĸӀҺ̜ԬжУąŜԬͥȩŨԬîʼ ϏԺ
K562 ˽̱ӁңҩӔӲԍԞӝӰԤөЃČuӁӑӔ two-pore × K+ӺԙԃԠ K2P5.1 ʫʆԦɍŲΖ˧Ԯˢ 65 ÉǆǪ͢ā.τʝƲϥî.ԨîЂԩ 2015.10.
148. ϘͥüԬлĸӀҺ̜ԬжУąŜԬͥȩŨԬîʼ ϏԺpre-mRNA ӲԍԞӝӰԤөЃČӁӑӔT ԟԤԇʇ two-pore × K+ӺԙԃԠ K2P5.1 ɍŲqťԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟ
Ԗ 2015Ԩǲԩ 2015.8.
149. Susumu Ohya. Downregulation of Ca2+-activated Cl- channel TMEM16A by histone
deacetylase inhibition in breast cancer cells. World Congress on Breast Cancer.
(Birmingham, UK) 2015.8.
150. ǯıȿ|Ԭ H5¸Ԭ5ͥ̌Ԭʾʊ˳ԬǯɴĈľԬʑ ɗԬϘͥüԬлĸӀҺ̜ԬжУąŜԬͥȩŨԬîʼϏԺpH ſ¡Ų K+ӺԙԃԠ K2P5.1 ʫʆЃČӁӑӔӽӦӲӾԞԤˁϫԀӾԟӟԖΒʫŲɶʢŲ̽ʠŸʢɿӃƳÁԮˢ 127 ÉǆǪ͢ʈā.τʝϥ.ԨĭЁԩ 2015.6.
151. ǨƉ!̜Ԭͷ£žŒԬʼϯǘîԬɦɏȎԬȸΡǚǌԬ¬ϯ1ԬîʼϏԬˍʹͫԬóϞKԺÂŴ̮ӁңҩӔ IL-33 ʏʎӃӲӼԢӝӿſ¡ŲӃȖ΅Ԯˢ 127 ÉǆǪ͢ʈā.τʝϥ.ԨĭЁԩ
2015.6.
152. îʼ ϏԺT ԟԤԇʇɍŲqťӁңҩӔӤԟӟԖӺԙԃԠӃŞxҾʡƁԮǆǪ͢ā.ˢ 135 ń.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ԨˊƉԩ 2015.3.
153. ϱãǈľԬ Ïʹo͙Ԭǳ͛˷'ԬɈíϯ˳ͫԬжУąŜԬ ̟ϭĈԬͥȩŨԬϳǨÿˌԬǯǨSŚԬîʼϏԺʩ˽̱ӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČӁӑӔ Ca2+ɍŲ K+ӺԙԃԠ KCa3.1 ηbӆɍŲΖ˧ԮǆǪ͢ā.ˢ 135 ń.ԨˊƉԩ 2015.3.
154. ϘͥüԬлĸӀҺ̜Ԭ H5¸Ԭʾʊ˳ԬжУąŜԬͥȩŨԬîʼϏԺSpliceosome ЃČ͢ӁӑӔ pH ſ¡Ų K+ӺԙԃԠ TASK2 ʫʆԦɍŲqťԮǆǪ͢ā.ˢ 135 ń.ԨˊƉԩ
2015.3.
155. ϘͥüԬлĸӀҺ̜Ԭ H5¸Ԭ5ͥ ̌Ԭʾʊ˳ԬжУąŜԬ ̟ϭĈԬͥȩŨԬîʼϏԺTwo-pore × K+ӺԙԃԠ K2P5.1 ϛƒʮӲԍԞӝӰԤө7ӃʎʈāʮŽ̞Ԯˢ 92 ÉǆǪʎ
ʈā.ԨˊƉԩ 2015.3.
156. îʼϏԬǳ͛˷'ԬϱãǈľԬ Ïʹo͙Ԭ ̟ϭĈԬǯǨSŚԬɈíϯ˳ͫԬжУąŜԬͥȩŨԬϳǨÿˌԺԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČuӁӑӔʩ˽̱ YMB-1 ӁңҩӔ Ca2+ɍŲ Cl-ӺԙԃԠ TMEM16A ӃηbƏqԮˢ 92 ÉǆǪʎʈā.ԨˊƉԩ2015.3.
157. ϘͥüԬлĸӀҺ̜Ԭ H5¸ԬжУąŜԬ ̟ϭĈԬͥȩŨԬîʼ ϏԺTwo-pore × K+ӺԙԃԠ K2P5.1 ӿԕԀԤӾԃӥӼӜԌ7ӃȤ̲΁ǵҾʫʆqťԮˢ 88 ÉǆǪ͢ʈā.ń.Ԩ®
¤Ĩԩ 2015.3.
158. ǳ͛˷'Ԭ Ïʹo͙Ԭϱãǈ˳ԬжУąŜԬ ̟ϭĈԬǯǨSŚԬɈíϯ˳ͫԬͥȩŨԬϳǨÿˌԬîʼ ϏԺԈӾʩ˽̱ȅ YMB-1 ӁңҩӔ Ca2+ɍŲ Cl-ӺԙԃԠ TMEM16A ӃӡԊӱӠԃӼӜӻӨqťԮˢ 88 ÉǆǪ͢ʈā.ń.Ԩ®¤Ĩԩ 2015.3.
159. 5ͥ ̌Ԭ H5¸Ԭʾʊ˳ԬϘͥüԬлĸӀҺ̜ԬжУąŜԬ ̟ϭĈԬͥȩŨԬîʼϏԺɶʢŲ̽ʠŸӃ̹̓ʒǱ CD4 ЈŲ T ˽̱ӁңҩӔ two-pore × K+ӺԙԃԠ K2P5.1 ӃʫʆԦȤ̲΁ǵԮˢ 88 ÉǆǪ͢ʈā.ń.Ԩ®¤Ĩԩ 2015.3.
160. ǶʶȢҚÈǂÜÅҚͥǪˋ'Қ ǯΧҚǳʶҚʾĬśóҚsĸ́Қšͥʶȩ. III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ̎͂͗Ӄ IV ×̐ȵ pilT Ҿ pilU Ϝ/üӃŬ͸Ų. ˢ
68 ÉǆǪ˽͗ā.ЀͷƲϥ̍. (ϧ) 2015.11.
161. ĬǪǋ̜Қ¤ǞŭӋӓüҚȓʑʹʒҚˍͷǗҚȠΡ˩ҚǶʶȢҚšͥʶȩ. ̎͂͗ҥʱ˽̱ӘſʽҰӔԗӤԁӳԖӃ΁ǵ. ˢ 68 ÉǆǪ˽͗ā.ЀͷƲϥ̍. (ϧ) 2015.11.
162. ȠΡ˩Қ¤ǞŭӋӓüҚȓʑʹʒҚˍͷǗҚĬǪǋ̜ҚǶʶȢҚšͥʶȩ. ̎͂͗ҥʱ˽̱ӘſʽҰӔȤȚӃ΁ǵ. ˢ 65 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ) 2015.10.
163. ǶʶȢҚšͥʶȩ. ̎͂͗ҥ III ×ӡԋӠӨӸԧExoS Әʱ˽̱^ӁɉUҰӔҶӎӁŬ͸Ӏ IV×̐ȵӃԗӤԁӳԖ΁ǵ. ˢ 63 ÉǆǪ āʨɇā.ͷǆǪƲϥ̍. ˢ 58 ÉǆǪſǼʢā. ǆǪÔǂ.āͬА. ˢ 85 ÉǆǪſǼʢͷǆǪÔǂ.āͬА. «­ā. (ó͇)
2015.10.
164. ¤ǞŭӋӓüҚǶʶȢҚšͥʶȩ. ̎͂͗Ӄʱ˽̱ӘſʽҰӔȤȚӃ΁ǵ. ˢ 63 ÉǆǪāʨɇā.ͷǆǪƲϥ̍. ˢ 58 ÉǆǪſǼʢā. ǆǪÔǂ.āͬА. ˢ 85 ÉǆǪſǼʢͷǆǪÔǂ.āͬА. «­ā. (ó͇) 2015.10.
165. Hayashi N, Nishizawa H, Kitao S, Deguchi S, Nakamura T, Fujimoto A, Shikata M, Gotoh
N. Pseudomonas aeruginosa PAO1 strain injects type III effector ExoS into epithelial cells
through the function of type IV pili. ASM Conference on Pseudomonas 2015. (Washington
D.C.) 2015.9.
166. ǶʶȢҚšͥʶȩ. ̎͂͗ҥ III ×ӡԋӠӨӸԧExoS Әʱ˽̱^ӁɉUҰӔҶӎӁŬ͸Ӏ IV×̐ȵӃȤ̲΁ǵ. ŃƆ 27 ńŌ τʝ̽˦ŧʎɽʿ˚.̍.Ԧʿ˚ʫͯ. (îЂ) 2015.6.
167. ǶʶȢҚšͥʶȩ. III ×ӡԋӠӨӸԧExoS Ӄ̱^ɉUӁңҩӔ̎͂͗Ӄ IV ×̐ȵ PilT ԘԧӸԧӸԤԇӨέӃŬ͸Ų. ˢ 63 ÉǆǪ āʨɇā.̍. (ǲ) 2015. 6.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

168. ǶʶȢҚšͥʶȩ. Pseudomonas aeruginosa ӁӑӔ III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉ
UӁңҩӔ IV ×̐ȵӃŞx. ˢ 89 ÉǆǪſǼʢā.āͬΜɫ. (ϧ) 2015. 4.
169. ͥǪˋ'Қ ǯΧҚsĸ́ҚǳʶҚǶʶȢҚšͥʶȩ. ̎͂͗ӁңҩӔ×iɆӡԋӠӨӸԧӃď˽̱^ӈӃɉUӁӄ×̐ȵҥŬ͸ҽҟӔ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ)
2015. 3.
170. ǶʶȢҚšͥʶȩ. ̎͂͗Ӄʱ˽̱īωϓƈʚ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3
171. ͥɰŜąҚǶʶȢҚšͥʶȩ. ̎͂͗ҥiɆҰӔďԖӺԤi΁ԍԢӼӛԧӴӃƤ˻. ˢ 88ÉǆǪ˽͗ā.̍. (ĭЁ) 2015. 3.
172. ǶʶȢҚšͥʶȩ. III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ̎͂͗Ӄ IV ×̐ȵ pilTϜ/üӃŬ͸Ų. ˢ 88 ÉǆǪ˽͗ā.̍. (ĭЁ) 2015. 3.
173. ǯΧҚǶʶȢҚšͥʶȩ. ̎͂͗Ӄ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ×̐ȵӃԘԧӸԧӸԤԇӨέ PilT ӃŬ͸Ų. ˢ 49 É̎͂͗ſǼʢʿ˚. (ǲ) 2015. 2.
174. îãп dҚ^ɓîʽҚȠʑп ϗҚǾʑɮϤҚïԥɴ˳üҚˡ^ÿɂҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔ^ÊŲӴԢӾԁԤңӑӆԵ−HTԳ¡Ď7ӃЀ. ˢ
10 ÉǆǪɕ ˦ā.̍.āͬА. (ˍĳ) 2014.2.
175. ʑ1ŅҚȠʑп ϗҚʑ 6»Қįʑ¸ĈҚïԥɴ˳üҚˡ^ÿɂҚʼϥĞҚ|ͥ1: ӾԟԁӾԢԏԤӵԤӲԠԑԤϫԨTNBSԩΒΰî̽ɶӃʡƁӁңҩӔ NADPH oxidase 1ԨNOX1ԩӃŞx. ˢ 10 ÉǆǪɕ ˦ā.̍.āͬА. (ˍĳ) 2014.2.
176. ıǪŷľҚϼɰ˴͛ҚǾʑɮϤҚîãп dҚǶп µ8Қïԥɴ˳üҚϽ̴п ʺҚ|ͥ1: 5ԋԠӣԢӟԞӰԠ(5-FU)Βΰ̽ɶӁėҰӔ˼͋ɦӃǸ:Ġ̽̿˜ӁңҩӔӛԓӾԧӰӲΒğӃƏq. ǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014.3.
177. Kenjiro Matsumoto, Kimihito Tashima, Shinichi Kato and Syunji Horie: Role of transient
receptor potential melastatin 2 (TRPM2) channels in visceral pain and hypersensitivity inrats. American Gastroenterological Association (Chicago, USA) 2014.5.
178. Haruka Yokota, Daichi Utsumi, Hiroyo Nakajima, Riho Tanaka, Mari Yamada, Yuya
Tanaka, Kikuko Amagase and Shinichi Kato: NADPH Oxidase 1 (NOX1) expressed incolonic macrophages plays a crucial role in trinitrobenzene sulfonic acid (TNBS)- inducedcolonic inflammation in mice. American Gastroenterological Association (Chicago, USA)2014.5.
179. ^ɓîʽҚîȣĝ Қʑ 6»ҚĠÙȩîҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔ^ÊŲӴԢӾԁԤ/5-HT3 ¡Ď7ӃŞx. ˢ 125ÉǆǪ͢ʈā.τʝϥ. (ĮĬ) 2014.6.
180. ϼɰ˴͛ҚıǪŷľҚǾʑɮϤҚîãп dҚǶп µ8Қïԥɴ˳üҚϽ̴п ʺҚ|ͥ1: 5ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔ˼͋ɦӃǸԺĠ̽̿˜ӛԓӾԧӰӲΒğӃƏq. ˢ 125ÉǆǪ͢ʈā.τʝϥ. (ĮĬ) 2014.6.
181. "ȍĶҚʑ1ŅҚȠʑп ϙҚįʑ¸ĈҚǳǪKȧϤҚïԥɴ˳üҚʼϥĞҚ|ͥ1:ӾԟԁӾԢԏԤӵԤӲԠԑԤϫ(TNBS)Βΰî̽ɶӃʡƁӁңҩӔ NADPH oxidase1 (NOX1)
ӃŞx. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2014 (îЂ) 2014.8.
182. ρ¥͘üҚЕϯ!̜Қͷп CǌҚϼɰ˴͛ҚгǡŏƆҚǶп µ8ҚǳǪKȧϤҚïԥɴ˳üҚϽ̴п ʺҚ|ͥ1: Ǿ͋ɦӃ 5-ԋԠӣԢӟԞӰԠӁӑӔĠ̽̿˜ӃӛԓӾԧӰӲΒğЃČӘ#ҮҶ̽ɶƏqǸ. ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ 2014 (îЂ) 2014.8.
183. ^ɓîʽҚΚУɢóҚĬʑйϭҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔӴԢӾԁԤ/5-HT3 ¡Ď7ңӑӆӮԌӲӸԤӲ P/NK1 ¡Ď7ӃЀ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2014 (îЂ) 2014.8.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

184. Еϯ!̜Қϼɰ˴͛ҚгǡŏƆҚǶп µ8ҚǳǪKȧϤҚïԥɴ˳üҚϽ̴п ʺҚ|ͥ1:5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔǾ͋ɦ(ӮӝԡӝӾӟ)ӃǸ. ȧ 'Әƕҡy͢Ԧʨ͢
ʈӰԤԓӱӟԖ 2014 (îЂ) 2014.8.
185. îȣĜ Қʑ 6»ҚĳʑˉͻҚɁśüҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: DSS Βΰî̽ɶӁėҰӔ NK1 ¡Ď7ƛƑ͢ӃǸ. ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2014(îЂ) 2014.8.
186. ĳēҚȊʑ˷ŒҚʑ1ŅҚ"ȍĶҚȠʑп ϙҚįʑ¸ĈҚǳǪKȧϤҚïԥɴ˳üҚʼϥĞҚ|ͥ1: ӾԟԁӾԢԏԤӵԤӲԠԑԤϫΒΰî̽ɶӃʡƁӁңҩӔ NADPH
oxidase 1 (NOX1)ӃŞx. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014.10.
187. ͷп CǌҚρ¥͘üҚϼɰ˴͛ҚгǡŏƆҚǶп µ8ҚǳǪKȧϤҚïԥɴ˳üҚϽ̴п ʺҚ|ͥ1: 5-ԋԠӣԢӟԞӰԠΒΰ̽ɶӁėҰӔǾ͋ɦӃǸ—Ġ̽̿˜ӁңҩӔӛԓӾԧӰӲΒğЃČҾӃЀώ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014.10.
188. ^ɓîʽҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1: ӽӦӲӾԞԤˁϫԀӾԟӟԖΒΰî̽ɶӃʡƁӁңҩӔӴԢӾԁԤ/5-HT3 ¡Ď7ӃЀ. ˢ 42 ÉǆǪɯʧā. (ǲ) 2014.10.
189. ǳǪKȧϤҚʑķX Қïԥɴ˳üҚ|ͥ1ҚÞȻCɂ: î̽ɶԘӽԠԞӻӾӃ^̓ʤͽϓƵɿƁӁңҩӔ Transient Receptor Potential Melastatin 2 ӺԙԃԠӃЀ. ˢ 42 ÉǆǪɯʧā. (ǲ) 2014.10.
190. ƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥ. ˽̱́ӘγáҾҰӔ˽̱×iɆͲ̚ӃÉηϒӃͿĔҾҫӕӁÜһҠҶӡԋӠӨӸԧiɆȤȚӃȖ΅Ԯ́ӰԤԓӱӟԖ 2014 (ˊƉ) 2014.
11.
191. ƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥ. г˯Ųʌåҥ˽͗×iɆͲ̚ӃÉηϒԭӡԋӠӨӸԧiɆʷЀӁӊҰŝНӃȖ΅Ԯˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ)
2014. 10.
192. Ohgita T, Hayashi N, Gotoh N, Kogure K. Evaluation of physicochemical effect of viscouspolymers toward rotation and effector secretion of bacterial type  secretion apparatusԮˢ 52 ÉǆǪʎɽɽʈā. (ǫł) 2014. 9.
193. Ohgita T, Hayashi N, Gotoh N, Kogure K. Analysis of bacterial Type  effector secretionmechanism based on the observation of rotation of type secretion apparatus. IUPABINTERNATIONAL BIOPHYSICS CONGRESS (Brisbane, Australia) 2014. 8.
194. ǯ-²Қɲп ϏҚǴHˋüҚĠǛKðǥ. ʩŧĠʌåqťӁӑӔʩɂʨƈʚԮǆǪ͢uā.
ˢ 29 ń. (Ýʄ) 2014. 5.
195. Nakamura I, Hama S, Itakura S, Kogure K. Stabilization of Hypoxia Inducible Factor-1a by
Lipocalin2-mediated Fe3+ influx into normoxic tumor cells Ԯ EMBO|EMBL Symposium
Tumor Microenvironment and Signalling (Heidelberg, Germany) 2014. 5.
196. Hama S, Nakamura I, Itakura, Takasaki I, Tabuchi Y, Kogure K. Lipocalin2 as a plasma
marker for tumors with hypoxic regions Ԯ EMBO|EMBL Symposium Tumor
Microenvironment and Signalling (Heidelberg, Germany) 2014. 5.
197. ƋʑЉ©ҚǶ ʶȢҚšͥʶȩҚĠǛKðǥ. ˽͗×iɆͲ̚ӃÉηϒ-ӡԋӠӨӸԧiɆʷЀӁėҰӔг˯ŲʌåӃɽʈ āʮŝНԮǆǪ́ā.ˢ 36 ń. (ǲ) 2014. 5.
198. ǯ-²Қɲп ϏҚǴHˋüҚĠǛKðǥ. Lipocalin2 ӁӑӔ Hypoxia Inducible Factor-1α Ӄăć Ә#ҮҶ4ϫ˹ӰөԀԠӃɍŲ ԮǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.
199. ƋʑЉ©ҚǶп ʶȢҚšͥʶȩҚĠǛKðǥ. ӉәȵҾӃШ2ŲӁÜһҠҶ̎͂͗ 3 ×iɆͲ̚ӃȤ̲ԗӤԁӳԖӃ΁ǵԮˢ 87 ÉǆǪ˽͗ā.̍. (ǲ) 2014. 3.
200. Kyoko Endo, Natsumi Kurokawa, Sawa Nakakura, Mizuki Ishii, Masanori Fujii, SusumuԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

Ohya: Identification and functional role of the dominant-negative splice variant of
pH-sensitive, two-pore domain K+ channel K2P5.1. The 45th NIPS International Symposium(Okazaki, Japan) 2014.11.
201. Sayo Matsuba, Satomi Niwa, Saki Kanatsuka, Yurika Nakazono, Katsuhiko Muraki,
Noriyuki Hatano, Masanori Fujii, Peng Zhan, Takayoshi Suzuki, Susumu Ohya:
Down-regulation of Ca2+-activated Cl- channel TMEM16A by the inhibition of histone
deacetylase in TMEM16A-expressing breast cancer cells. The 45th NIPS International
Symposium (Okazaki, Japan) 2014.11.
202. ǳ͛˷'ԬϱãǈľԬ Ïʹo͙Ԭ ̟ϭĈԬͥȩŨԬϳǨÿˌԬîʼ ϏԺԈӾҥә˽̱ȅӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČӁӑӔ Ca2+ɍŲ Cl-ӺԙԃԠ TMEM16A ʫʆΖ˧ȤȚԮˢ 126 ÉǆǪ͢ʈā.τʝϥ.Ԩ¸ȨĬԩ 2014.10.
203. îʼ ϏԬǳ͛˷'Ԭ ̟ϭĈԬǯǨSŚԬϱãǈľԬ Ïʹo͙ԬɈíϯ˳ͫԬͥȩŨԬ
Zhan PengԬϳǨÿˌԺԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČӁӑӔҥә˽̱ӤԠӰӟԖɍŲ ӨԢԞӝӿӺԙԃԠ TMEM16A ӃʫʆƏqԮˢ 87 ÉǆǪʎ ā.î.Ԩϧԩ 2014.10.
204. óϞKԬͷ£žŒԬʼϯǘîԬɦɏȎԬǨƉ!̜ԬÃʑϙЮԬɩ£ǭóԬ͍ȓʹʎԬîʼϏԬȸΡǚǌԬ¬ϯ 1Ժȷ˦ƲÂŴӁңҩӔ̮ҽӃӝԤӸԧԢӝӦԤ (IL) -33 ʏʎ˽̱Ӄ΁ǵԮˢ 64 ÉǆǪ͢ā.τʝƲϥî.Ԩϧԩ 2014.10.
205. 5ͥ ̌Ԭ H5¸Ԭʾʊ˳Ԭ ̟ϭĈԬͥȩŨԬîʼ ϏԺɶʢŲ̽ʠŸԘӽԠԔӟӲӃ
̹̓ʒǱ CD4 ЈŲ T ˽̱ӁңҩӔӛԠӤԟ pH ɍŲ K+ӺԙԃԠ TASK2 ӃŞxԮˢ 64 ÉǆǪ͢ā.τʝƲϥî.Ԩϧԩ 2014.10.
206. Ïʹo͙Ԭǳ͛˷'ԬϱãǈľԬ ̟ϭĈԬǯǨSŚԬɈíϯ˳ͫԬͥȩŨԬϳǨÿˌԬîʼϏԺHDAC ЃČӁӑӔ Ca2+ɍŲ Cl-ӺԙԃԠηbƏqҾƑҥә8ʐԮˢ 64 ÉǆǪ͢ā.τʝƲϥî.Ԩϧԩ 2014.10.
207. ǯıȿ|ԬǯɴĈľԬǳǩǱԬ!ɹąȢԬǾĮϭóԬͥȩŨԬóϞп KԬ"ɅˉɂԬîʼп ϏԺɶʢŲ̽ʠŸԘӽԠԔӟӲ T ԟԤԇʇӁңҩӔ Ca2+ɍŲ K+ӺԙԃԠ KCa3.1 ɍŲÊü nucleoside diphosphate kinase-B (NDPK-B) ӃŞxԮˢ 64 ÉǆǪ͢ā.τʝƲϥî.Ԩϧԩ 2014.10.
208. ǳʑĜԬлʑϣȻԬȑȣп OԬîʼϏԬóϞKԺӛӾԊԧʠŸӃTʟʨɇӁoʐ¥̲ӀΒğ×qťŲ T ˽̱ (Tr1 ˽̱)ӃƑɾʜʮ IL-10 ʏʎԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟ
Ԗ 2014ԨîЂԩ 2014.8.
209. H5¸Ԭʾʊ˳Ԭ5ͥ̌Ԭ ̟ϭĈԬͥȩŨԬîʼϏԺɶʢŲ̽ʠŸԘӽԠԔӟӲӃ
CD4 ЈŲ T ˽̱ӁңҩӔ two-pore × K+ӺԙԃԠ TASK2 ӃŞxԮȧ 'Әƕҡy͢Ԧʨ͢
ʈӰԤԓӱӟԖ 2014ԨîЂԩ 2014.8.
210. ϱãǈľԬ Ïʹo͙Ԭǳ͛˷'Ԭ ̟ϭĈԬͥȩŨԬϳǨÿˌԬîʼп ϏԺԈӾҥә˽̱ȅӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČuӁӑӔ Ca2+ɍŲ K+ӺԙԃԠ KCa3.1 ʫʆԦɍŲqťԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2014ԨîЂԩ 2014.8.
211. ǳ͛˷'ԬϱãǈľԬ Ïʹo͙Ԭ ̟ϭĈԬǯǨSŚԬɈíϯ˳ͫԬͥȩŨԬϳǨÿˌԬîʼϏԺԈӾҥә˽̱ȅӁңҩӔԈӲӾԤ̷ӛӴӺԠ Ϫ˹ЃČuӁӑӔ Ca2+ɍŲ Cl-ӺԙԃԠ TMEM16A ʫʆԦɍŲƏqԮȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖ 2014ԨîЂԩ
2014.8.
212. ȑȣ OԬǳʑĜԬлʑϣȻԬͥЩƀԬΧĳʺΧԬȸΡǚǌԬ¬ϯ 1Ԭîʼ ϏԬóϞ KԺӛӾԊԧʠŸӃɂʨӘƞ¯ҮҶ Tr1 ˽̱ӁӑӔǁͻTʟʨɇӃÜ˅ʮȖ΅Ԯˢ 125 ÉǆǪ͢
ʈā.τʝϥ.ԨĮĬԩ 2014.6.
213. !ɹąȢԬǾĮϭóԬǳǩǱԬ ̟ϭĈԬͥȩŨԬóϞKԬ"ɅˉɂԬîʼϏԺɶʢŲ̽Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ʠŸԘӽԠӃ CD4 ЈŲԟԤԇʇӁңҩӔ Ca2+ɍŲ K+ӺԙԃԠ KCa3.1 ɍŲ Êü NDPK-BʫʆϏҾ NDPK-B ЃČuӡԞөϫӁӑӔɶʢƳÁǸԮˢ 125 ÉǆǪ͢ʈā.τʝϥ.
ԨĮĬԩ 2014.6.
214. H5¸Ԭʾʊ˳Ԭ5ͥ̌Ԭ ̟ϭĈԬͥȩŨԬîʼϏԺɶʢŲ̽ʠŸԘӽԠԔӟӲӃ
CD4 ЈŲԟԤԇʇӁңҩӔ two-pore ×ӤԟӟԖӺԙԃԠ TASK2 (K2P5.1) ӃʫʆԦȤ̲ϏԮˢ 125 ÉǆǪ͢ʈā.τʝϥ.ԨĮĬԩ 2014.6.
215. ǳʑĜԬͥЩƀԬΧĳʺΧԬлʑϣȻԬȑȣOԬîʼϏԬȸΡǚǌԬ¬ϯ1ԬóϞKԺӛӾԊԧʠŸӃqťӘƞ¯ҮҶ IL-10 ʏʎŲ Tr1 ˽̱Ӄ in vitro ΒğӁЀҰӔʿ˚ԮǆǪ͢ā.ˢ
134 ń.ԨɹǪԩ 2014.3.
216. ͷ£žŒԬɩ£ǭóԬÃʑϙЮԬ͍ȓʹʎԬʼϯǘîԬȸΡǚǌԬ¬ϯ1ԬîʼϏԬóϞKԺ
ÉңӑӆŦӃƑżΰӁӑӔԔӟӲÂŴ̮ҤӒӃӝԤӸԧԢӝӦԤ-33 ʏʎҚӀӒӆӁҫӕӒ
ӁӊҰӽӦӮԗӮӷԤӃŝНԮˢ 87 ÉǆǪ͢ʈā.ń.Ԩ&¦ԩ 2014.3.
217. ǶʶȢҚšͥʶȩ. III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ̎͂͗Ӄ IV ×̐ȵ pilAңӑӆ pilT Ϝ/üӃŬ͸Ų. ˢ 67 ÉǆǪ˽͗ā.ЀͷƲϥ̍. (ZŎ) 2014. 11.
218. ǶʶȢҚʯĸ µҚšͥʶȩ. ̎͂͗Ӄ III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ IV×̐ȵӃŬ͸Ų: ˢ 62 ÉǆǪ āʨɇā.ͷǆǪƲϥ̍. ˢ 57 ÉǆǪſǼʢā. ǆ
ǪÔǂ.āͬА. ˢ 84 ÉǆǪſǼʢͷǆǪÔǂ.āͬА. 3 ā.«­ā. (ĮĬ)
2014. 10.
219. ǳʶҚsĸ́Қ ǯΧҚͥǪˋ'Қh£ȋüҚǶʶȢҚšͥʶȩ. ʱ˽̱^ӈӃ×ӡԋӠӨӸԧExoS ɉUӁңҩӔ̎͂͗Ӄ pilT Ϝ/üӃŬ͸Ų. ˢ 64 ÉǆǪ͢ā.τʝƲϥ
̍.Ԧî. (ϧ) 2014. 10.
220. ˍͷǗҚĬǪǋ̜Қ¤ǞŭӋӓüҚȓʑʹʒҚǶʶȢҚšͥʶȩ. ̎͂͗Ӄʱ˽̱ӈӃίӰөԀԠӃ΁ǵ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10
221. ͥɰŜąҚƆċ̜ҚǶʶȢҚšͥʶȩ. ̎͂͗ӃďԖӺԤi΁ԍԢӼӛԧӵӃƤ˻. ˢ
64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10.
222. ʑǯOĈҚ͝ȻʺĺҚϥɥðϤҚÈǂÜÅҚǶʶȢҚšͥʶȩ. IV ×̐ȵҾ asialo-GM1 Ӄ́«Ә#ҮҶ̎͂͗Ӄ%ʻȤȚӃ΁ǵ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ)
2014. 10.
223. ĠʘŭDҚʾĬśóҚǲĸˋüҚÈǂÜÅҚǶʶȢҚšͥʶȩ. IV ×̐ȵӁʻʵҮҶ̎͂͗ӁӑӔ Caco-2 ˽̱ԘԄԡӝԚωϓӃ΁ǵ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ)
2014. 10.
224. ǶʶȢҚ ǯΧҚͥǪˋ'ҚÈǂÜÅҚšͥʶȩ. III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ̎͂͗Ӄ IV ×̐ȵ pilT Ϝ/üӃŬ͸Ų. ˢ 26 ÉŧʎɽӰԤԓӱӟԖ (ǲ)2014 .9.
225. ǶʶȢҚšͥʶȩ. Pseudomonas aeruginosa ӁӑӔʱ˽̱ӸӝӾӱԙԤӨӰԝԤˀ̋ӁңҩӔ IV ×̐ȵӃŬ͸Ų. ˢ 88 ÉǆǪſǼʢā.āͬΜɫ. ˢ 62 ÉǆǪ āʨɇā.̍.
«­ā. (ˍĮ) 2014. 6.
226. ǶʶȢҚšͥʶȩ. ̎͂͗Ӄ IV ×̐ȵӄ III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ӈӃɉUӃҶӎӃŬСÊüҽҟӔ. ŃƆ 25 ńŌ τʝ̽˦ŧʎɽʿ˚.̍.. (îЂ) 2014. 6.
227. ͥǪˋ'ҚǶʶȢҚ ǯΧҚͷɰ͏ҚĤ̥»Қšͥʶȩ. Pseudomonas aeruginosaӁӑӔ III ×ӡԋӠӨӸԧExoS ӃɉUӁңҩӔ×̐ȵӃŬ͸Ų. ǆǪ͢ā. 134 ń. (ɹǪ)
2014. 3.
228. ϥɥðϤҚ¤ǞŭӋӓüҚ¬ʑó̜̏ҚǶʶȢҚšͥʶȩ. Pseudomonas aeruginosa Ӄ%ʻӁңҩӔʱ˽̱˖ɾʜŲӃ΁ǵ. ǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

229. Ɔċ̜ҚǶʶȢҚ˫ü9ľҚšͥʶȩ. ̎͂͗Ӄʱ˽̱īωϓӁңҩӔЛȵӃŞx. ǆǪ͢ā. 134 ń. (ɹǪ) 2014. 3.
230. ǶʶȢҚͷɰ͏ҚĤ̥»Қh£ȋüҚ ǯΧҚͥǪˋ'Қšͥʶȩ. ̎͂͗ӁӑӔʱ˽̱ӸӝӾӱԙԤӨӰԝԤˀ̋ӁңҩӔ IV ×̐ȵӃŬ͸Ų. ǆǪ͢ā.ˢ 134 ń. (ɹǪ)
2014. 3.
231. ǶʶȢҚšͥʶȩ. ̎͂͗Ӄ III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ IV ×̐ȵӃŬ͸Ų. ˢ 87 ÉǆǪ˽͗ā.̍. (ǲ) 2014. 3.
232. ǶʶȢҚšͥʶȩ. ̎͂͗Ӄ IV ×̐ȵӘ#ҮҶʱ˽̱īωϓȤȚӃ΁ǵ. ˢ 48 É̎͂͗ſǼʢʿ˚. (ϼĵ) 2014. 1.
233. ȼʑ̞ ҚÑΡҚɲп ϏҚȐǪ¸ǑҚĠǛKðǥ. ̳̬˽̱ӁėҰӔ siRNA ğUӁӑӔӛӽӜԓӤӝԤ”ԡӱӲӺԤ”ӃȤ̲΁ǵҾԗӸԒԟӻӨӰԤӿԢԧԖɂʨӈӃĩǦԮˢ 23 ÉӛԤӺӴԤӲӰԤԓӱӟԖ (Ũĳ) 2013. 11.
234. ƋʑЉ©ҚǶ ʶȢҚɲ ϏҚšͥʶȩҚĠǛKðǥ. ˽͗×iɆͲ̚ӃȤ̲ԗӤԁӳԖ΁ǌӘʵƞҮҶÉη-iɆʷЀӃ΁ǵԮˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2013.10.
235. Ohgita T, Hayashi N, Hama S, Gotoh N, Kogure K. ӡԋӠӨӸԧiɆȤȚ΁ǌӘʵƞҮҶ˽
͗×iɆͲ̚ӃÉη-iɆʷЀӃ΁ǵԮǆǪʎɽɽʈā.ˢ 51 Éń. (ϧ) 2013. 10.
236. ǯ-²Қɲп ϏҚȊ̞¸ҚˍǪп āҚĠǛKðǥ. 4ϫ˹ʌåӄԔӝӾԋӚӱԧӃΒğӘ#ҮҼ̈́ňʮƴě̤̐Ų˽̱ӃʎþɍŲӘæŗҭҲӔԮˢ 72 ÉǆǪʩā.āͬ̍. (Ƞɐ)
2013. 10.
237. ǯ-²Қɲп ϏҚǴHˋüҚгĵǥҚʑɜÓ˟ҚĠǛKðǥ. 4ϫ˹ʌåӃʩ˽̱ҥʏʎҰӔ Lipocalin 2 ӁӑӔȩŁϫ˹ʌåӃʩ˽̱^4ϫ˹ӰөԀԠӃæŗԮˢ 17 Éϫ˹ӹӝԀԕӨӲʿ˚. (Еȓ) 2013. 8.
238. ǯ-²Қɲ ϏҚǴHˋüҚгĵǥҚʑɞÓ˟ҚĠǛKðǥ. Lipocalin2 ӁӑӔ Hypoxia
Inducible Factor-1α Ӄăć Ә#ҮҶ4ϫ˹ӰөԀԠӃæŗԮˢ 21 ÉӨԟԁӤԠԋӚԧԔӰԧӰԤԓӱӟԖʨ͢āԋӢԧԞԖ 2013 (ʾĸ) 2013. 7.
239. ɲ ϏҚ ǯ-²ҚǴHˋüҚгĵǥҚʑɞÓ˟ҚĠǛKðǥ. 4ϫ˹Ӄʩ˽̱ӘȖh¥̲ӀͪɬԔԧӤԧLipocalin2 Ӄ­ćҾȤ̲΁ǵԮ2013 ńŌ(ˢ 19 É)ÎЌʩɂʨæſʿ˚.
(ǲ) 2013. 6.
240. ƋʑЉ©ҚǶп ʶȢҚɲп ϏҚÑΡҚšͥʶȩҚĠǛKðǥ. ˽͗ӉәȵҾӃШ2ŲӁÜһҨ×iɆͲ̚ӃȤ̲ԗӤԁӳԖӃ΁ǵԮǆǪ́ā.ˢ 35 ń. (ǲ) 2013. 5.
241. óϞKҚɩ£ǭóҚÃʑϙЮҚ͍ȓʹʎҚîʼϏҚȸΡǚǌҚ¬ϯ1ԺԔӟӲÂŴԘӽԠӁңҩӔԔӲӾ˽̱ңӑӆöäÜʇӃɍŲ ӁЀҰӔ΁ǵԮˢ 63 ÉǆǪӛԡԠӧԧā.ːĀāͬ
î.Ԩǲԩ 2013.11.
242. ʼϯǘîԬ͍ȓʹʎԬɩ£ǭóԬÃʑϙЮԬͷ£žŒԬȸΡǚǌԬ¬ϯ1ԬîʼϏԬóϞKԺԔ
ӟӲÂŴ̮ӁңҩӔƑӃŦżΰӁӑӔ interleukin (IL)-33 ʏʎҾʏʎ˽̱Ӄ΁ǵԮˢ 124ÉǆǪ͢ʈā.τʝϥ.Ԩϧԩ 2013.11.
243. ǶʶȢҚʯĸµҚšͥʶȩ. ̎͂͗Ӄ III ×ӡԋӠӨӸԧExoS Ӄʱ˽̱^ɉUӁңҩӔ IV ×̐ȵӃŬ͸Ų. ˢ 61 ÉǆǪ āʨɇā.ͷǆǪƲϥ̍. ˢ 56 ÉǆǪſǼʢā. ǆǪ
Ôǂ.āͬА. ˢ 83 ÉǆǪſǼʢā.ͷǆǪÔǂ.āͬА. Y­ϾM (îЂ) 2013.11.
244. ˫ü9ľҚǶʶȢҚʯĸµҚšͥʶȩ. ̎͂͗Ӄ̽˦̀ʒͪɖſǼӁңҩӔЛȵϒӃŬ͸
Ų. ˢ 61 ÉǆǪ āʨɇā.ͷǆǪƲϥ̍. ˢ 56 ÉǆǪſǼʢā. ǆǪÔǂ.āͬ
А. ˢ 83 ÉǆǪſǼʢā.ͷǆǪÔǂ.āͬА. Y­ϾM (îЂ) 2013. 11.
ӼԧԔԲԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

245. ĠǛKðǥҚîĳŏ§ҚͦĤп ˉҚǯ̜ë˳ҚͥĸǉȢҚMahadi HasanҚɲп ϏҚˍʑϕҚʑ͇ĳ\üҚʑ п DҚĸ\ǑԮŧŖДɎgʈӁӑӔгiü͢Ӄ˽̱έχϕҾȤ̲ʫʆԮˢ 39 Éʎ7́Ҿ͢ɽӃʷ8ʐӰԤԓӱӟԖ(ϱɀ) 2017.10.
246. ͦĤп ˉҚǯ̜ë˳Қîĳŏ§ҚͥĸǉȢҚMahadi HasanҚɲп ϏҚʑ п DҚĠǛKðǥԮŧŖДɎgʈӁӑӔԜԁԧӨӀӡԤӿӮӝӾԧӰӲӃ΁ǵԮˢ 33 ÉǆǪ DDS ā.āͬА.(ϧ) 2017.7.
247. ǯ̜ë˳Қîĳŏ§ҚͦĤп ˉҚMahadi HasanҚɲп ϏҚʑDҚĠǛKðǥԮŧŖДɎgʈӁӑҹҼΒΰҭӕӔԜԁԧӨӀӡԤӿӮӝӾԧӰӲԮǆǪ͢uā.ˢ 32 ń.(Ýʄ) 2017.5
248. Ϩп άҚĳΡŷϭҚMahadi HasanҚĂϯǓŃҚɲп ϏҚĠǛKðǥԮǽζȚύӁӑҹҼ̼ʧ˿̗Ӂɔω¥̲Ӏ siRNA ӦԙԟӛԧӃϾʫԮǆǪ͢ā.ˢ 137 ń.(&¦) 2017.3.
249. ɲп ϏҚ ĳϬЮҚͷ ΧҚˍɰKɂҚƾͥŅҚĠǛKðǥԮ͢ṳŲʩӃSǤӘʵƞҮҶӾӬԋӠԢԧԠӬԅӨϫԀԄԏӰӨԠӃϾʫԮˢ 28 ÉԉӸԕԤ E ʿ˚.(ǲ) 2017.1.
250. ǳɑ ŶҚͺ͏ȩҚϳǨąǹҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ӛԕԄϫFЫӘoʐҮҶ̺ӸԧӫӼӜԤө×гiüӦԙԟӛӃy͵. ˢ 33 ÉǆǪ DDS ā. (ϧ), 2017.7.
251. ĬF³Қͺ͏ȩҚ˄ϥ³ҚʼǨë̜üҚʑ 6ǸҚĬʑȿĀҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ӛӲԇԞӧԤϫFЫӘoʐҮҶбӸԧӫӼӜԤө×ԀԄ˭üӃϾʫӆʩбη˓ɂʨӈӃŮʐ. ˢ 33 ÉǆǪ DDS ā. (ϧ), 2017.7.
252. ǳɑп ŶҚͺ͏ȩҚϳǨąǹҚĬǪ ǋ: ӴԟԤFЫӘoʐҮҶǁͻ̺ӸԧӫӼӜԤө×гiüӦԙԟӛӃy͵. ˢ 26 É DDS ӤԤԋӚԞԤӲ (ЗĮ), 2017.9.
253. ͺ͏ȩҚǳɑп ŶҚϳǨąǹҚǶп ͏ΏҚŃóϧüҚĬǪ ǋ:п ӴԟԤFЫӘoʐҮҶǁͻ̺ӸԧӫӼӜԤө×гiüӦԙԟӛӃy͵.п ǆǪ͢ɽƁā.ˢ 32 Éń. (ǲ), 2017.11.
254. ĬF³Қͺ͏ȩҚ˄ϥ³ҚʼǨë̜üҚĬǪ ǋ:п ӛӲԇԞӧԤϫFЫӘoʐҮҶбƞ¯ŲгiüԕӴԠӃϾʫӆʩбη˓ɂʨӈӃŮʐ.п ǆǪ͢ɽƁā.ˢ 32 Éń. (ǲ), 2017.11.
255. ^ͥĞҚͺ͏ȩҚϳǨǘüҚ͒ȓɒλҚȟп ͏əҚˊĬƼʔҚÕȇ˕ŏҚĬǪ ǋ:п ԈӛԠԢԤϫԔӝӨԢԁԧӿԠӘʐҠҶ hPTH1-34 Ӄ̀ΨχϕҾбˮеʢɂʨӈӃŮʐ.п ǆǪ͢ɽ
Ɓā.ˢ 32 Éń. (ǲ), 2017.11.
256. ͺ͏ȩ: бʠŸɂʨӃʃ ӘʵƞҮҶ DDS Ͼʫ.п InnoPack Japan ӬԤԋӚԡԤӲ (ǲ), 2017.4.
257. GPŵʋóҚÈċЏ ҚȪ͐ŚҚĠͷƹüҚhϕ: ˭üͯЙӁңҠҼɽέΑΞ̲ӘǢҰӔԓԟӱӛӴӺԡԤԟԓӶԧԖ×ӝӨӣԟԤʫRӽԆӝӲӃϾʫӁЀҰӔÜ˅ʮʿ˚. ˢ 67ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ˊƉ), 2017. 10.
258. Îŋ͑ϭüҚȪ͐ŚҚĠͷƹüҚhϕ: ԋӻ˹°Ǣ «ɽӘ́«ҭҲҶөԠӸӺӣԤӘȱ7ҾҰӔ 19F-MRI ԍԢԧԌӃ«ƆҾ΋?. ˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ˊƉ),
2017. 10.
259. ɰǩòҚȝ£ƃҚȪ͐ŚҚĠͷƹüҚhϕ: ;ȸŲ̳̬Ǆ˲ӝӣԤɖ7ԀԄ˭üӃΖ͵ҾíȆ NMR ΁ǵ. ˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ˊƉ), 2017. 10.
260. Takegamiп S, Watanabe K, Yamada C, Kaneda H, Yoshida M, Konishi A, Kitade T. 1H, 19F
and 31P NMR spectroscopic studies on the formation of ionic liquid submicron particles
prepared by different surfactants. Euroanalysis 2017 (Stockholm, Sweden), 2017. 8
261. ĲǳóòҚʑĳȂҚЩϿ͕˷ҚȪ͐ŚҚĠͷƹüҚhϕ: ӾԟӛԞӦӱԤԀԄӡԔԠӰԝԤӁęUҮҶ 19F-NMR ԍԢԧԌӃ̒¸ǒϿ T1 Ҿ T2 ӃɢŌ>þŲ. ˢ 77 Éiǵ ā΅Ι.
(ϧ), 2017. 5.
262. ʑĳȂҚĲǳóòҚЩϿ͕˷ҚȪ͐ŚҚĠͷƹüҚhϕ: 19F-NMR ӘʐҠҶ˖ҜӃ̳έԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ԀԄӡԔԠӰԝԤӃɢŌŮˤӁėҰӔ Ų̳έӃŝНӃȖ΅. ˢ 77 Éiǵ ā΅Ι. (ϧ), 2017. 5.
263. Ȫ͐ŚҚɡπǙʎҚĬʑ͒ҚϱʑɒǌҚ¬ʑʺüҚĠͷƹüҚhϕ: íȆ NMR ӘʐҠҶӝӣԤɖ7ԀԄ˭üřƆӁӊҰʗЙɍŲuӃŝНӃȖ΅. ǆǪ͢ā.ˢ 137 ń.
(&¦), 2017. 3
264. ЩϿ͕˷ҚĲǳóòҚʑĳȂҚȪ͐ŚҚĠͷƹüҚhϕ: 19F-NMR ӘʐҠҶ̳έԀԄӡԔԠӰԝԤӃɢŌŮˤŲӃȖ΅. ǆǪ͢ā.ˢ 137 ń. (&¦), 2017. 3.
265. Hama S, Itakura S, Matsui R, Kogure K. Development of liposomal siRNA carriers usingslightly acid pH-sensitive peptide SAPSP for cancer therapy. 3rd International Conference
on Biomaterials Science in Tokyo (ǲ) 2016.11.
266. Kogure K, Fujikawa K, Hasan M, Hama S, Kashida H, Asanuma H. Effective cytoplasmic
delivery of functional macromolecules by faint electricity. 3rd International Conference on
Biomaterials Science in Tokyo (ǲ) 2016.11.
267. Fujikawa K, Hasan M, Hama S, Tanaka T, Kogure K. Faint electric treatment induces
cytoplasmic delivery of functional macromolecules via changing endosome property. 3rd
International Conference on Biomaterials Science in Tokyo (ǲ) 2016.11.
268. ǳ ΘҚϳǨǘüҚǴHˋüҚĠǛKðǥҚƾͥŅҚɲ ϏԮŧĠʌåŮˤŲӿԞӻөӽԟԆԟԧӰӲӼԖӃ̼ʧ^ωϓŲӃƳÁ. ˢ 14 ÉҥәҾԅӝԓӦӰӛʿ˚.(ĭЁ) 2016.11
269. ĳϬЮҚͷ ΧҚˍɰKɂҚĠǛKðǥҚƾͥŅҚɲ ϏԮíЙʮӀƑʩ8ʐӘǢҰӔԉӸԕԤ E Βğ7ҤӒȚƆҭӕӔԀԄ˭üӁӑӔ͢ṳŲӃSǤ. ˢ 14 ÉҥәҾԅӝԓӦӰӛʿ˚.(ĭЁ) 2016.11.
270. Hama S, Itakura S, Kogure K. Slightly Acidic pH Sensitive Peptide-Modified Nanoparticles
for Nucleic Acid Delivery to Cancer Cells. BIT’s 6th Annual World Congress of Nano
Science & Technology-2016(Singapore) 2016.10.
271. ĳϬЮҚͷ ΧҚˍɰKɂҚĠǛKðǥҚƾͥŅҚɲ ϏԮƑҥәԀԄԏӰӨԠӃ˽̱^ƁqťӁӑӔ͢ṳŲӃSǤ. ˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.(îЂ) 2016.10
272. ǳ ΘҚϳǨǘüҚĠǛKðǥҚƾͥŅҚɲп ϏԮ̼ʧɚϥӈӃ͢ɽχϕҥ¥̲ӀŧĠʌåŮˤŲԟԓӶԧԖӃϾʫ. ˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.(îЂ) 2016.10.
273. ɲ ϏҚǴHˋüԮД͔η×ԐԍӺӿӁӑӔʩɂʨ DDS ҤӒӃ siRNA ӃʃʮӀ˽̱έƴ
h. ˢ 75 ÉǆǪʩā.āͬ̍.(Ƞɐ) 2016.10.
274. Hasan MahadiҚʑ͇ĳ\üҚͥĸǉȢҚƋʑЉ©Қɲ ϏҚʑDҚƾͥŅҚĸ\ǑҚĠǛKðǥԮIntracellular delivery of a novel functional nucleic acid iRed by faint electric
treatment for effective regulation of target genes. ˢ 32 ÉǆǪ DDS ā.āͬА.(ЗĮ)
2016.6.
275. ǳ ΘҚɲ ϏҚϳǨǘüҚǴHˋüҚĠǛKðǥҚƾͥŅԮ̼ʧ^ωϓŲҾŧŖ4 pH ŮˤŲӘ:ҲƝҺ͢ɽӦԙԟӛԧӃϾʫ. ˢ 32 ÉǆǪ DDS ā.āͬА.(ЗĮ) 2016.6.
276. ͷ ΧҚɲ ϏҚͷǪǌ{ҚϳǨǘüҚȉǯʶüҚƾͥŅҚˍɰKɂҚĠǛKðǥԮ̻̾^Φʙ×ӾӬԋӠԢԧԠӬԅӨϫ°ǢԀԄ˭üӃ̾́Ʊ˖ɂʨӈӃŮʐ. ǆǪԉӸԕԤā.ˢ 68
Éî.(ĒĬ) 2016.6.
277. ͥĸǉȢҚMahadi HasanҚɲ ϏҚʑ DҚĠǛKðǥԮϥŖДɎgʈӁӑҹҼΒΰҭӕӔӡԤӿӮӝӾԧӰӲӃ΁ǵ. ǆǪ͢uā.ˢ 31 ń.(ĭЁ) 2016. 5.
278. ͷ ΧҚɲ ϏҚͷǪǌ{ҚȉǯʶüҚϳǨǘüҚˍɰKɂҚĠǛKðǥԮ̾́Ʊ˖ɂʨӁǢʐӀӾӬԋӠԢԧԠӬԅӨϫӘÜʴҾҮҶԀԄԏӰӨԠӃϾʫ. ǆǪ͢ā.ˢ 136 ń.(Ƞɐ)
2016.3.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

279. Mahadi HasanҚͷǪǌ{ҚƋʑЉ©Қɲ ϏҚȡʑ ÀҚɏɃɒҚĠǛKðǥԮŧŖДɎgʈӄ˽̱ ςӌҾ˽̱ένχӘBϏҰӔ. ǆǪ͢ā.ˢ 136 ń.(Ƞɐ) 2016.3.
280. ĠǛKðǥҚɲ ϏԮԉӸԕԤ E ӬԅӨϫӃíśӀʎʈ8ʐҾ͢āӈӃĩϾ. ǆǪ͢ā. 136
ń.(Ƞɐ) 2016.3.
281. Mahadi HasanҚͷǪǌ{ҚƋʑЉ©Қɲ ϏҚȡʑÀҚɏɃɒҚĠǛKðǥ. ŧŖДɎgʈӄ˽̱ ӓςӌҾ˽̱ένχӘBϏҰӔԮǆǪ͢ā.ˢ 136 ń.ԨȠɐԩ 2016.3.
282. ͷ ΧҚɲ ϏҚͷǪǌ{ҚȉǯʶüҚϳǨǘüҚˍɰKɂҚĠǛKðǥԮ̾́Ʊ˖ɂʨӁǢʐӀӾӬԋӠԢԧԠӬԅӨϫӘÜʴҾҮҶԀԄԏӰӨԠӃϾʫԮǆǪ͢ā.ˢ 136 ń.ԨȠɐԩ
2016.3.
283. ĬF³Қͺ͏ȩҚǆȴϯľ̜Қ˄ϥ³ҚʼǨë̜üҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ӛӲԇԞӧԤϫFЫӘʐҠҶбȞʮ ԟԓӶԧԖӃϾʫ. ǆǪ͢uā.ˢ 31 ń. (ĭЁ),
2016.5.
284. Hidemasa Katsumi, Tomomi Mizuyama, Shoko Maruyama, Kosuke Kusamori, Toshiyasu
Sakane, Akira Yamamoto. Pharmacokinetics and preventive effects of platinum
nanoparticles as reactive oxygen species scavengers on peritoneal dissemination of tumor
cells. The 1st workshop for Japan-Korea Young Scientists on pharmaceutics (Kyoto),
2016. 6.
285. Shugo Yamashita, Hidemasa Katsumi, Nozomi Hibino, Kosuke Kusamori, Toshiyasu
Sakane, Akira Yamamoto. Development of PEGylated carboxylic acid modified
polyamidoamine dendrimer as a bone targeting carrier for the treatment of bone diseases.
The 1st workshop for Japan-Korea Young Scientists on pharmaceutics (Kyoto), 2016. 6.
286. ĬF³Қͺ͏ȩҚǆȴϯľ̜Қ˄ϥ³ҚʼǨë̜üҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ӛӲԇԞӧԤϫԟԓӶԧԖӘʐҠҶбӸԧӫӼӜԤөӰӲӼԖӃϾʫҾҴӃʩбη˓ɂʨӈӃŮ
ʐ. ˢ 32 ÉǆǪ DDS ā.āͬА. (ЗĮ), 2016.7.
287. Hidemasa Katsumi, Tomomi Mizuyama, Shoko Maruyama, Noriko Kitamura, Kosuke
Kusamori, Toshiyasu Sakane, Akira Yamamoto. Pharmacokinetics and preventive effectsof platinum nanoparticles as reactive oxygen species scavengers on peritoneal
dissemination of tumor cells. 43th Annual Meeting & Exposition of the Controlled
Release Society, (Seattle, U.S.A), 2016. 7.
288. Shugo Yamashita, Hidemasa Katsumi, Nozomi Hibino, Yugo Isobe, Yumiko Yagi, Kosuke
Kusamori, Toshiyasu Sakane, Akira Yamamoto. Development of PEGylated carboxylic
acid modified polyamidoamine dendrimer as a bone targeting carrier for the treatment ofbone diseases. 43th Annual Meeting & Exposition of the Controlled Release Society,(Seattle, U.S.A), 2016. 7.
289. ͺ͏ȩҚĬF³Қǆȴϯľ̜Қ˄ϥ³ҚʼǨë̜üҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ӤԠԒԤϫFЫӘoʐҮҶбӸԧӫӼӜԤө× PAMAM ӽԤӿԟԔԧӃϾʫ. ˢ 25 É DDS ӤԤԋӚԞԤӲ (ЗĮ), 2016.9.
290. ͺ͏ȩҚˍΛðϤҚ5ͥЮ͘üҚâ ЮλҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ɍŲϫ˹ɕ
̲ӁOӕӔԍԞӺԀԀԄ˭üӃ DDS ϾʫҾʠŸɂʨӈӃŮʐ. Ϝ/üԦӽԟԆԟԧʿ˚.ˢ
16 ÉêǧӴԕԀԧ (ϼĵ), 2016.9.
291. ͺ͏ȩҚĬF³Қǆȴϯľ̜Қ˄ϥ³ҚʼǨë̜üҚ͒ȓɒλҚÕȇ˕ŏҚĬǪ ǋ: ӤԠԒԤϫFЫӘoʐҮҶǁͻбƞ¯Ųгiü͢ɽӦԙԟӛӃϾʫ. ˢ 22 ÉyuԋӢԧԞԖ͍ƌʿ˚. (ĮĬ), 2016.11.
292. Hidemasa Katsumi, Kosuke Kusamori, Shoko Maruyama, Toshiyasu Sakane, AkiraԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

Yamamoto: Pharmacokinetics and preventive effects of platinum nanoparticles as reactive
oxygen species scavengers on hepatic metastasis. 6th FIP Pharmaceutical Scaiences
World Congress 2017, (Stockholm, Sweden), 2016. 5.
293. Shugo Yamashita, Nozomi Hibino, Yugo Isobe, Hidemasa Katsumi, Kosuke Kusamori,Toshiyasu Sakane, Yumiko Yagi, Saki Yamada, Akira Yamamoto: Deveropment ofpegylated aspartic acid modified liposome as a bone-targeting carrier for the delivery of
paclitaxel and treatment of bone metastasis. 6th FIP Pharmaceutical Scaiences World
Congress 2017, (Stockholm, Sweden), 2016. 5.
294. Hidemasa Katsumi, Ying-Shu Quan, Fumio Kamiyama, Akira Yamamoto. Development ofan efficient transdermal drug delivery system using self-dissolving microneedle arrays forthe treatment of migraine and osteoporosis.п The 2nd Korea-Japan micro needles
symposium 2016 (Seoul, Korea), 2016.11.
295. Hidemasa Katsumi, Akira Yamamoto. Development of an efficient transdermal drugdelivery system using self-dissolving microneedle arrays fabricated from hyaluronic acid.
AAPS Annual Meeting & Exposition 2016, (Denver, U.S.A), 2016. 11.
296. ͺ͏ȩ: ԈӛԠԢԤϫԔӝӨԢԁԧӿԠӘʐҠҶГ±Ų͢ɽӃ̀ʱӽԟԆԟԧ. ӬԢӝӿQˠΜō 2016 ԗӽӜӤԠӶԋӾԔӸԧՎʎ7Ӂ8ʐҰӔӐӗӒҤҠǮƿӃʗЙ āՎ (ǲ),
2016.10.
297. ĬF³Қͺ͏ȩҚǆȴϯľ̜Қ˄ϥ³ҚʼǨë̜üҚ͒ȓɒλҚÕȇ˕ŏҚĬǪп ǋ.
ӤԠԒԤϫFЫӘoʐҮҶǁͻбƞ¯Ųгiü͢ɽӦԙԟӛӃϾʫ. ǆǪ͢ā.ˢ 136 ń.
(Ƞɐ), 2016.3.
298. Ȫ͐ŚҚ Ĥ9ϡ̜Қˍʑɒ§ҚĬʑҮңӓҚĠͷƹüҚhϕ: ӝӣԤɖ7ңӑӆӝӣԤ
ɖ7ԀԄ˭ü ӃԊԡԤӃͨRæŗӃȴι. ˢ 7 ÉӝӣԤɖ7΅Ι. (ϱɀ), 2016. 10299. Ĭʑ͒ҚϱʑɒǌҚ¬ʑʺüҚȪ͐ŚҚĠͷƹüҚhϕ: кԑӲԋӚӺӱԠӬԟԤӘʗЙɍŲuҾҮҶӝӣԤɖ7ԀԄ˭üӃΖ͵Ҿ˭üřƆӃíȆ NMR ΁ǵ. ˢ 66 Éп ǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ), 2016. 10300. ĬǪɗüҚȪ͐ŚҚĠͷƹüҚËυɤҚǳĸ˷Қhϕ: ԒԢԤϫΒğ7°ǢԓԟӱӛӴӺԡԤԟԓӶԧԖ×ӝӨӣԟԤʫRӽԆӝӲӁӑӔӿԇԕԤӃćϰiǵɇӃϾʫԭŮˤŲңӑӆϛƒŲӃÜ˅ʮȖ΅ԭ. ǆǪiǵ ā.ˢ 65 ń. (ǫł), 2016. 9301. ͥ  й ͮ ҚĮ о З Қ ) Ρ ̜ϭ Қ Ȫ ͐ ŚҚ Ġͷ ƹ ü Қ h ϕ  : 19F-NMR Ә ʐ Ҡ ҶNonyl-β-D-glucopyranoside ңӑӆ n-Decyl-β-D-maltoside °Ǣ̳έԀԄӡԔԠӰԝԤӃͪɪʙŲӃȴιʿ˚. ˢ 29 ÉԆӝӣԗӽӜӤԠiǵˑāӰԤԓӱӟԖ (ϧ), 2016. 9302. ĮоЗҚͥйͮҚ)Ρ̜ϭҚȪ͐ŚҚĠͷƹüҚhϕ: 19F-NMR ӘʐҠҶ̳έԀԄӡԔԠӰԝԤӃͪ ɪʙŲӁӊҰ Nonyl-β-D-glucopyranoside °ϰӃŝНӃȖ΅. ˢ 29ÉԆӝӣԗӽӜӤԠiǵˑāӰԤԓӱӟԖ (ϧ), 2016. 9303. ËυɤҚĬǪɗüҚǳĸ˷ҚȪ͐ŚҚĠͷƹüҚhϕ: ӿԇԕԤӃгſŌiǵӘʵƞҮҶԒԢԤϫΒğ7°ǢԓԟӱӛӴӺԡԤԟԓӶԧԖ×ӝӨӣԟԤʫRӽԆӝӲӃϾʫ. ˢ 29ÉԆӝӣԗӽӜӤԠiǵˑāӰԤԓӱӟԖ (ϧ), 2016. 9304. Yamamoto R, Takegami S, Konishi A, Horikawa H, Yonezawa Y, Kitade T. Development ofpolydiacetylene liposomal aequorin bioluminescent device as a novel signal generator for
detection of hydrophobic compounds.
19th International Symposium on
Bioluminescence & Chemiluminescence (Tsukuba), 2016. 5305. ĠǛKðǥҚ΢ʑʺòҚɲ ϏҚȼʑ ΢ҚϼĵŅñ. ʩԣӨӺԤӘʵƞҮҶӝӣԤӾԋӢԡӰӲӁӑӔƑԐԍӺӿƕƝԀԄӫԠӃ̀ʱχϕԮˢ 25 ÉǆǪ MRS ńȧî.(ǲ) 2015.12.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

306. Mahadi HasanҚƋʑЉ©Қɳ ϏҚȡʑ ÀҚɏɃɒҚĠǛKðǥ. ŧŖДɎӁӑӔȆϫ͢ӃʃʮӀ˽̱έӽԟԆԟԧԮǆǪȆϫ͢ā.ˢ 1 Éń.(ϧ) 2015.11.
307. ĠǛKðǥҚȷΩɰ ϣҚǨǯǢľҚɳ ϏҚȐǪ¸Ǒ. ӝӣԤӾԋӢԡӰӲӁӑӔȆϫ͢ӃʃʮӀʱ^χϕԮǆǪȆϫ͢ā.ˢ 1 Éń.(ϧ) 2015.11.
308. Kogure K, Hasan M, Nishimoto A, Ohgita T, Hama S. Faint electric treatment-enhanced
cellular uptake and cytoplasmic delivery of functional macromoleculesԮ3rd International
Symposium on Nanomedicine Molecular Science“NMMS 2015” (ǲ) 2015.11.
309. Kogure K, Hasan M, Toyoda M, Ohgita T, Hama S, Ikeda Y, Nagasaki Y. Faint electric
treatment-induced delivery of macromolecules into the skin and cytoplasmԮ7th Asian
Association of Schools of Pharmacy Conference (Taipei,Taiwan) 2015.11.
310. ɲ ϏҚĠǛKðǥԺҥә˽̱^ӈӃʃʮӀ͢ɽƴh¥̲ӀԍԢӼӛԧӵŮˤŲԟԓӶԧԖӃϾʫԮˢ 74 ÉǆǪʩā.āͬ̍.(®¤Ĩ) 2015.10.
311. ĠǛKðǥҚMahadi HasanҚƋʑЉ©Қɲ ϏҚȡʑ ÀҚɏɃɒ. ŧŖДɎӁӑӔȆϫ͢Ӄ˽̱έӽԟԆԟԧԮˢ 24 É DDS ӤԤԋӚԞԤӲ(ЗĮ) 2015.9.
312. ɲп ϏҚǴHˋüҚǳΘҚĠǛп Kðǥ. pH ŮˤŲԐԍӺӿ SAPSp ҤӒȚƆҭӕӔȆϫfА
7ӘӬӛҾҰӔȆϫӦԙԟӛԧҤӒӃ siRNA ƴhBϏԮˢ 31 ÉǆǪ DDS ā.āͬА. (ǲ) 2015. 7.
313. ͷ ΧҚɲ ϏҚȉǯʶüҚϳǨǘüҚǴHˋüҚˍɰKɂҚĠǛп Kðǥ. ̾́Ʊ˖ɂʨӘʵƞҮҶϰüӿӻӾęUӾӬԋӠԢԧԠӬԅӨϫԀԄԏӰӨԠӃϾʫԮǆǪԉӸԕԤā.ˢ 67 Éî. (ó͇) 2015. 6.
314. ɲ ϏҚîʾoҚˍɰKɂҚĠǛп KðǥԺӾӬԋӠԢԧԠӬԅӨϫԀԄԏӰӨԠӃ˽̱^ƁqťӁӑӔƑ̼ʧǸӃæŗԮǆǪԉӸԕԤā.ˢ 67 Éî. (ó͇), 2015. 6.
315. ʑ ʺʎҚ͠ðҚгȣÿ\ҚĖʑЖüҚWǨʶ Қʾʑ˞Ŕ. ͨR X ̐iǵӘʐҠҶԟԓӶԧԖ Oxaliplatin Ӄ̼ʧ^iļӃ΋?. ǆǪ͢uā.ˢ 30 ń. Ԩϼĵԩ2015. 5.
316. ɡϞó̜Қăͥ͏˳Қʾʑ˞Ŕ. ̯ҥә̾́Ʊ˖ɽԘӽԠӁңҩӔӣӦӮԟԍԞӺԤęUԟԓӶԧԖӃɂʨǸӁЀҰӔȖ΅. ǆǪ́ā.ˢ 37 ń. Ԩǲԩ2015. 5.
317. ˡ^ßǥҚʑξːҚĤЀ½. ԡԧӯԧŮˤŲ siRNA ƴhϱԀԄӦԙԟӛӃϾʫ. Ϝ/üԦӽԟԆԟԧʿ˚.ˢ 15 ÉӰԤԓӱӟԖ. Ԩϧԩ2015. 5.
318. ɝȸðϤҚͷĤ̜˘ҚȣǪɋ6Қ ɴҚЌʑŔŭҚʾʑ˞Ŕ. ӣӦӮԟԍԞӺԤęUԟԓӶԧԖӃФÉƐҥ̼ʧTʟ˲ӁҢӔŝН. ǆǪ͢ā.ˢ 135 ń. ԨˊƉԩ2015. 3.
319. ʾʑ˞Ŕ. ̼ʧ^ŧĠʌåӃ̲ʮqťӁÜһҨǁͻ DDS ӃϾʫ. &¦“ԍԞӳԔԋӢԧԞԖ”Ԩ&¦ԩ2015. 2.ԨƗŠΜɫԩ
320. Hidemasa Katsumi, Ying-Shu Quan, Fumio Kamiyama, Akira Yamamoto. Development oftransdermal delivery system of peptide and protein drugs using self-dissolving
microneedle arrays fabricated from hyaluronic acid. IEEE-NANOMED 2015 (Hawaii),
2015.11.
321. ĬF³Қͺ͏ȩҚ͒ȓɒλҚÕȇ˕ŏҚĬǪп ǋ: бӸԧӫӼӜԤө̲ӁOӕҶ PAMAM ӽԤӿԟԔԧΒğ7ӃϾʫ. ˢ 31 ÉǆǪ DDS ā.āͬА.п Ԩǲԩ2015. 7.
322. ĬF³Қͺ͏ȩҚ͒ȓɒλҚÕȇ˕ŏҚĬǪп ǋ: бӸԧӫӼӜԤө̲ӁOӕҶ PAMAM ӽԤӿԟԔԧΒğ7ӃϾʫ. ǆǪ͢uā.ˢ 30 ń. (ϼĵ) 2015. 5.
323. âп ЮλҚͺ͏ȩҚ͒ȓɒλҚͷĸPҚÕȇ˕ŏҚĬǪп ǋ: ɍŲϫ˹ɕ̲ӁOӕҶԍ
ԞӺԀԀԄ˭üӁӑӔη˓Ų̩ʩӃƏq. ǆǪ͢ā.ˢ 135 ń. ԨˊƉԩ2015.3.
324. ĬǪɗüҚȪ͐ŚҚĠͷƹüҚhϕ. ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ӝӨӣԟԤʫRӽԆӝӲӃԟӿӤӝԤӁėҰӔŮˤŲӃ΋?. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016. 3

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

325. Ȫ͐ŚҚɡπǙʎҚĠͷƹüҚhϕ. ӝӣԤɖ7ӃԀԄ˭üřƆӁңҩӔ 1H ңӑӆ 19F
NMR ΁ǵ. ˢ 6 ÉӝӣԤɖ7΅Ι. (ϧ) 2015. 10.
326. ĬǪîμҚȪ͐ŚҚƆп KˎҚγĤîȢҚĠͷƹüҚhϕ. 1H-NMR ӘʐҠҶ϶ԭӮӝӨԡԤϸ7ӁӑӔˁ ȸ˹ɣćɇӃϾʫӁЀҰӔÜ˅ʮȖ΅. ˢ 65 Éп ǆǪ͢ā.τʝƲϥ
̍.Ԧî. (îЂ) 2015. 10.
327. ĬǪɗüҚȪ͐ŚҚĠͷƹüҚhϕ. ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRӽԆӝӲӘʐҠҶӽӣԋӜԟԤӃćϰiǵӈӃӤԋӠӝԤӃŝН. ǆǪ͢ā.ˢ 135 ń. (ˊƉ). 2015. 3.
328. ǴHˋüҚɲ ϏҚƋʑЉ©ҚĠǛKðǥ. ԟԓӶԧԖ́ăć ԐԍӺӿӘoʐҮҶǁͻ
DDS ӃϾʫԮˢ 36 Éʎ7́Ҿ͢ɽӃʷ8ʐӰԤԓӱӟԖ (Ũĳ) 2014. 11.
329. ɲ ϏҚîʾoҚǴHˋüҚĠǛKðǥ. ̼ʧ^Ŋ pH ŮˤŲԐԍӺӿӘoʐҮҶ͢ɽƴhӦԙԟӛԧӃϾʫԮˢ 36 Éʎ7́Ҿ͢ɽӃʷ8ʐӰԤԓӱӟԖ (Ũĳ) 2014. 11.
330. ɲ ϏҚĠǛKðǥ. ̼ʧŧĠʌåӁŮˤҰӔǁͻԐԍӺӿӘFЫҮҶԀԄ˭üӄԓԟӡӺԡԤөԟӬԧԠӃӱԡԤԔӘSǤҰӔԮˢ 73 ÉǆǪʩā.āͬ̍. (Ƞɐ) 2014. 9.
331. ɲ ϏҚЎðҚˍɰKɂҚĠǛKðǥ. ӲԧԇԧӣӦӰӿ#ÒŲӣԧӾԋӚӱԧӃƏqӁӑӔӾӬԋӠԢԧԠӬԅӨϫΒğӛԓӾԧӰӲӃæŗԮˢ 67 ÉǆǪϫ ӲӾԡӲā.āͬА. (ϧ) 2014. 9.
332. Fujiwara Y, Nakamura H, Ishida T, Kiwada H. Increased PEG-coated liposomal l-OHP
accumulation in the liver relates antitumor effect against M5076 ovarian sarcoma liver
metastasis. Liposome Research Days 2014 (Copenhagen, Denmark) 2014. 8.
333. ɲп ϏҚǴHˋüҚϳǨǘüҚ Ĭ9'üҚȓǪǘçҚĠǛKðǥ. ̼ʧ^Ɓqť¥̲Ӏ4pH ŮˤŲԐԍӺӿFЫ͢ɽӦԙԟӛԧӃϾʫԮˢ 33 Éiüʡʈʿ˚. (ċÙ) 2014. 7.
334. Õ̜ЮҚɲп ϏҚǴHˋüҚȣĢʬҚʺĳ͏©ҚĠǛKðǥ. Ƒ7 Fc ТÚӁгҠ;¸ŲӘǢҰӔ proteinA-R28 ӘoʐҮҶȞʮ ԀԄ˭üӃϾʫԮˢ 30 ÉǆǪ DDS ā.āͬА.
(ǲ) 2014. 7.
335. Doi Y, Ishida T, Kiwada H. Characterization of optimally designed liposomal formulation of
Oxaliplatin. The 41st Annual Meeting & Exposition of the Controlled Release Society,
Hilton Chicago. (Chicago, IL, USA) 2014. 7.
336. ЎðҚɲп ϏҚˍɰKɂҚĠǛKðǥ. 8ʐԗӤԁӳԖ΁ǵźàӁÜһҨӾӬԋӠԢԧԠӬԅӨϫӃƑʩǸӃæŗԮǆǪԉӸԕԤā.ˢ 66 Éî. (ùδ) 2014. 6.
337. ʾʑ˞Ŕ. ̼ʧ^ŧĠʌåӃ̲ʮqťӁÜһҨǁͻ DDS ӃϾʫ. ˢ 32 ÉɽŲɽʈ āʿ
˚. Ԩϧԩ2014. 6.ԨƗŠΜɫԩ
338. ɲп ϏҚĠǛKðǥ. ̼ʧʌåŮˤŲ˹üҾ̳έ́ҾӃʷ8ʐӘoʐҮҶ DDS Ӄy͵ԮǆǪ́ā.ˢ 36 ń. (ǲ) 2014. 5. ԨƗŠΜɫԩ
339. ɲп ϏҚĠǛKðǥ. ȞʮӁŮүҶȚύɾŲӘǢҰӔʩɂʨ DDSԮǆǪ͢uā.ˢ 29 ń.
(Ýʄ) 2014. 5. ԨƗŠΜɫԩ
340. ǴHˋüҚɲп ϏҚƋʑЉ©ҚĠǛKðǥ. ʩ˽̱́^ԍԢӼӛԧӵӁŮˤҮҼ˽̱^ӈӃ͢ɽƴhҥ¥̲Ӏǁͻ DDS ӃϾʫԮǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.
341. Õ̜ЮҚɲп ϏҚǴHˋüҚȣĢʬҚʺĳ͏©ҚĠǛKðǥԺȞʮ ʩɂʨӃҶӎӁ˪@ӁƑ7ӘͯЙ́«¥̲ӀԍԢӼӝԤ A FЫԀԄ˭üӃϾʫԮǆǪ͢ā.ˢ 134 ń. (ɹǪ)
2014. 3.
342. ɲп ϏҚ͓ʑ̜ĽüҚ ǯ-²ҚǴHˋüҚ¬ΧϕēҚĠǛKðǥ. Ƒ C7orf24 siRNA ӃӱӠӻӾӝԤӱӠӨӰԝԤӁӑӔ̼ʧƆϼƏqԮǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.
343. ͥʒ9üҚ ǯɒҚʾʑ˞ŔҚЌʑŔŭ. η˓Ų̩̓ҥәӃþÒҥӣӦӮԟԍԞӺԤęUPEG FЫԟԓӶԧԖӃ̩˓ͫŲӈҢӔŝН. ǆǪ͢ā.ˢ 134 ń. ԨɹǪԩ2014. 3.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

344. Hama S, Ohishi T, Nakamura I, Fukuda Y, Kuwahara Y, Li L, Fukuzawa K, Fukumoto M,
Kogure K. Tocopheryl succinate-induced cytotoxicity depends on the balance between
production and elimination of superoxide in radioresistant cancer cells. 17th Biennial
Meeting of Society for Free Radical Research International (Kyoto) 2014. 3.
345. Hama S, Itakura S, Nakai M, Nakayama K, Morimoto S, Kogure K. Tumoral pH-sensitive
nanoparticles for delivery of cargos into cells under tumor microenvironment. Institute for
Chemical Research International Symposium 2014 (Kyoto) 2014. 3.
346. ϳǨǘüҚɲп ϏҚ^ɓп ϕҚˍʑ˳ҚˍɰKɂҚĠǛKðǥ. ӾӬԋӠԢԧԠӬԅӨϫԀԄԏӰӨԠӃ˽̱ȭæŗȤȚӈӃԕӾӬԤӿԟӛȤ̲ЍČӃЀԮˢ 25 ÉԉӸԕԤ E ʿ˚. (з )2014. 1.
347. ЎðҚɲп ϏҚ ǯ-²ҚîʾoҚˍɰKɂҚĠǛKðǥ. ӣԧӾԋӚӱԧЃČӁӑӔӾӬԋӠԢԧԠӬԅӨϫΒğӛԓӾԧӰӲӃæŗԮˢ 25 ÉԉӸԕԤ E ʿ˚. (з ) 2014. 1.
348. Ishida T. Improvement of tumor-targeting therapy with nanocarrier system by changing thetumor microenvironment. Synchrotron Radiation in Nano-medicine and Advanced HealthCare (SRNAHC). (Kobe)2014. 1.ԨƗŠΜɫԩ
349. â ЮλҚ͒ȓɒλҚĠķžǩҚǆȴϯľ̜Қͺ͏ȩҚÕȇ˕ŏҚĬǪ ǋ. ʭϱԀԄ˭üӁӑӔʩη˓ƏqԗӤԁӳԖӃ΁ǌ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10350. Kusamori K, Katsumi H, Liu S, Tanaka Y, Hitomi K, Hayashi R, Hirai Y, Sakane T,
Yamamoto A. Development of a novel self-dissolving microneedle array of alendronate, anitrogen-containing bisphosphonate. 5th FIP Pharmaceutical Sciences World Congress(Melbourne, Australia) 2014. 4.
351. ͺ͏ȩҚĬǪп ǋ. OӕҶɍŲϫ˹˖ɕ̲ӘǢҰӔԍԞӺԀԀԄ˭üӘʐҠҶϫ ӲӾԡӲʠŸɂʨƈʚ. ǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.(ӰԤԓӱӟԖΜɫ)352. ɳ®ɢŭҚͺ͏ȩҚ ĳиҚȟп ͏əҚˊĬƼʔҚĬʑÓ³Қ΀ʑCϤҚıп ¸ȩҚȣ̟S\Қ͒ȓɒλҚÕȇ˕ŏҚĬǪп ǋ. QˠϥƮκ×ԔӝӨԢԁԧӿԠӘʐҠҶӝԤӸԧԋӠԢԤӃȧ '×̀ʱ±͵uӃϾʫ. ǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3
353. ĸʺʈҚĬǪɗüҚȪ͐ŚҚĠͷƹüҚĸˋŃҚĳʑ͙͌Қ ϯˉϭҚhϕ. ԓԟӱӛӴӺԡԤԟԓӶԧԖӘʐҠҶͨRÉŦɇӁӑӔԗӦӰԡӺԤӃǁͻćϰiǵɇӁЀҰӔÜ˅ʮȖ΅. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10.
354. Ǭʑ˼ĽҚĸ ϙҚȪ͐ŚҚĠͷƹüҚȼʑ̭ ҚξĺϭҚhϕ. 19F-NMR ӘʐҠҶ̳έԀԄӡԔԠӰԝԤӃͪ ɪʙŲӁӊҰ n-decyl-β-D-maltoside ӃŝНӃȖ΅. ǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.
355. ĬǪɗüҚ Ȫ͐ŚҚĠͷƹüҚȄϯǢμҚhϕ. ԓԟӱӛӴӺԡԤԟԓӶԧԖ×ʫRӽԆӝӲӘʐҠҶԗӦӰԡӺԤӃćϰiǵӁЀҰӔÜ˅ʮȖ΅. ǆǪ͢ā.ˢ 134 ń. (ɹǪ)
2014. 3.
356. Hama S, Itakura S, Mitsuhashi N, Majima E, Kogure K. A novel antibody delivery systemusing a protein A being capable of quick linkage between cell-penetrating device andantibodies. Asian Federation for Pharmaceutical sciences Conference (Jeju, Republic ofKorea) 2013. 11.
357. Õ̜ЮҚɲ ϏҚǴHˋüҚȣĢʬҚʺĳ͏©ҚĠǛKðǥԺȞʮ Ƒ7Ә˪@ӁFЫ¥̲ӀƳ͇×ԍԢӼӝԤ A ͯЙƩˆԀԄ˭üӃϾʫԮˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.
(ϧ) 2013. 10.
358. ɲ ϏҚ^ɓ ϕҚˍʑ˳ҚĮǯǢϭüҚîʾoҚȊ̞¸ҚˍǪ āҚĠǛKðǥ. ƑʩuӃɽŲӁʻʵҮҶʩɂʨʐǁͻԀԄӦԙԟӛԧӃy͵íЙʮӀƑʩ8ʐӘǢҰӔԉӸԕԤ E

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035Βğ7ӘʐҠҶƑʩԀԄ˭üӃȚ˨Ԯˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2013.
10.
359. ͠ðҚͷĤ̜˘Қʾʑ˞ŔҚЌʑŔŭ. Oxaliplatin ęU PEG FЫԟԓӶԧԖ͵uɂʨǒӃ̼ʧ^Ϝ/üʫʆé Ӄ̛̊ʮȖ΅. ˢ 52 ÉǆǪ͢ā.ԦǆǪ͢uĿ.ԦǆǪʡЅ͢uĿ. ÎÈÎƲϥāͬî. Ԩžûԩ2013. 10.
360. ɲ ϏҚĠǛKðǥ. ӾӬԋӠԢԧԠӬԅӨϫӄӛԤӱӣԓӝӡӺԤԭ2 ӃʫʆƏqӘ#ҮҼ̼ʧͪ˦ǁʎӘƏqҰӔԮˢ 72 ÉǆǪʩā.āͬ̍. (Ƞɐ) 2013. 10.
361. ɲп ϏҚĮǯǢϭüҚˍʑ˳ҚîʾoҚЎðҚȊ̞¸ҚˍǪп āҚˍɰKɂҚĠǛK
ðǥ. ӾӬԋӠԢԧԠӬԅӨϫӃíЙʮӀƑʩ8ʐԮǆǪԉӸԕԤā.τʝÔ 2013 ńŌ«­Ňĳî. (Ňĳ) 2013. 9.
362. Hama S, Itakura S, Mitsuhashi N, Majima E, Kogure K. Efficient delivery of antibody intocytoplasm of living cell using a cell-penetrating polymer-modified protein A derivative. The
5th Asian Arden Conference (®¤Ĩ) 2013. 8.
363. Itakura S, Hama S, Nakai M, Nakayama K, Morimoto S, Kogure K. Mechanism analysis ofefficient cytoplasmic delivery of macromolecules by novel tumoral pH sensitive liposomes.
The 5th Asian Arden Conference (®¤Ĩ) 2013. 8.
364. Fukuda Y, Hama S, Utsumi S, Nakayama K, Okamura Y, Fukuzawa K, Harashima H,
Kogure K. Enhancement of antitumor activity by control of membrane property of
nanovesicles consisting of antitumor agent tocopheryl succinate. The 5th Asian Arden
Conference (®¤Ĩ) 2013. 8.
365. ͠ðҚͷĤ̜˘Қʾʑ˞ŔҚЌʑŔŭ. ԔӝӨԢӛԡӝ΁ǵӁӑӔ Oxaliplatin ęU PEG FЫԟԓӶԧԖ͵uɂʨšӃ̼ʧ^Ϝ/üʫʆé ӃȖ΅. ԀԄԞӝԋӮӝӡԤӲԦӣԧԍԤӴԕԀԧ2013 ԨîЂԩ2013. 8.
366. дȣÿ\Қ ǯɒҚͷĤ̜˘Қʾʑ˞ŔҚЌʑŔŭ. Oxaliplatin ęU PEG FЫԟԓӶԧԖФÉƐӁӑӔƑ̼ʧǸӃȖ΅. ԀԄԞӝԋӮӝӡԤӲԦӣԧԍԤӴԕԀԧ2013 ԨîЂԩ2013.8.
367. ǴHˋüҚɲп ϏҚ й̜Қ Ĭ9'üҚȓǪǘçҚîʾoҚĠǛKðǥ. ̼ʧʌå4pH ŮˤŲԐԍӺӿFЫԀԄ˭üӁӑӔ siRNA ӃʃʮӀ˽̱^χϕԗӤԁӳԖӃ΁ǵԮϜ/üӽԟԆԟԧʿ˚.ˢ 13 ÉêǧӴԕԀԧ (Hawaii, U.S.A.) 2013. 7.
368. ɲп ϏҚ^ɓп ϕҚˍʑ˳ҚĮǯǢϭüҚîʾoҚ ǯ-²ҚĠǛKðǥ. íЙʮӀƑʩɍŲӘǢҰӔӾӬԋӠԢԧԠӬԅӨϫӘoʐҮҶ͢ɽӦԙԟӛԧӃϾʫԮϜ/üӽԟԆԟԧʿ˚.ˢ 13 ÉêǧӴԕԀԧ (Hawaii, U.S.A.) 2013. 7.
369. Itakura S, Hama S, Nakai N, Nakayama K, Morimoto S, Tsuchiya H, Kogure K. Efficient
cytoplasmic delivery of siRNA by tumoral pH sensitive nanoparticles via membrane fusion
under tumor microenvironmentԮ40th Annual Meeting & Exposition of the Controlled
Release Society (Hawaii, U.S.A.) 2013. 7.
370. Hama S, Utsumi S, Fukuda Y, Nakayama K, Okamura Y, Tsuchiya H, Fukuzawa K,
Harashima H, Kogure K. Development of novel nanovesicles consisting of an antitumor
agent tocopheryl succinate for cancer combination therapyԮ40th Annual Meeting &Exposition of the Controlled Release Society (Hawaii, U.S.A.) 2013. 7.
371. Nishio M, Nakamura H, Ishida T, Kiwada H. PEGylated liposomes injected sequentiallydistribute in different region of solid tumor. 40th Annual Meeting & Exposition of theControlled Release Society. (Hawaii, USA) 2013, 7.
372. îʾoҚɲп ϏҚˍʑ˳ҚˍɰKɂҚĠǛKðǥԺƑʩƆiӾӬԋӠԢԧԠӬԅӨϫӘÜʴҾҮҶǁͻ pH ŮˤŲԀԄ˭üӃϾʫԮˢ 29 ÉǆǪ DDS ā.āͬА. (ϧ) 2013. 7.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

373. ɲп ϏҚǴHˋüҚ й̜Қ Ĭ9'üҚȓǪǘçҚĠǛKðǥ. ̼ʧ4 pH ŮˤŲԀԄ˭üӃʃʮӀ˽̱έχϕԗӤԁӳԖӃ΁ǵԮˢ 29 ÉǆǪ DDS ā.āͬА. (ϧ) 2013.
7.
374. ȓǪǘçҚɲп ϏҚǴHˋüҚ й̜Қ Ĭ9'üҚÑΡҚĠǛKðǥ. ̼ʧА˙Ų¯ӃҶӎӃ̼ʧŧŖ4 pH ŮˤŲԟԓӶԧԖӃƳ͇ҾȤ̲Ų΋?Ԯˢ 29 ÉǆǪ DDS ā.
āͬА. (ϧ) 2013. 7.
375. ǴHˋüҚɲп ϏҚ й̜ҚȣĢʬҚÑΡҚʺĳ͏©ҚĠǛKðǥ. ˽̱^ӸԤԇӨέӘȞʮ¥̲ӀǁͻƑ7ğUӦԙԟӛԧӃϾʫԮˢ 29 ÉǆǪ DDS ā.āͬА. (ϧ)2013 .7.
376. ʾʑ˞ŔҚЌʑŔŭ. ƑҥәuӁӑӔ̼ʧ^ŧĠʌåé ӘoʐҮҶǁͻ DDS ӃϾʫҚԣԧӨӰԝӻԍԱԦҥәɂʨҾ DDS. ˢ 29 ÉǆǪ DDS ā.āͬА. Ԩϧԩ2013. 7.
377. Õ̜ЮҚɲп ϏҚǴHˋüҚȣĢʬҚʺĳ͏©ҚĠǛKðǥ. Ȟʮ ɂʨӃҶӎӃƳ͇×ԍԢӼӝԤ A FЫԀԄ˭üӃϾʫԮǆǪ͢uā.ˢ 28 ń. (®¤Ĩ) 2013. 5.
378. ǴHˋüҚɲп ϏҚîʾoҚƋʑЉ©ҚĠǛKðǥ. ˽̱^ԍԢӼӛԧӵjǀԐԍӺӿӘoʐҮҶǁͻ͢ɽƴhӦԙԟӛԧӃϾʫԮǆǪ͢uā.ˢ 28 ń.(®¤Ĩ) 2013. 5.
379. Ĭ9'üҚɲп ϏҚǴHˋüҚ й̜ҚȓǪǘçҚîʾoҚÑΡҚĠǛKðǥ.
̼ʧӃŧŖ4 pH ӁŮˤҮҼ˽̱^ ӓςӌҥBϏҭӕӔ SAPS ԐԍӺӿFЫԀԄ˭üӃȤ̲Ų΋?ԮǆǪ͢uā.ˢ 28 ń. (®¤Ĩ) 2013. 5.
380. ˍʑ˳Қɲп ϏҚ^ɓп ϕҚĮǯǢϭüҚÑΡҚˍɰKɂҚĠǛ Kðǥ. ƑʩɍŲuӾӬԋӠԢԧԠӬԅӨϫӘӦԙԟӛԧÜǮӁʐҠҶʩɂʨӃҶӎӃǁͻԀԄ˭üӃϾʫԮǆǪ͢uā.ˢ 28 ń. (®¤Ĩ) 2013. 5.
381. ĮǯǢϭüҚɲп ϏҚˍɰKɂҚĠǛKðǥ. ӾӬԋӠԢԧԠӬԅӨϫӁӑӔ angiopoietin-2 Ə
qӘ#ҮҶͪ˦ӃȚύăć 8ʐԮǆǪԉӸԕԤā.ˢ 65 Éî. (ǲ) 2013. 5.
382. ЎðҚɲп ϏҚ ǯ-²ҚîʾoҚˍʑ˳ҚĮǯǢϭüҚÑΡҚˍɰKɂҚĠǛKðǥ. ɍŲϫ˹Ә#ҮҶӾӬԋӠԢԧԠӬԅӨϫΒğӣԧӾԋӚӱԧӁӑӔӛԓӾԧӰӲ̤ŲӃʂŤԮǆǪԉӸԕԤā.ˢ 65 Éî. (ǲ) 2013. 5.
383. ǴHˋüҚɲп ϏҚîʾoҚƋʑЉ©ҚĠǛKðǥԺ˽̱^ԍԢӼӛԧӵŮˤŲǁͻ͢ɽƴhӦԙԟӛԧӃϾʫԮˢ 13 ÉϜ/üԦӽԟԆԟԧʿ˚.ӰԤԓӱӟԖ (ǲ) 2013. 5.
384. ĬF³Қͺ͏ȩҚȓ ̜ŵҚɡϟǈʒϭҚÕȇ˕ŏҚĬǪ ǋ. ӛԡԤӿԢԃԧӾFЫӘoʐҮҶбӸԧӫӼӜԤө×гiüӦԙԟӛӃϾʫԺԗӾӾԡӦӮԧӾӃб˓ͫŲӃƳÁӆбη˓Əq. ˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2013. 10.
385. ͺ͏ȩҚ͒ȓɒλҚÕȇ˕ŏҚĬǪп ǋ. бˮеʢɂʨ͢ԉӲԑӲԑԃԧӾӃȧ '×̀ʱ±͵uӃϾʫ. ˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2013. 10.
386. Yamashita S, Katsumi K, Mori K, Watanabe S, Kusamori K, Nishikawa M, Sakane T,
Yamamoto A. Development of a novel bone-selective drug carrier, alendronate-modified
PEGylated PAMAM dendrimer, for inhibition of bone metastasis of tumor cells. 5th Asian
Arden Conference (Nagoya) 2013. 8.
387. Katsumi H, Fukui K, Sato K, Kusamori K, Sakane T, Yamamoto A. Development of
platinum nanoparticles, liver-targeting reactive oxygen species scavenger, for preventionof hepatic ischemia/reperfusion injury. 5th Asian Arden Conference (Nagoya) 2013. 8388. Kusamori K, Katsumi H, Liu S, Tanaka Y, Hitomi K, Hayashi R, Hirai Y, Sakane T,
Yamamoto A. Development of a novel self-dissolving microneedle array of alendronate, anitrogen-containing bisphosphonate. 5th Asian Arden Conference (Nagoya) 2013. 8.
389. Hamana A, Katsumi H, Kusamor Ki, Sakane T, Yamamoto A. Development of a novelԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

self-dissolving microneedle arrays of interferon α: evaluation of transdermal absorption
and safety after application in rats. 5th Asian Arden Conference (Nagoya) 2013. 8.
390. Katsumi H, Fukui K, Sato K, Sakane T, Yamamoto A. Development of platinum
nanoparticles, liver-targeting reactive oxygen species scavenger, for prevention of hepaticischemia/reperfusion injury. 40th Annual Meeting & Exposition of the Controlled Release
Society (Hawaii) 2013, 7.
391. ͺ͏ȩҚÐĬ̠üҚǯŨüҚͷĸPҚÕȇ˕ŏҚĬǪ ǋ. ԍԞӺԀԀԄ˭üӃ̩̓ӸԧӫӼӜԤөӁӑӔ̩η˓Əq.ˢ 29 É DDS ā.āͬА. (ϧ) 2013. 7392. ĬF³Қȓ̜ŵҚɡϟǈʒϭҚͷĸPҚÕȇ˕ŏҚĬǪ ǋ. бӸԧӫӼӜԤө×
PAMAM ӽԤӿԟԔԧӁӑӔԗӾӾԡӦӮԧӾӃб˓ͫŲӃƳÁӆбη˓Əq.ˢ 29 É DDS
ā.āͬА. (ϧ) 2013. 7.
393. ɲ®ɢŭҚͺ͏ȩҚȟ ͏əҚˊĬƼʔҚĬʑÓ³Қ΀ʑCϤҚı ¸ȩҚȣ̟S\ҚÕȇ˕ŏҚĬǪ ǋ. ͅĺɨ΁×ԔӝӨԢԁԧӿԠӘʐҠҶӝԤӸԧԋӠԢԤӃȧ '×̀ʱ±͵uӃϾʫ. ˢ 29 É DDS ā.āͬА. (ϧ) 2013. 7.
394. ͺ͏ȩҚ5ͥЮ͘üҚˍΛðǥҚĬF³ҚȸǪŵoЮҚÕȇ˕ŏҚĬǪп ǋ. ɍŲϫ˹ɕ̲ӁOӕӔԍԞӺԀԀԄ˭üӃy͵ҾҴӃ̩ͧͪԦaɵɎЍČƏqǸ. ˢ 66 ÉǆǪϫӲӾԡӲā.āͬА. (®¤Ĩ) 2013. 6.
395. ĬF³Қͺ͏ȩҚȓ ̜ŵҚɡϟǈʒϭҚͷĸPҚÕȇ˕ŏҚĬǪ ǋ. бӸԧӫӼӜԤө× PAMAM ӽԤӿԟԔԧӁӑӔԗӾӾԡӦӮԧӾӃб˓ͫŲӃƳÁӆбη˓Əq.ǆǪ͢uā.ˢ 28 ń. (®¤Ĩ) 2013. 5.
396. Wu D, Tanaka Y, Jin Y. R, Yoneto K, Quan Y. S, Kamiyama F, Katsumi H, Sakane T,
Yamamoto A. Development of a novel transdermal patch system containing sumatriptan
succinate for the treatment of migraine: In vitro and in vivo characterization. ǆǪ͢uā.
ˢ 28 ń. (®¤Ĩ) 2013.5.
ӼԧԔԳ
397. мͥɋŃҚʮĵЏ§ҚɦĸǌҚíʑ_ЮҚ Ĭˉɂ: ɺӲӾԡӲӁӑӔ Stat3 ɍŲ ӄ HspΒğҾɢɺ̤ŲʂŤӁĐҰӔ. ǆǪ͢ā.ˢ 138 ń. (ϱɀ) 2018.3.
398. Ɯʾ5¸ҚčΧĘҚмͥɋŃҚĬ£ʶ Қ ĬˉɂԺRab35 ҥqťҰӔνχӁėҰӔ
v-Src ӃŝН. ǆǪ͢ā.ˢ 138 ń. (ϱɀ) 2018.3.
399. ħͥŕҚčΧĘҚɓÞˉϤҚмͥɋŃҚ ĬˉɂԺԕӻӿӷԧԤqťȤȚӃ΁ǌӘʵƞҮҶǁͻTʟͨRǼ͈ɇӃȚ˨. ǆǪ͢ā.ˢ 138 ń. (ϱɀ) 2018.3
400. ĬıҟҤӂҚôǯîÃҚмͥɋŃҚ Ĭ ˉɂ: IGF1R ЃČuӁӑӔǼ͈7ƻkʜŁҾ˽̱ȭӃΒğ. ǆǪ͢ā.ˢ 138 ń. (ϱɀ) 2018.3.
401. ǴØп ɟҚǳ ΘҚƾͥŅҚĠǛKðǥҚɲп ϏԮŧŖ4 pH ŮˤŲ͢ɽӦԙԟӛԧӃ̼ʧ
^ωϓBϏԮˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.(ZŎ) 2017.10.
402. ʾʑʺ˷üҚǬǪɢüҚɡϥ§ҚʑÀȧҚͥĊЏŔ. B ×̩ɶӟӝԠӲ(HBV)ʒǱӟӝԠӲț˭ü(VLP)Ӄ DDS ӈӃŮʐԮˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.ԨˊƉԩ 2017. 10.
403. ȓ£̜ϭҚʭʾîʈҚɡϥ§ҚͥĊЏŔ. ӤԍӮӝӰԤӃ B ˽̱ŲԟԤԇ̼ӁėҰӔƑ̼ʧɍŲԮǆǪ͢ā.ˢ 137 ń.Ԩ&¦ԩ 2017. 3.
404. ʾʑʺ˷üҚͥʑǉŭҚǬǪɢüҚɡϥ§ҚʑÀȧҚͥĊЏŔ. B ×̩ɶӟӝԠӲʒǱӟӝԠӲț˭üԨVLPԩӃ DDS ӈӃŮʐԮ ǆǪ͢ā.ˢ 137 ń.Ԩ&¦ԩ 2017. 3.
405. ħͥŕҚčΧĘҚɓÞˉϤҚмͥɋŃҚ Ĭˉɂ: ˽̱iͱšǧԬ˾ǧӁřƆҭӕӔӲԊԤӿԠԕӻӿӷԧԤɾʜʮӀǁͻǼ͈ǂɇ. 2017 ńŌʎ·ˑā˲ā.«­ńȧî. (ˢ 40Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ÉǆǪiüʎɽā.ń.Ԧˢ 90 ÉǆǪʎ ā.î.) (ˊƉ) 2017.12.
406. îΧҚмͥɋŃҚĮǪ̜͘üҚčΧĘҚ Ĭˉɂ: HIF-1 Ӄ͟˙ңӑӆηbɍŲ Ӂӄ
Hsp105 ҥŬ͸ҽҟӔ. ǆǪ͢ā.ˢ 137 ń. (&¦) 2017.3.
407. ˊΡ ̭Ĉ, ɼϯ ž̜, îʾ ǓŔ, ͷʑ Kðǥ, Ñ ˉλ, ăͥ ͏˳, ʾʑ ˞Ŕ, ϼɰ Ȣ. Polyethylene glycol (PEG) FЫԟԓӶԧԖ oxaliplatin ƐԞӻӾӁңҩӔʍ¶ſ¡ŲӃé ӁЀҰӔʿ˚Ԯˢ 67 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ˊƉ) 2017. 10408. ɡϥ§Қͷǯй6ҚWǨĜðҚȣǪ śҚͥĊЏŔ. Ӥԓӱ̨̼ЀώԎԠԐӲӟӝԠӲ
ORF34 ӄӟӝԠӲŲηbsϾøͶ«7řƆӘ#ҮҶšǧϜ/üʫʆӁЀҰӔԮˢ 39 ÉǆǪiüʎɽā.ń.ԨȠɐԩ 2016. 11.
409. ɌʙİŚҚɡϥ§ҚͥĊЏŔ. ӲԠԋӢԞԋӚԤҥǢҰӔ˶ԎԠԐӲӟӝԠӲ 1 ×ӁėҰӔƑӟӝԠӲɍŲԮ ˢ 66 ǆǪ͢ā.τʝƲϥ̍.Ԧî.ԨгȜԩ2016. 10.
410.  ĢüҚϮͺÁŃҚɡϥ§ҚΩĸʹΧҚͥĊЏŔ. Na+ӝӣԄԋӢӛ Monensin ӄӟӝԠӲſǼԟԤԇ̼ӃԕӾӬԤӿԟӛЍČҾ JNK ɍŲ Ә#ҮҶӛԓӾԧӰӲӘΒğҰӔԮ ǆǪ͢ā.ˢ 136 ń.ԨȠɐԩ 2016. 3.
411. ʑ͘Ɍ̜ҚįǪ̅ϭЮҚôǯîÃҚčΧĘҚмͥɋŃҚ Ĭˉɂ: iͱǧŧĠ˦ӃƁӘƞȞҾҮҶҚǁͻ˽̱iͱЀώӸԤԇӨέӃƤ˻. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
412. ħͥŕҚčΧĘҚмͥɋŃҚ Ĭˉɂ: ǁͻӺԛԧԌԟԤTʟǼ͈ɇӁӑӔŧĠ˦ȚύqťӁЀώҰӔiüӃƤ˻. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
413. įǪ̅ϭЮҚʑ͘Ɍ̜ҚǳO˳ҚčΧĘҚмͥɋŃҚĬ£ʶ Қ Ĭˉɂ: ERK ӁӑӔǼ͈7ƻkӃqť. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
414. мͥɋŃҚʮĵЏ§ҚɦĸǌҚíʑ_ЮҚčΧĘҚ Ĭˉɂ: Hsp70 Βğңӑӆɢɺſ¡ŲӁңҩӔӮӝӾӤӝԤӰөԀԠ/ϕ˲ηbÊü Stat3 ӃЀ. ǆǪ͢ā.ˢ 136 ń. (Ƞɐ) 2016.3.
415. мͥɋŃҚĬȇϴŃҚĳʑЏ§Қ|ͥÓ˘ҚčΧĘҚ Ĭˉɂ: ƑҥәuƔƑŲӁӊҰ
Hsp105aӃȆĦÒ ӃЀ. ˢ 63 ÉǆǪʎ ā.τʝƲϥ<. (ˊƉ) 2016.5.
416. ϼϯŷ6ҚмͥɋŃҚčΧĘҚĬı1ͫҚ Ĭˉɂ: Src ӁӑӔҥәη˓ΒğҾǼ͈7ʜŁҾӃЀώŲ΁ǌӘʵƞҮҶ v-Src ΒğʫʆȅӃȢ˝. ˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.
(îЂ) 2016.10.
417. îΧҚмͥɋŃҚčΧĘҚ Ĭˉɂ: 4ϫ˹ΒğÊü HIF-1 ӃʫʆңӑӆηbɍŲӁңҩӔɺӰԝӻӨӸԤԇӨέ Hsp105 ӃЀ. ˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ)
2016.10.
418. ĮǪ̜͘üҚƌĳʰüҚȀ͉ϬϡҚмͥɋŃҚčΧĘҚ Ĭˉɂ: Hsp105 ԋӚԕԟԧӸԤԇӨέ Hsp105 ңӑӆ Apg Ӄ˽̱iͱӁңҩӔȤ̲. ˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ) 2016.10.
419. ƓŵüҚȼ^ȩtҚǪʑƖҚčΧĘҚмͥɋŃҚĬ£ʶ Қ Ĭˉɂ: v-Src ӁӑӔíȘ˺
Ϸ7ӃřƆ. ˢ 39 ÉǆǪiüʎɽā.ń. (Ƞɐ) 2016.12.
420. мͥɋŃҚĬȇϴŃҚĳʑЏ§Қ|ͥÓ˘ҚčΧĘҚ Ĭˉɂ: ɺӰԝӻӨӸԤԇӨέ
Hsp105aӃȆĦÒ ҾƑҥәuƔƑŲӈӃĐ. ˢ 39 ÉǆǪiüʎɽā.ń. (Ƞɐ)
2016.12.
421. ǻǨ̜¹ҚͷʑKðǥҚǾ CλҚĊǨ ˚ҚîʾǓŔҚÑˉλҚăͥ͏˳Қʾʑ˞ŔҚϼɰȢ. Oxaliplatin ӃԟԓӶԧԖ͵u ӁӑӔԞӻӾš̪ʱ̀ӁңҩӔȳŲӆʭϱ͟˙ӈӃŝНԮˢ 66 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ) 2016. 10422. ͷʑKðǥҚǻǨ̜¹ҚĊǨ ˚ҚǾ CλҚȼʑʈ˷ҚîʾǓŔҚʾʑ˞ŔҚϼɰȢ. ӣӦӮԟԍԞӺԤęUԟԓӶԧԖƐԞӻӾӃš̪ʱ̀˿̗ҽӃƌγʢJ̝țʢɿӃ΋?Ԯˢ 53 ÉԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ǆǪʩɂʨā.āͬА.Ԩϧԩ2015. 10.
423. ϳǨǘüҚɲп ϏҚǴHˋüҚ Ĭ9'üҚĠǛKðǥ. ̼ʧ4 pH ŮˤŲԐԍӺӿ SAPSp FЫԟԓӶԧԖӃӛӨӺԤ̷Ϯ«Ә#ҮҶ̼ʧ^ωϓԮˢ 31 ÉǆǪ DDS ā.āͬА. (ǲ)
2015. 7.
424. ϳǨǘüҚɲ ϏҚǴHˋüҚ йʒ̜Қ Ĭ9'üҚȓǪǘçҚĠǛKðǥ. ŧŖ4 pH ŮˤŲԐԍӺӿ SAPSp FЫԟԓӶԧԖӃ̼ʧ^ƁԮǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3.
425. ЯáŷλҚп ĢüҚϮͺÁŃҚΩĸʹΧҚɡϥ§ҚͥĊЏŔ. ӛԠӨӺӫԁԤӄĠ̱7ӲӾԡӲŮˤƏqӘ#ҮҼӟӝԠӲſǼ B ˽̱ŲԟԤԇ̼ӃæȮӘƏqҰӔ. ˢ 65 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (îЂ) 2015. 10.
426. ʺϹ¸ȢҚϮͺÁŃҚΩĸʹΧҚɡϥ§ҚͥĊЏŔ. ӴԡԤϫԀӾԟӟԖӃʫŲ7̻ŲԟԤԇ̼ӁėҰӔƑ̼ʧɍŲԮǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3.
427. ϮͺÁŃҚΩĸʹΧҚ¤ĸÃͻҚǳŐɛŃҚɡϥ§ҚͥĊЏŔ. ԈӾҥәӟӝԠӲӄĠ̱7ӲӾԡӲŮˤӘƏqҰӔ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3.
428. мͥɋŃԬʮĵЏ§ԬɦĸǌԬíʑ_ЮԬčΧĘԬĬı1ͫԬ Ĭˉɂ: ɺӰԝӻӨӁӑӔӮӝӾӤӝԤӰөԀԠ/ϕ˲ηbÊü Stat3 ӃɍŲ BMB2015 ˢ 38 ÉǆǪiüʎɽā.
ń.ԯˢ 88 ÉǆǪʎ ā.î.«­î. ԨˊƉԩ2015.12.
429. мͥɋŃҚɦĸǌҚʮĵЏ§ҚîΧҚĬı1ͫҚčΧĘҚ Ĭˉɂ: Nmi ӁӑӔ Stat3
ɍŲ Ә#ҮҶ Hsp70 ʫʆΒğ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
430. îΧҚмͥɋŃҚčΧĘҚĬı1ͫҚ Ĭˉɂ: HIF1a>þʮӀä ӬԆԠӾӁӑӔ
Hsp105 ӃȆĦÒ . ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
431. ĮǪ̭ŭϤҚмͥɋŃҚčΧĘҚĬı1ͫҚ Ĭˉɂ: űŲбвŲʭͪʡÊϜ/ü AF9
ӁӑӔ Hsp70 ӃηbɍŲ . ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
432. ȼ^ȩtҚǪʑƖҚˍǪɊ\ҚčΧĘҚмͥɋŃҚĬı1ͫҚĬ£ʶ Қ Ĭˉɂ: v-Src
ӁӑӔ chromosome bridge řƆȤȚ. ǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015.3.
433. îʾǓŔҚÑħǌǆЮҚͣ ̜ǖҚãǪEҚĠͷΓҚͷʑKðǥҚϼɰȢ. ԞӻӾ¶͡ҽӃ˽̱µǧӁėҰӔӣӦӮԟԍԞӺԤӃŝНԮǆǪ¶Ҿā.ˢ 49 Éî. (ĭЁ) 2015. 9.
434. îʾǓŔҚĬ OϭҚċǪ͉eҚʛ¹ĽҚͣ ̜ǖҚͷʑKðǥҚϼɰȢ. ӣӦӮԟԍԞӺԤӁӑӔԞӻӾ¶ͽſ¡ŲӃé ԮǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3.
435. ĊǨп ˚Қˡ^¸Қ˽ʑ̜̌ҚͷʑKðǥҚϼɰȢ. Oxaliplatin ƐԞӻӾӃȤȏʮӛԢӽӜԁӛ/ʤͽϓƵӄ̵вšȇˊ̀˧ӁңҩӔʭϱ͟˙Ӂ>þҰӔԮǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3.
436. ċǪ͉eҚîʾǓŔҚʛ¹ĽҚ"ʊЮҚ ͷȔüҚͷʑKðǥҚϼɰȢ. Bortezomib ƐԔӟӲӁңҩӔ¶ͽſ¡ŲӃé ԮǆǪ͢ā.ˢ 135 ń. (ˊƉ) 2015. 3.
437. ϳǨǘüҚɲ ϏҚǴHˋüҚ йʒ̜Қ Ĭ9'üҚȓǪǘçҚĠǛKðǥ. ŧŖ4 pH ŮˤŲԐԍӺӿ SAPSp FЫԀԄ˭üӃ̼ʧ^ωϓԗӤԁӳԖӃ΁ǵԮˢ 36 Éʎ7́Ҿ͢ɽӃʷ
8ʐӰԤԓӱӟԖ (Ũĳ) 2014. 11.
438. ϮͺÁŃҚ¤ĸÃͻҚΩĸʹΧҚɡϥ§ҚͥĊЏŔ. Diallyl trisulfide Ӄ NF-κB ӰөԀԠƏq
Ә#ҮҶƑ̼ʧǸ. ˢ 87 ÉǆǪʎ ā.î. Ԩϧԩп 2014. 10.
439. ȌĬ ϙҚϮͺÁŃҚɡϥ§ҚΩĸʹΧҚͥĊЏŔ. K+ӝӣԄԋӢӛ Nigericin ӄӤԓӱ̨̼ЀώԎԠԐӲӟӝԠӲſǼԟԤԇ̼˽̱Ӄ Wnt ӰөԀԠӘƏqҮӛԓӾԧӰӲӘΒğҰӔ.п ˢ
64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.п Ԩϧԩп 2014. 10.
440. ʾͳŷľҚɡϥ§ҚȌĬп ϙҚΩĸʹΧҚʺϹ¸ȢҚͥĊЏŔ. Ӥԓӱ̨̼ЀώԎԠԐӲӟӝԠӲԨKSHVԩſǼ B ˽̱ŲԟԤԇ̼ӁėҰӔӲԠԋӢԞԋӚԤӃƑ̼ʧɍŲ.ǆǪ͢ā.ˢ
134 ń.п ԨɹǪԩ2014. 3.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

441. ϮͺÁŃҚЯáŷλҚΩĸʹΧҚɡϥ§ҚͥĊЏŔ. Ӥԓӱ̨̼ЀώԎԠԐӲӟӝԠӲӄĠ
̱7ӲӾԡӲŮˤԨUPRԩӘƏqҰӔ.ǆǪ͢ā.ˢ 134 ń. ԨɹǪԩ2014. 3.
442. ɡϥ§Қ ǯƆñҚîȻʽҚæϯŚҚΩĸʹΧҚͥĊЏŔ.п Ӥԓӱ̨̼ЀώԎԠԐӲӟӝԠӲΒğŲԟԤԇ̼ӘȞʮҾҮҶ āʨɇӃƤ˻.ǆǪ͢ā.ˢ 134 ń. ԨɹǪԩ2014. 3.
443. мͥɋŃҚɦĸǌҚʮĵЏ§ҚîΧҚĬı1ͫҚčΧĘҚ Ĭˉɂ: Nmi enhances
the Hsp105b-mediated Hsp70 expression through the Stat signaling pathway. ˢ 37 ÉǆǪiüʎɽā.ń. (Ƞɐ) 2014.11.
444. îΧҚмͥɋŃҚȁɰēҚčΧĘҚĬı1ͫҚ Ĭˉɂ: HIF-1aӁӑӔɺӰԝӻӨӸԤԇӨέ Hsp105 ӃȆĦÒ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014.10.
445. ȕ ΧCҚîΧҚčΧĘҚмͥɋŃҚĬı1ͫҚ Ĭˉɂ: Src ɍŲӃʜŁϏӁңҩӔ˽̱iͱʜŁ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014.10.
446. ȼ^ȩtҚįǪ̅ϭЮҚƓ ŵüҚǪʑƖҚмͥɋŃҚčΧĘҚĬı1ͫҚĬ£ʶ Қ Ĭ
ˉɂ: v-Src ʫʆӁӑӔ chromosome bridge řƆԗӤԁӳԖӃ΁ǌ. ˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014.10.
447. мͥɋŃҚ ǯÆҚ Ɂǘ̜Қ ĸǞҚȀ͉ϬϡҚĮǪ̭ŭϤҚčΧĘҚĬı1ͫҚĬˉɂ: Ȇ^4iüԟԒȆӸԤԇӨέ SNRPE ӁӑӔ Hsp70 ӃʫʆϏ. ǆǪ͢ā.ˢ 134
ń. (ɹǪ) 2014.3.
448. îΧҚмͥɋŃҚčΧĘҚ Ĭˉɂ: ä ӬԆԠӾӁӑӔɺӰԝӻӨӸԤԇӨέ Hsp105
ӃʫʆΒğ. ǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014.3.
449. Nishida K, Ohishi A, Nagasawa N. Expression profile of ectonucleotidases andequilibrative nucleoside transporter in the rat circumvallate papillae. NEUROSCIENCE
2014 (Washihgton DC, USA) 2014. 11.
450. ͷʑKðǥҚĬ OϭҚċʑй>Қʛ¹ĽҚċǪ͉eҚîʾǓŔҚϼɰȢ. Oxaliplatin ΒʫŲ¶ͽЍČʫʢԗӤԁӳԖӃ΁ǵ ―¶ͽſ¡ŲҚ¶¡Ď7Ӄʫʆӆ¶˽̱ƺӃ̄«ʮ΁ǵ―Ԯˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10.
451. ˡ^¸Қ˽ʑ̜̌ҚȓĵŵʈҚʑŔȰҚȠʑŏ#ҚĊǨп ˚ҚǾп CλҚȼʑʈ˷ҚͷʑKðǥҚϼɰȢԺӣӦӮԟԍԞӺԤƐԞӻӾӃˊ̀ȳŲӁėҰӔӡԠӭӺӣԃӝԤӃŝНԮˢ64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10.
452. ċǪ͉eҚîʾǓŔҚʛ¹ĽҚ"ʊЮҚ ͷȔüҚĠͷΓҚͷʑKðǥҚϼɰȢ. ԒԠӼӷԕԌƐӄԔӟӲӃ¶ͽſ¡ŲӁŝНӘҢӔԮˢ 64 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2014. 10.
453. îʾǓŔҚċǪ͉eҚ"ʊЮҚ ͷȔüҚĠͷΓҚͷʑKðǥҚϼɰȢ. ԒԠӼӷԕԌƐԔӟӲӁңҩӔ¶ͽſ¡ŲӃé ԮǆǪ¶Ҿā.ˢ 48 Éî. (ЗĮ) 2014. 10.
454. ˽ʑ̜̌Қˡ^¸ҚȓĵŵʈҚ͖ϯǊŃҚʑŔȰҚȠʑŏ#ҚͷʑKðǥҚϼɰȢ.
Oxaliplatin ƐԞӻӾӃ̵вšȇˊ̀˧ӁңҩӔʭϱ͟˙ӈӃ organic cation/carnitinetransporters (OCTN) 1 ӆ 2 ӃЀӁҺҠҼԮǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.
455. ʛ¹ĽҚċʑй>ҚĬ OϭҚċǪ͉eҚĠͷΓҚͣп ̜ǖҚîʾǓŔҚͷʑKðǥҚϼɰȢ. Oxaliplatin ƐԞӻӾӁңҩӔ¶ͽȤ̲Ӄé ԮǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014.
3.
456. îʾǓŔҚDʑǓ'ҚǳǪȿľҚ|ͥɛΧҚÑ̫ʒЮϭҚͷʑKðǥҚϼɰȢ. ԞӻӾ¶͡ӁңҩӔ adenine nucleotide/nucleoside ¶ͽźà/ϕȤȚӃ΁ǌԮǆǪ͢ā.ˢ 134 ń. (ɹǪ) 2014. 3.
457. ϳǨǘüҚɲ ϏҚǴHˋüҚ Ĭ9'üҚȓǪǘçҚĠǛKðǥ. ̼ʧ4 pH ŮˤŲ SAPSp
FЫԀԄ˭üӃ in vivo Ȥ̲Ų΋?Ԯˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2013. 10.

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035

458. ϮͺÁŃҚΩĸʹΧҚɡϥ§ҚͥĊЏŔ.п Ġ̱7ӲӾԡӲΒğu Diallyl trisulfide ӃӟӝԠӲſǼŲԟԤԇ̼ӁėҰӔƑ̼ʧɍŲ,п ǆǪʎɽгiüā. 2013 ńŌî. ԨîЂԩ2013. 10.
459. мͥɋŃҚɦĸǌҚíʑ_ЮҚʮĵЏ§ҚĬı1ͫҚčΧĘҚ Ĭˉɂ: Nmi promotes
Hsp70 expression through its interaction with Hsp105Ҋ. ˢ 36 ÉǆǪiüʎɽā.ń.
(ˊƉ) 2013.12.
460. м ͥ ɋ Ń Қ Õ £ ó Ɍ ü Қ ͷ ĸ ē Қ ɦ ĸ ǌ  Қ Ĭ ı 1 ͫ Қ Ĭ ˉ ɂ : Hsp105 Ҿ Golgi
membrane protein 73 ҾӃ́«Ų. ˢ 86 ÉǆǪʎ ā.î. (Ƞɐ), 2013.9.
461. ĮǪ̭ŭϤҚмͥɋŃҚȀ͉ϬϡҚ ĸǞҚĬı1ͫҚ Ĭˉɂ: AF9 ӁӑӔ Hsp70 ӃʫʆϏ. ˢ 86 ÉǆǪʎ ā.î. (Ƞɐ) 2013.9.
462. ǯÆҚмͥɋŃҚ Ɂǘ̜Қ ĸǞҚȀ͉ϬϡҚĮǪ̭ŭϤҚĬı1ͫҚ Ĭˉɂ:
Hsp105ҊӁӑӔ Hsp70 ӃʫʆΒğӁӊҰ SNRPE ӃŝН. ˢ 60 ÉǆǪʎ ā.τʝƲ
ϥ<. (îЂ) 2013.5.
463. ʎĸǓüҚDʑǓ'ҚǳǪȿľҚͣп ̜ǖҚĠͷΓҚʑ ̜ǈҚͷʑKðǥҚϼɰȢ.
ԞӻӾ¶͡Ӄ×ӆ×¶˽̱ӁңҩӔϵӾԞԤӲԓԧӸ ZnT3 Ӄʫʆ΁ǵԮˢ 63 ÉǆǪ͢ā.τʝƲϥ̍.Ԧî. (ϧ) 2013. 10.
464. ͣп ̜ǖҚċʑй>ҚĬ OϭҚĠͷΓҚʛ¹ĽҚċǪ͉eҚͷʑKðǥҚϼɰȢ.
Oxaliplatin ƐԞӻӾӁңҩӔ¶͡ӃTʟ˿̗āʮӆ¶ͽӃͫāʮ΁ǵԮˢ 63 ÉǆǪ͢
ā.τʝƲϥ̍.Ԧî. (ϧ) 2013. 10.
465. ͷʑKðǥҚDʑǓ'ҚǳǪȿľҚʎĸǓüҚʑ ̜ǈҚϼɰȢԺ¶˽̱ӁӄϵӾԞԤӲԓԧӸ ZnT3 ҥʫʆҰӔԮԗӸԠԆӝӣӮӝӡԤӲʿ˚. 2013 (ЗĮ) 2013. 9.
466. ͷʑKðǥҚĬ OϭҚċʑй>Қʑ ̜ǈҚʛ¹ĽҚċǪ͉eҚîʾǓŔҚϼɰȢ.
Oxaliplatin ƐԞӻӾӁңҩӔʍ¶ſ¡ŲӃé ӁҺҠҼԮǆǪ¶Ҿā.ˢ 47 Éî. (&¦) 2013. 9.
467. ͷʑKðǥҚĬ OϭҚċʑй>ҚĠͷΓҚͣп ̜ǖҚʎĸǓüҚʑ ̜ǈҚʛ¹ĽҚċǪ͉eҚîʾǓŔҚϼɰȢ. Oxaliplatin ӁӑӔ¶ͽЍČʫʢȤŉӃÜ˅ʮȖ΅ Վ¶¡Ď7Ӄʫʆӆ¶˽̱ƺӈӃŝНՎԮˢ 86 ÉǆǪʎ ā.î. (Ƞɐ) 2013. 9.
468. ͷʑKðǥҚĬ OϭҚċʑй>ҚĠͷΓҚͣп ̜ǖҚãǪEҚîʾǓŔҚϼɰȢԺԞӻӾӃʍ¶ſ¡ŲӁėҰӔӣӦӮԟԍԞӺԤӃŝНԮNeuro2013 (ϧ) 2013. 6.
469. ċʑй>ҚĬ OϭҚĠͷΓҚͣп ̜ǖҚͷʑKðǥҚϼɰȢԺԞӻӾӃҡӋ¶ſ¡ŲӁėҰӔ oxaliplatin ӃŝНԮǆǪ͢ā.ˢ 133 ń. (Ƞɐ) 2013. 3.
470. Ĭ OϭҚʑ ̜ǈҚʛ¹ĽҚċǪ͉eҚͷʑKðǥҚϼɰȢԺOxaliplatin ƐԞӻӾӁңҩӔ¶¡Ď7Ӄʫʆӆ¶ſ¡ŲӈӃŝНԮǆǪ͢ā.ˢ 133 ń. (Ƞɐ) 2013. 3.
471. Ɂʲ9ϡüҚϯǯЮҚͷʑKðǥҚϼɰȢԺʽͽˊ̀˽̱ԭͭǎ˽̱ϿӁңҩӔ˽̱ìATP 'ΝȤȚӃ΁ǌԮǆǪ͢ā.ˢ 133 ń. (Ƞɐ) 2013. 3.
472. ǳǪȿľҚDʑǓ'Қ|ͥɛΧҚʎĸǓüҚͷʑKðǥҚϼɰȢԺԞӻӾǢϦУӁңҩӔ
ԂӨԡӣӺӿ'ΝϪ˹Ӄʫʆ΁ǵԮǆǪ͢ā.ˢ 133 ń. (Ƞɐ) 2013. 3.

пԻʿ˚ƆǸӃXϾɿɄԼԨΆ(ìԩпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ӰԤԓӱӟԖԦā.ˣӃĈǃɿɄҚӝԤӸԧԃӻӾҽӃXϾɿɄˣпԻǅӁĈǃҮҼҠӔӏӃԼпґ ǪԍԢӱӠӨӾӃԑԧԖԐԧӱӄ(Ӄ ѩѦѡ ҽXϾҮҼҠӔқп
Ѷ҂҂ѾёццѺѯѰѽхѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѼѯѼѽѲѲҁцѷѼѲѳ҆хѶ҂ѻѺпҒ ǪԍԢӱӠӨӾӃӦӻӨӣԋӰԤԓӱӟԖӘҚŃƆ щь ń шч ǡ щы ǆӁϾMҮҶқпѶ҂҂Ѿёцц҅҅҅хѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѳѲ҃ѱѯ҂ѷѽѼѮҀѳҁѳѯҀѱѶцѾҀѽѸѳѱ҂щцԨà´ǝӘîāԑԧԖԐԧӱӁƧκҮҼҠӔԩпғ ŃƆ щь ńŌƆǸʫͯ.ӘŃƆ щэ ń ъ ǡ шч ǆӁĈǃҮҶқпѶ҂҂ѾёццѺѯѰѽхѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѼѯѼѽѲѲҁцѯѱѶѷѳ҄ѳхѶ҂ѻѺԨĈǃș͸ӘԍԢӱӠӨӾԑԧԖԐԧӱӁƧκҮҼҠӔԩпҔ ˢ ш É͍ƌʿ˚̣ӴԕԀԧӘǪԍԢӱӠӨӾMҽŃƆ щэ ń ы ǡ ѐ ǆӁϾMҮҶқпѶ҂҂ѾёццѺѯѰѽхѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѼѯѼѽѲѲҁцѯѱѶѷѳ҄ѳхѶ҂ѻѺԨϾMș͸ӘԍԢӱӠӨӾԑԧԖԐԧӱӁƧκҮҼҠӔԩпҕ ŃƆ щэ ńŌƆǸʫͯ.ӘҚǪāҽӏҡҺƣƒҭӕҼҠӔˏ˝îāƈʚʮʿ˚ÜʴřƆƲƬȗҝԆӝӣԗӸԠҾʎ7ŮӃώЀ΁ǌӁÜһҠҶʠŸɂʨԋӚԠԔӬԗӸԢԕӨӲӃ˃˝Ԩ'ͯԺăʹƷƢԩҞҾ«­ҽҚŃƆ щэ ń шш ǡ щѐ ǆӁϾMҮҶқпѶ҂҂Ѿёцц҅҅҅хѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѳѲ҃ѱѯ҂ѷѽѼѮҀѳҁѳѯҀѱѶцѾҀѽѸѳѱ҂щцԨà´ǝӘîāԑԧԖԐԧӱӁƧκҮҼҠӔԩп
Ϝ/üԦӽԟԆԟԧʿ˚.ӰԤԓӱӟԖҝȧ'ӃϜ/üԦӽԟԆԟԧӘ̢ҢӔҞҾХҮҼҚ
ԍԢӱӠӨӾԗԤԆԧӃĠǛҥǪāӁңҠҼϾMҮҶқпѶ҂҂Ѿёцц҅҅҅хѵѳѼѳфѲѳѺѷ҄ѳҀ҇хѽҀѵцѷѼѴѽҀѻѯ҂ѷѽѼцѷѼѴѽҀѻѯ҂ѷѽѼѮѲѳ҂ѯѷѺхѯҁѾѕѷѲѓъьэюь Ԩ Ӱ Ԥ ԓ ӱ ӟԖӃș͸ӄʿ˚.ԑԧԖԐԧӱӁƧκҭӕҼҠӔԩпҖ ǪԍԢӱӠӨӾӃ Ͽà´.Ә]ӂҶXϾƆǸʫͯ.ӘҚǪāҽӏҡҺƣƒҭӕҼҠӔˏ˝îāƈʚʮʿ˚ÜʴřƆƲƬȗҝԆӝӣԗӸԠҾʎ7ŮӃώЀ΁ǌӁÜһҠҶʠŸɂʨԋӚԠԔӬԗӸԢԕӨӲӃ˃˝Ԩ'ͯԺăʹƷƢԩҞҾ«­ҽҚŃƆ щю ńя ǡ шя ǆӁϾMҮҶқǪ«­ƆǸʫͯ.ӁӄҚìϥ΋?̣ҾҮҼЗĮʸ˝îāîāЅ͢āʿ˚Ѕ͢ʎ· āƷĊƷƢӃôʶ QʎңӑӆîЂîāîāЅ͢āʿ˚ˑ͢uāiϯƷƢӃ ĸǔ8QʎӁҬ̈́ŀΪӓҚҴӕҵӕΜ΋ӘҠҶҷҠҶқп
Ѷ҂҂Ѿёцц҅҅҅хѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѳѲ҃ѱѯ҂ѷѽѼѮҀѳҁѳѯҀѱѶцѾҀѽѸѳѱ҂щцԨà´ǝӘîāԑԧԖԐԧӱӁƧκҮҼҠӔԩпҗ ǪāʀͅӃʿ˚Ʒ̭ӰԤԓӱӟԖҝϧ͢ˑîā Ѡѥѩ ӰԤԓӱӟԖҞӘŃƆ щъ ńŌҤӒń шՎщ É̇̈ʮӁϾMҮҼңӓҚԍԢӱӠӨӾ|̣ҥā^Ʒ¼ңӑӆāϥāʎԦîāЅʎӁ¯ҩʿ˚ƆǸӘʫͯҮҼҠӔқп
Ѷ҂҂Ѿёцц҅҅҅хѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѳѲ҃ѱѯ҂ѷѽѼѮҀѳҁѳѯҀѱѶцѹѾ҃Ѯҁ҇ѻѾѽҁѷ҃ѻцԨà´ǝӘîāԑԧԖԐԧӱӁƧκҮҼҠӔԩппԻҫӕҤӒĈǃҰӔćӃӏӃԼпҘ ǪԍԢӱӠӨӾӃƆǸà´.ӘŃƆ ъч ń э ǡ шэ ǆӁϾMҰӔćқпѶ҂҂Ѿёцц҅҅҅хѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѳѲ҃ѱѯ҂ѷѽѼѮҀѳҁѳѯҀѱѶцѾҀѽѸѳѱ҂щцԨϾMș͸ӘîāԑԧԖԐԧ
ӱӁƧκćԩппԱԴп ҴӃ$Ӄʿ˚ƆǸˣпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ǪԍԢӱӠӨӾӁʖҰӔƷ¼ԦîāЅʎԦāϥāʎҥªā.ˣӁңҠҼ¡ΫҮҼҠӔқԨ¡ΫŘǒӃ̧3ԦāńӁӑӓiԩпԻƷ¼Լпшх ǶʶȢҚšͥʶȩхп ̎͂͗ſǼʢʿ˚.ˢ шы ÉӌӃӔԗԘԟӛԠΫ¡ΫԨŃƆ щѐ ńŌԩ̎͂͗ ѥіѤш ȅҥÛЬʱ˽̱ӘſʽҰӔԗӤԁӳԖӃ΁ǵхп ˢ ьщ É̎͂͗ſǼʢʿ˚.хпщх ѧѶѷѹѯ҂ѯпѢупѝѯ҇ѯҁѶѷпѣупћ҃Ѹѷѻѽ҂ѽпіупѣѯѹѯѻ҃ҀѯпѨупѢѯ҂ҁ҃ѷпѨупўҁѶѷ҇ѯѻѯпіупѢѯѳѹѯ҅ѯпѫупќѽ҂ѽѶпѣхп п ѣххпџѽ҃ҀѼѯѺпѽѴпўѼѴѳѱ҂ѷѽѼпѯѼѲпјѶѳѻѽ҂ѶѳҀѯѾ҇прџўјспі҅ѯҀѲпщчшэ ¡ΫԨŃƆ щѐ ńŌԩѨѶѳп ѾѷѺѨп ѵѳѼѳп ѱѽѼ҂ҀѷѰ҃҂ѳҁп ҂ѽп ҂҇Ѿѳп ўўўп њ҆ѽѧп ѳѴѴѳѱ҂ѽҀп ѷѼѸѳѱ҂ѷѽѼп ѷѼ҂ѽп ѳѾѷ҂ѶѳѺѷѯѺп ѱѳѺѺҁп ѷѼпѥҁѳ҃ѲѽѻѽѼѯҁпѯѳҀ҃ѵѷѼѽҁѯхпъх ǶʶȢҚšͥʶȩхп ˢ ья ÉǆǪſǼʢā. ǆǪÔǂ.āͬА.āͬõ~Ϋ¡ΫԨŃƆ щю ńŌԩ̎͂͗ҥ ўўў ×ӡԋӠӨӸԧњ҆ѽѧ Әʱ˽̱^ӁɉUҰӔҶӎӁŬ͸ӀўѪ ×̐ȵӃԗӤԁӳԖ΁ǵхп ˢ ья ÉǆǪſǼʢā. ǆǪÔǂ.āͬА.хп
ых ƋʑЉ©хп ŃƆ щя ńŌˢ шы Éȧ 'Әƕҡ͍ƌӃҶӎӃԋӜӱӤԠԦԋӚԧԔԋӢԧԞԖп рѥѥћщчшэсп ͍ƌʿ˚̣õ~Ϋ¡Ϋхп ҝ˽͗ҏ×iɆͲ̚ӃӡԋӠӨӸԧνχȤȚ
΁ǌӃҶӎӃÉηфiɆʷЀӃȖ΅Ҟхпьх ɲп Ϗхп ŃƆ щэ ńŌǆǪԉӸԕԤā.õ~Ϋ¡Ϋхп ҝԉӸԕԤԿӬԅӨϫӃ ѷѼп҄ѷ҂Ҁѽ ԗӤԁӳԖ΁ǵҤӒ ѷѼп҄ѷ҄ѽ ʩɂʨӰӲӼԖӈӃĩϾҞпэх ѝѯ҇ѯҁѶѷпѣупќѽ҂ѽѶпѣхпѨѶѳпшъ҂ѶпѠѽҀѳѯпфпџѯѾѯѼпўѼ҂ѳҀѼѯ҂ѷѽѼѯѺпѧ҇ѻѾѽҁѷ҃ѻпѽѼпѢѷѱҀѽѰѷѽѺѽѵ҇п
їѳҁ҂п Ѿѽҁ҂ѳҀп ѯ҅ѯҀѲ ¡ΫԨŃƆ щэ ńŌԩѨҀѯѼҁѺѽѱѯ҂ѷѽѼп ѽѴп ѥҁѳ҃ѲѽѻѽѼѯҁп ѯѳҀ҃ѵѷѼѽҁѯп
҂ѶҀѽ҃ѵѶп҂ѶѳпѳѾѷ҂ѶѳѺѷѯѺпѱѳѺѺпѺѯ҇ѳҀхпѨѶѳпшъ҂ѶпѠѽҀѳѯпфпџѯѾѯѼп ўѼ҂ѳҀѼѯ҂ѷѽѼѯѺпѧ҇ѻѾѽҁѷ҃ѻп ѽѼпѢѷѱҀѽѰѷѽѺѽѵ҇хпюх ǶʶȢҚšͥʶȩхп ˢ эю ÉǆǪ˽͗ā.ЀͷƲϥ̍.п ͍ƌʿ˚̣õ~Ϋ¡ΫԨŃƆ щэ ńŌп ўўў ×ӡԋӠӨӸԧњ҆ѽѧ Ӄʱ˽̱^ɉUӁңҩӔ̎͂͗Ӄ ўѪ ×̐ȵ ѾѷѺіңӑӆ ѾѷѺѨ Ϝ/üӃŬ͸Ųхпях ǶʶȢҚʯĸµҚšͥʶȩхп ˢ ью ÉǆǪſǼʢā. ǆǪÔǂ.п āͬõ~Ϋ¡ΫԨŃƆ щэ ńŌԩ̎͂͗Ӄ ўўў ×ӡԋӠӨӸԧњ҆ѽѧ Ӄʱ˽̱^ɉUӁңҩӔ ўѪ ×̐ȵӃŬ͸Ųхпѐх ͷʑKðǥхп ǆǪ͢ā.τʝƲϥõ~Ϋ¡ΫԨŃƆ щэ ńŌԩҝѤ҆ѯѺѷѾѺѯ҂ѷѼ ΒʫŲ¶ͽЍČʫʢԗӤԁӳԖӃ΁ǵп ҋ¶ͽſ¡ŲҚ¶¡Ď7Ӄʫʆӆ¶˽̱ƺӃ̄«ʮ΁ǵҋҞпшчх ɲп Ϗхп ŃƆ щь ńŌǆǪ͢ā.τʝƲϥõ~ΫӘ¡Ϋхп ҝƑʩuӃɽŲӁʻʵҮҶʩɂʨʐǁͻԀԄӦԙԟӛԧӃy͵п ҋíЙʮӀƑʩ8ʐӘǢҰӔԉӸԕԤ њ Βğ7ӘʐҠҶƑʩԀԄ˭üӃȚ˨ҋҞпшшх ͺ͏ȩхп ˢ я ÉǆǪ љљѧ ā.õ~Ϋп рŃƆ щя ńŌсп ҝбӘȞʮҾҮҶКǁʮ љљѧϾʫҾʠŸɂʨӈӃŮʐҞппԻîāЅʎԼпшщх ѣѯѶѺѯп ѝѯѻѽ҃Ѳѯуп ѠѳѼѸѷҀѽп Ѣѯ҂ҁ҃ѻѽ҂ѽуп Ѡѷѹ҃ѹѽп іѻѯѵѯҁѳуп ѧѶѷѼѷѱѶѷп Ѡѯ҂ѽхп ѧ҂Ҁѳҁҁёп
ѥѶ҇ҁѷѽѺѽѵѷѱѯѺпѳѴѴѳѱ҂ҁупѥѯ҂ѶѽѺѽѵѷѱѯѺпѱѽѼҁѳѿ҃ѳѼѱѳҁпѯѼѲп҂ѶѳѷҀпѾҀѳ҄ѳѼ҂ѷѽѼпрӮԤӨӾԦԐӼԠ
ӲԌԠөуп ԢӰӛс͍ƌOˎʫͯΫ¡ΫԨŃƆ щѐ ńŌԩҝіѾѽѾ҂ѽҁѷҁуп Ѳ҇ҁѰѷѽҁѷҁуп ѯѼѲпѳ҆ѾҀѳҁҁѷѽѼп ѽѴп ѷѼѴѺѯѻѻѯ҂ѽҀ҇п ѱ҇҂ѽѹѷѼѳҁп ѯҀѳп ҁѳѿ҃ѳѼ҂ѷѯѺп ѳ҄ѳѼ҂ҁп ѷѼп ҂Ѷѳп ѽѱѱ҃ҀҀѳѼѱѳп ѽѴпьфѴѺ҃ѽҀѽ҃ҀѯѱѷѺфѷѼѲ҃ѱѳѲпѷѼ҂ѳҁ҂ѷѼѯѺпѻ҃ѱѽҁѷ҂ѷҁпѷѼпѻѷѱѳҞп

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨шъх

261006
S1311035

ǯ-²Қɲп ϏҚǴHˋüҚĠǛKðǥхп ǆǪ͢uā.ˢ щѐ ń.ā.MӰԤԓӱӟԖрѧѣѥњњщчшысп ǠOˎʫ̣ͯΫ¡ΫԨŃƆ щэ ńŌԩҝʩŧĠʌåqťӁӑӔʩɂʨƈʚҞпǴHˋüҚɲп ϏҚƋʑЉ©ҚĠǛKðǥхп ˢ ъэ Éʎ7́Ҿ͢ɽӃʷ8ʐӰԤԓӱӟԖп OˎʫͯΫ¡ΫԨŃƆ щэ ńŌԩҝԓӶԧԖ́ăć ԐԍӺӿӘoʐҮҶǁͻљљѧ ӃϾʫҞщѐпǴHˋüҚɲп ϏҚƋʑЉ©ҚĠǛKðǥԮǆǪ͢ā.ˢ шъы ń.п OˎʫͯΫ¡ΫԨŃƆ щь ńŌԩҝʩ˽̱́^ԍԢӼӛԧӵӁŮˤҮҼ˽̱^ӈӃ͢ɽƴhҥ¥̲Ӏǁͻ љљѧ ӃϾʫҞпў҂ѯѹ҃ҀѯпѧупѝѯѻѯпѧупѣѯѹѯѷпѢупѣѯѹѯ҇ѯѻѯпѠупѢѽҀѷѻѽ҂ѽпѧупѠѽѵ҃ҀѳпѠхпѨѶѳпь҂ѶпіҁѷѯѼпіҀѲѳѼп
јѽѼѴѳҀѳѼѱѳп щчшъп їѳҁ҂п ѥѽҁ҂ѳҀп і҅ѯҀѲ Ә¡ΫԨŃƆ щь ńŌԩҝѢѳѱѶѯѼѷҁѻп ѯѼѯѺ҇ҁѷҁп ѽѴпѳѴѴѷѱѷѳѼ҂п ѱ҇҂ѽѾѺѯҁѻѷѱп ѲѳѺѷ҄ѳҀ҇п ѽѴп ѻѯѱҀѽѻѽѺѳѱ҃Ѻѳҁп Ѱ҇п Ѽѽ҄ѳѺп ҂҃ѻѽҀѯѺп Ѿѝп ҁѳѼҁѷ҂ѷ҄ѳп
ѺѷѾѽҁѽѻѳҁҞп
ǴHˋüҚɲп ϏҚîʾoҚƋʑЉ©ҚĠǛKðǥхп ǆǪ͢uā.ˢ щя ń.п îāЅʎӲӤԞӰӻԍңӑӆǠOˎʫ̣ͯΫ¡ΫԨŃƆ щь ńŌԩҝ˽̱^ԍԢӼӛԧӵjǀԐԍӺӿӘoʐҮҶǁͻ͢ɽƴhӦԙԟӛԧӃϾʫҞпƋʑЉ©ҚǶп ʶȢҚɲп ϏҚÑΡҚšͥʶȩҚĠǛKðǥхп ǆǪ́ā.ˢ ъь ń.п āʎΫ¡ΫԨŃƆ щь ńŌԩҝ˽͗ӉәȵҾӃШ2ŲӁÜһҨҏ×iɆͲ̚ӃȤ̲ԗӤԁӳԖӃ΁ǵҞпȼʑ̞ ҚÑΡҚɲп ϏҚȐǪ¸ǑҚĠǛKðǥхп ˢ щъ ÉӛԤӺӴԤӲӰԤԓӱӟԖп õ~ΫԨĸΫԩ¡ΫԨŃƆ щь ńŌԩҝ̳̬˽̱ӁėҰӔ ҁѷѦѣі ğUӁӑӔӛӽӜԓӤӝԤҌԡӱӲӺԤҍӃȤ̲΁ǵҾԗӸԒԟӻӨӰԤӿԢԧԖɂʨӈӃĩǦҞпȼʑ̞ ҚĠǛKðǥхп ˢ ъ ÉԴîāώƯʿ˚ԋӢԧԞԖп ԓӲӸԧʫͯǠOˎΫӘ¡ΫԨŃƆ щь ńŌԩҝԗӸԒԟӻӨӰԤӿԢԧԖɂʨӘʵƞҮҶԡӱӲӺԤӃ̳̬˽̱ӁңҩӔʎʈ8ʐӃ΁ǌҞпϳǨǘüҚɲп ϏҚǴHˋüҚ йʒ̜Қ Ĭ9'üҚȓǪǘçҚĠǛKðǥхп ǆǪ͢ā.ˢ шъь ń.п OˎʫͯΫ¡ΫԨŃƆ щэ ńŌԩҝŧŖ4 Ѿѝ ŮˤŲԐԍӺӿ ѧіѥѧѾ
FЫԟԓӶԧԖӃ̼ʧ^ƁҞпЎðҚɲп ϏҚˍɰKɂҚĠǛKðǥхп ǆǪԉӸԕԤā.ˢ ээ Éî.п āʎOˎʫ
ͯΫ¡ΫԨŃƆ щэ ńŌԩҝ8ʐԗӤԁӳԖ΁ǵźàӁÜһҨӾӬԋӠԢԧԠӬԅӨϫӃƑʩǸӃæŗҞпĮǯǢϭüҚɲп ϏҚˍɰKɂҚĠǛKðǥхп ǆǪԉӸԕԤā.ˢ эь Éî.п āʎOˎʫͯΫ¡ΫԨŃƆ щь ńŌԩҝӾӬԋӠԢԧԠӬԅӨϫӁӑӔ ѯѼѵѷѽѾѽѷѳ҂ѷѼфщ ƏqӘ#ҮҶͪ˦ӃȚύăć 8ʐҞп
Ĭ9'üҚɲп ϏҚǴHˋüҚ й̜ҚȓǪǘçҚîʾoҚÑΡҚĠǛKðǥхǆǪ͢uā.ˢ щя ń.п ȹΤËҺǎ͢ĿΫ¡ΫԨŃƆ щь ńŌԩҝ̼ʧӃŧ
Ŗ4 Ѿѝ ӁŮˤҮҼ˽̱^ ӓςӌҥBϏҭӕӔ ѧіѥѧ ԐԍӺӿFЫԀԄ˭üӃȤ̲Ų΋?Ҟп
ĬF³Қͺ͏ȩҚǆȴϯľ̜Қ˄ϥ³ҚʼǨë̜üҚ͒ȓɒλҚÕȇ˕ŏҚĬǪп ǋхп ǆǪ͢uā.ˢ ъш ń.п ǠOˎʫ̣ͯΫп рŃƆ щя ńŌсп ҝӛӲԇԞӧԤϫF
ЫӘʐҠҶбȞʮ ԟԓӶԧԖӃϾʫҞп
п

шых

шьх

шэх

шюх

шях

шѐх

щчх

щшх

щщх

щъх

щых

щьх

п

Ԩțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035ђāϥāʎєпщэх Ɯʾ5¸ҚčΧĘҚмͥɋŃҚĬ£ʶ Қ Ĭˉхп ǆǪ͢ā.ˢ шъя ń.п āʎOˎʫͯΫ¡ΫԨŃƆ щѐ ńŌԩҝѦѯѰъьп ҥqťҰӔνχӁėҰӔп ҄фѧҀѱп ӃŝНҞпщюх иͺҭӐҤҚɡϥ§ҚͥĊЏŔхп ǆǪ͢ā.ˢ шъя ń.п āʎOˎʫͯΫ¡ΫԨŃƆщѐ ńŌԩҝӤԓӱ̨̼ЀώԎԠԐӲӟӝԠӲͶ͵ӃӬԧӿҰӔӟӝԠӲŲԍԢӼӛԧӵѤѦћшԷӄӟӝԠӲʏʎӁŬСҽҟӔҞп
щях -ͥʽŵҚɡϥ§ҚͥĊЏŔхп ǆǪ͢ā.ˢ шъя ń.п āʎOˎʫͯΫ¡ΫԨŃƆщѐ ńŌԩҝӤԓӱ̨̼ЀώԎԠԐӲӟӝԠӲͶ͵ӁңҩӔӟӝԠӲŲӸԤԇӨέ ѤѦћшш
ӃȤ̲΁ǵҞп
щѐх sʑп 9üҚɡϥп §ҚͥĊп ЏŔхп ˢ эю ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.п OˎԓӲӸԧΫ¡ΫҝӤԓӱ̨̼ЀώԎԠԐӲӟӝԠӲӁңҩӔӟӝԠӲŲϾøsͶ«7ӸԤԇӨέӃʷ8ʐ΁ǵҞпъчх ǴØɟҚǳΘҚǴHˋüҚƾͥŅҚɲϏԮǆǪ͢ā.п ˢ шъя ń.п āʎOˎʫͯΫԨԓӲӸԧʫͯӃϥԩԨŃƆ щѐ ńŌԩҝ̼ʧɚϥӃŧŖ4 Ѿѝ Ӄҥә˽̱ӈ͢ɽχ
ϕ¥̲Ӏ̼ʧωϓŲԟԓӶԧԖӃϾʫҞпъшх Ʌп îÔҚãп ʼҚǳǪп KȧϤҚïԥɴп ˳üҚ|ͥп 1хп ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ щчшюп OˎʫͯΫ¡ΫԨŃƆ щѐ ńŌԩҝќѥѦъь ɍŲ ӄî̽ʱϑίBϏ8
ʐӘ#ҮҼî̽ɶӘƏqҰӔҞпъщх ĠǶµŃԬĬʑʒ͊ЮԬǳoȻüԬîʼп ϏԬͥȩŨхп ȧ 'Әƕҡy͢Ԧʨ͢
ʈӰԤԓӱӟԖ щчшюп OˎԓӲӸԧʫͯΫҝӛӾԊԧŲʱ̀ɶԔӟӲʒǱͯʱ˽̱ӁңҩӔ Ѩѧѡѥ ϓwʏʎȤȚӃ΁ǵҞпъъх ăŷʺԬɡπDŭԬîʼп ϏԬͥȩŨхп ȧ 'Әƕҡy͢Ԧʨ͢ʈӰԤԓӱӟԖщчшюп OˎԓӲӸԧʫͯҝјьюїѡцэ ԔӟӲӘʐҠҶƂŲƨʣԘӽԠӃ˃˝Ҟпъых ϘͥüԬĸʑľĽԬî¸O#Ԭ5ͥĘ§ԬжУąŜԬîʼп Ϗхп ʎ7Ȥ̲Ҿy͢ӰԤԓӱӟԖ щчшюп OˎԓӲӸԧʫͯΫҝѾѝ ſ¡ŲӤԟӟԖӺԙԃԠ Ѡщѥьхш ́«ӸԤԇӨјљяш Ӄ­ćҾ јљяш ӁӑӔ Ѡщѥьхш Ȥ̲qťҞп пъьх ҶҧҮ¸ЉԬɝȸśêԬϘͥüԬжУąŜԬͥȩŨԬîʼп Ϗхп ǆǪ͢ā.ˢ шъэń.ԨŃƆ щя ńŌԩп ń.OˎʫͯΫҝɍŲ јљы ЈŲ Ѩ ˽̱ӁңҩӔӲԍԞӝӰԤөЃČuӁӑӔ̰Ǖ ѠтӺԙԃԠ Ѡщѥьхш ɍŲqťҞпъэх ɝȸśêԬϘͥüԬӸӧӰ¸ЉԬî¸O#ԬлĸӀҺ̜ԬжУąŜԬͥȩŨԬîʼпϏхп ˢ эь ÉǆǪ͢ā.τʝƲϥî.ԨŃƆ щю ńŌԩп OˎԓӲӸԧʫͯΫҝѠьэщ ˽̱ӁңҩӔӲԍԞӝӰԤөЃČuӁӑӔ ҂҅ѽфѾѽҀѳ × ѠтӺԙԃԠ Ѡщѥьхш ʫʆԦɍŲΖ˧Ҟпъюх ˊΡп ̭Ĉуп ɼϯп ž̜уп îʾп ǓŔуп ͷʑп Kðǥуп Ñп ˉλуп ăͥп ͏˳уп ʾʑп ˞Ŕуп ϼɰп Ȣхп ˢ эю ÉǆǪ͢ā.τʝƲϥî.п OˎԓӲӸԧΫ¡ΫԨŃƆ щѐ ńŌԩҝѥѽѺ҇ѳ҂Ѷ҇ѺѳѼѳп ѵѺ҇ѱѽѺп рѥњќсп FЫԟԓӶԧԖ ѽ҆ѯѺѷѾѺѯ҂ѷѼ ƐԞӻӾӁңҩӔʍ¶ſ¡ŲӃé ӁЀҰӔʿ˚Ҟпъях ϘͥüԬҶҧҮ¸ЉԬɝȸśêԬжУąŜԬͥȩŨԬîʼп Ϗхп ˢ яѐ ÉǆǪ͢ʈā.ń.ԨŃƆ щя ńŌԩп āʎOˎʫͯΫҝѨ ˽̱ӁңҩӔ ѾҀѳфѻѦѣі ӲԍԞӝӰԤөЃČuӁӑӔ̰ǕӤԟӟԖӺԙԃԠ Ѡщѥьхш ɍŲƏqҞпъѐх -ͥп ǈ̗Қͥɰп ˸ľҚɡϥп §Қǆ˼Ãп ЉͫҚ|ͥп ƼҚĮϯп ʹΧҚʑ͇ĳп\üҚĸп \ǑҚͥĊп ЏŔхп ǆǪ͢ā.ˢ шъю ń.п āʎOˎʫͯΫ¡ΫԨŃƆ щяńŌԩҝȆϫȚύӘɍʐҮҶƑӽԤөӟӝԠӲ «ɽӃƤ˻Ҟпычх įǯп ͚̜уп îʾп ǓŔуп ĠǶп ųüуп Ƕп ľüуп ͷʑп Kðǥуп ϼɰп Ȣхп ǆǪ͢āԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

ышх

ыщх

ыъх

ыых

ыьх

ыэх

ыюх

ыях

ыѐх

ьчх

ьшх

261006
S1311035.ˢ шъю ń.OˎʫͯΫԨԓӲӸԧʫͯӃϥԩ¡ΫԨŃƆ щя ńŌԩҝїѽҀ҂ѳ҈ѽѻѷѰп ӄԔӟӲӃϫ¶ſ¡ŲӘ¥ψʮӁæîҭҲӔҞп
ɼϯп ž̜уп îʾп ǓŔуп Ƕп ľüуп ĠǶп ųüуп ͷʑп Kðǥуп ϼɰп Ȣхп ǆǪ͢ā.ˢ шъю ń.OˎʫͯΫԨԓӲӸԧʫͯӃϥԩ¡ΫԨŃƆ щя ńŌԩҝӰӲԍԞӺԤƐԔӟӲӁңҩӔ͎¶ſ¡ŲӃé ҞпĬǪп ƹüҚͷʑп KðǥҚDʑп Ǔ'ҚǳǪп ȿľҚÑħп ǌǆЮҚɡϥп ϠҚîʾп ǓŔҚϼɰп Ȣхп ˢ эь ÉǆǪ͢ā.τʝƲϥî.п OˎԓӲӸԧΫ¡ΫԨŃƆ щю ńŌԩҝԞӻӾ¶͡ӁңҩӔ іѨѥ i΁Ϫ˹ њѣѥѥ ӛӝӶԋӢԧԖӃʫʆĦÒ΁ǵҞпȣǪп śҚɡϥ§ҚͥĊЏŔхп ˢ ээ ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.п OˎԓӲӸԧΫ¡ΫԨŃƆ щю ńŌԩҝӤԓӱ̨̼ЀώԎԠԐӲӟӝԠӲϜ/ü ѤѦћъэԨӟӝԠӲŲӦԀԧӵԩӃŲɿ΁ǵҞп˽ĸǓŃҚĠɰƅ#Қɡϥ§ҚΩĸʹΧҚͥĊЏŔхп ˢ эь ÉǆǪ͢ā.τʝƲϥ
̍.Ԧî.п OˎԓӲӸԧΫ¡ΫԨŃƆ щэ ńŌԩҝӟӝԠӲŲ њъп ԜԉӦӺԤԞӝӫԧӲѠьп ӁӑӔ јљяшп i΁ȤȚҞпĬ ĴʹҚɡϥ§ҚΩĸʹΧҚͥĊЏŔхп ˢ эь ÉǆǪ͢ā.τʝƲϥ̍.Ԧî.п
OˎԓӲӸԧΫ¡ΫԨŃƆ щэ ńŌԩҝјѦўѧѥѦфјѯҁѐп ӘʐҠҶӤԓӱ̨̼ЀώԎԠԐӲӟӝԠӲӃӫԄԖӃăć Ҟпĸǯп ˂ҚǬɑп ̦ҚɁśüҚǳǪKȧϤҚïԥɴ˳üҚ|ͥ1хп ǆǪ͢ā. шъь
ń.п OˎʫͯΫ¡ΫԨŃƆ щэ ńŌԩҝьфԋԠӣԢӟԞп ӰԠңӑӆӝԟԄӼӤԤӁӑӓΒΰҭӕӔ̽ɶӃʡƁӃȴιҞпĠʘŭDҚʾĬśóҚǲĸˋüҚÈǂÜÅҚǶʶȢҚšͥʶȩхп ˢ эы ÉǆǪ͢ā.τ
ʝƲϥ̍.Ԧî.п OˎԓӲӸԧΫ¡ΫԨŃƆ щэ ńŌԩҝўѪ ×̐ȵӁʻʵҮҶ̎͂͗ӁӑӔ јѯѱѽфщ ˽̱ԘԄԡӝԚωϓӃ΁ǵҞпǯıȿ|ԬǯɴĈľԬǳǩǱԬ!ɹąȢԬǾĮϭóԬͥȩŨԬóϞKԬ"ɅˉɂԬîʼϏхп ˢ эы ÉǆǪ͢ā.τʝƲϥî.ԨŃƆ щэ ńŌԩп OˎԓӲӸԧʫͯΫҝɶʢŲ̽ʠŸԘӽԠԔӟӲ Ѩ ԟԤԇʇӁңҩӔ јѯщтɍŲ ѠтӺԙԃԠ Ѡјѯъхш ɍŲ ÊüѼ҃ѱѺѳѽҁѷѲѳпѲѷѾѶѽҁѾѶѯ҂ѳпѹѷѼѯҁѳфїпрѣљѥѠфїсп ӃŞxҞп
5ͥ̌Ԭ H5¸Ԭʾʊ˳Ԭ ̟ϭĈԬͥȩŨԬîʼϏхп ˢ эы ÉǆǪ͢ā.τʝƲϥî.ԨŃƆ щэ ńŌԩп OˎԓӲӸԧʫͯΫҝɶʢŲ̽ʠŸԘӽԠԔӟӲӃ̹̓ʒǱ
јљы ЈŲ Ѩ ˽̱ӁңҩӔӛԠӤԟ Ѿѝ ɍŲ ѠтӺԙԃԠ ѨіѧѠщ ӃŞxҞпȼ^ȩtҚǪʑƖҚˍǪɊ\ҚčΧĘҚмͥɋŃҚĬı1ͫҚĬ£ʶ Қ Ĭˉɂ хп ǆ Ǫ ͢ ā . ˢ шъь ń . п O ˎ ʫͯ Ϋ¡ Ϋ Ԩ Ń Ɔ щэ ń Ōԩ ҝ ҄ҐѧҀѱ Ӂ ӑ ӔѱѶҀѽѻѽҁѽѻѳпѰҀѷѲѵѳ řƆȤȚҞпĬF³Қͺ͏ȩҚȓп ̜ŵҚɡϟǈʒϭҚÕȇ˕ŏҚĬǪп ǋхп ˢ эъ Éп ǆǪ͢ā.τʝƲϥ̍.Ԧî.п OˎԓӲӸԧΫп ¡ΫԨŃƆ щь ńŌԩҝӛԡԤӿԢԃԧӾFЫӘoʐҮҶбӸԧӫӼӜԤө×гiüӦԙԟӛӃϾʫԺԗӾӾԡӦӮԧӾӃб˓ͫŲӃƳÁӆбη˓ƏqҞпԨțő 2ԩɇ ʛ¨ԍԢӱӠӨӾʛ¨

261006
S1311035пԱԵп ҝϛćǒҞӆҝ Ͽ΋?ǒҞӁ%ҭӕҶʙŽПӆėŮпԻҝϛćǒҞӁ%ҭӕҶʙŽПԼпљљѧ ӄǅӁíҨӃΌӌҥҟӔҫҾҤӒҚǅþӃƆǸ(ӃƆǸӘǧŠҰӔқппԻҝϛćǒҞӁ%ҭӕҶʙŽПӈӃėŮԼпʙŽПҾҮҼҬƞưӘ¡ҩҶӑҡӁҚљљѧ ӄǅӁíҨӃΌӌҥҟӔқɾӁҚҥәɂʨӁңҠҼӄ̼ʧ˿̗Ӄͪ˦ωϓŲϏҾгҠ͟˙ŲԨњѥѦ ǸԩӘoʐҮҶԀԄ˭üԨԕӴԠҚԟԓӶԧԖˣԩӃ љљѧ ͵uҥϾʫҭӕҚ̈́ňҽӏ;ʐҭӕҼҠӔқҴӃҶӎҚţǱҿңӓӃӛԍ
ԢԧӺҽӄҝǅþӃƆǸ(ӃƆǸҞӘŤӔҫҾӄГҮҠқǪԍԢӱӠӨӾҽӄҚτńɉʵҭӕҼҠӔŧĠʌåӃɾŲӁʻʵҮҚҴӃɾŲӁŮүҼɽŲˣӘé ҭҲӔҫҾҽ̼ʧӃӌӀӒұíțӀʠŸӁ͢ɽχϕ¥̲ӀКǁʮԀԄ љљѧ ӃyƆӘʵƞҰӏӃҽҟӔқţǱӃԀԄљљѧ ӄҚͪɖ ӁңҩӔʎ7ƆiҾӃʷ8ʐӘϝҩӔҶӎ;ȸŲгiüԓԟӡӺԡԤөԟӬԧԠԨѥњќԩӁӑӔͯЙFЫҥŘҶӓsҽҟҹҶҥҚǪԍԢӱӠӨӾҽϾʫӘʵƞҮҶԀԄљљѧ ӄҚǅþӃșůҤӒ̷ҮҚДȷʮŲέӁӑҹҼʎ7ƆiҾӃʷ8ʐӘqťҰӔԜԁԧӨӀӛԍԢԧӺӘʫŻҮҚʠŸŧĠʌåӁңҩӔɾŲԨ<ҢӅ ѾѝԩӁſŮҮҼɽʈ āʮŲέӘé ҭҲӔҫҾҽҚгҠͪ ɪʙŲҾʃӑҠ˽̱;¸ŲӘjӓǟҢ¥̲ӀǁҮҠљљѧ ӃϾʫӁƆ{ҮҼҠӔқҭӒӁҚљљѧ ĚϽТÚӃʿ˚̣ҷҩҽӀҨҚțҜӀТÚӃʿ˚̣ҥØȇӘβҢҼzҮҶʠŸŧĠʌåźà΁ǵʿ˚ҤӒҚ<ҢӅ4ϫ˹ТÚӘǢҰӔŹŲ̼ʧҥþÒҰӔá«Ӂ4ϫ˹ӁŮүҼ ѡѷѾѽѱѯѺѷѼщ ӸԤԇӨέҥiɆҭӕӔҫҾӐҚ̎͂͗ӃſǼǒӁ˯́ī ӁңҩӔӡԋӠӨӸԧӸԤԇӨέiɆҥ˯́īӃ˯ŲӁӑҹҼɽʈʮӁqťҭӕҼҠӔ¥̲ŲӀҿҚҫӕӋҽӁǌҽҟҹҶʠŸŧĠʌåźàӘͺhҰӁ͆ҹҼҠӔқппԻҝ Ͽ΋?ǒҞӁ%ҭӕҶʙŽПԼпп ìϥ΋?̣ҾҮҼҚЗĮʸ˝îāîāЅ͢āʿ˚Ѕ͢ʎ· āƷĊƷƢӃôп ʶ QʎңӑӆîЂîāîāЅ͢āʿ˚ˑ͢uāiϯƷƢӃ ĸǔ8QʎӁ Ͽ΋?ӘОҦҚҴӃ^Ďӄ(ӃԑԧԖԐԧӱӁƧκҮҼҠӔқп
Ѷ҂҂Ѿёцц҅҅҅хѹ҇ѽ҂ѽфѾѶ҃хѯѱхѸѾцѳѲ҃ѱѯ҂ѷѽѼѮҀѳҁѳѯҀѱѶцѾҀѽѸѳѱ҂щцпп ìϥ΋?̣ҤӒӄҠұӕӏϏơɿɄӄșӂРΖҽҚiӀƆǸҥҥҹҼҠӔҾ΋?
ОҠҶқǂҚiϯӘαҢҼӃY­ʿ˚ҥӋҷiҾӄ΃ҢӀҠҾӃʙŽПӘОҠҶқппԻҝ Ͽ΋?ǒҞӁ%ҭӕҶʙŽПӈӃėŮԼпп ìϥ΋?̣ҤӒӃƞưҽҟӔiϯӘαҢҼӃY­ʿ˚ӃƦϏӁҺҠҼӄҚӋұӄªʅ^ҽʆɿҾė˥ӁҺҠҼΟΙҮҚҴӕӒӘʅϼ.ΟҚҭӒӁӄV7.Οҽ̙ӎҚ[7ʮė˥ҾҮҼǂϲӘȽćҮҶқҰӀӗҸҚªʅ^ҽӃʿ˚ƆǸӘ ӓ̙ӎҚʅ^ҭӒӁӄԍԢӱӠӨӾԗԤԆԧV7ҽYǢ ҮҚʿ˚'̣ͯӘ ūӁªʅϼӘϋҮҼY­ʿ˚7qӃȚ˨ӘϏӎҶқ[7ʮӁӄҚш ʅҽŤӒӕҶʠŸӃʡƁЀώiüӁėҰӔ ҁѷѦѣі Ә8͵ҮҚҴӕӘ щ ʅҽϾʫҭӕҶԀԄ љљѧ ͵uӁƮκҭҲҚҁѷѦѣі ͅ7ҾԀԄ љљѧфҁѷѦѣі ͵uҾӃǸӃȴιȖ΅ӘʆÒͫҹҼҠӔқӋҶҚъ ʅӁңҠҼҚԀԄ љљѧфҁѷѦѣі Ӄʡéϥ3ӈӃ˓ͫӐ7^ƁҚҭӒӁӄv8ʐʫʆˣӃɣˣӘȖ΅ҰӔćҽҟӔқ$Ӂӏʅ^ӃiϯϿҚҭӒӁӄ
ʅӘαҢҼӃY­ʿ˚7qҥŢҜӁȚ˨ҭӕҚʆÒӏҴӕӒY­ʿ˚7qӃÜӁʿ˚ӘϏӎҼҠӔқҮҤҮҚʆǒɷҽӄҚXͯҽҦӔӋҽӃiӀʿ˚ƆǸӘŤӔӁӄ͆ҹҼҠӀҠқ
"šӏҚœҦ̈ҦY­ʿ˚7qӘÜӁӑӓǢȤʮӀ́ӆҺҨҫҾҽҚӑӓŗÍӀʿ˚ƘɷӃřƆӁ̖ҪҼҠҨćҽҟӔқп

ŌgIÎō
lz/ĹņĨĝġİz/ÎÒÍÌÌÒ
åÍÏÍÍÌÏÑŏőŌ(ōúúúúúúúúúúúúúúúúúúúúúú¥
FGŉ&

E Z ¤
N
 
Î
Ñ
¤ 
F
G  ¨
E Z ¤
N
 
Î
Ò
¤ 
F
G  ¨
E Z ¤
N
 
Î
Ó
¤ 
F
G  ¨
E Z ¤
N
 
Î
Ô
¤ 
F
G  ¨

T¿

lú
§úP

ú?
#úN

0
h»
§P

-¢
 

C¸

ĆĎŌúúúúúúúúúúō

ÌÌÍÕÉÎÏÒ

ÒÉÑÌÓÍÎÉÓÎÕ

ÏÐÉÎÐÏ

ÍÕÉÑÒÍ

ÍÐÉÒÔÎ

ÍÓÉÕÑÕ

ÍÑÉÑÐÍ

ÍÑÉÑÔÓ

ÍÐÉÓÏÍ

ÍÒÉÕÕÌ

ÍÏÉÏÎÍ

ÌÌÌÏÏÉÑÌÌ
ÌÌÌÏÌÉÏÍÔ
ÌÌÌÏÌÉÏÍÍ

E Z ¤
N
 
Î
Õ
¤ 
F
G  ¨

ÏÌÉÍÔÒ

ÍÒÉÑÏÓ

ÍÏÉÒÐÕ

Z ¤

Ì

Ì

Ì

Ì

Ì

Ì

Ì

 

Ì

Ì

Ì

Ì

Ì

Ì

Ì

¤ 

ÍÕÉÎÏÒ

ÒÉÑÌÓÍÎÉÓÎÕ

Ì

Ì

Ì

Ì



ÍÑÔÉÑÑÔ

ÔÒÉÒÏÐ

ÓÍÉÕÎÐÌÌÌÌÍÓÓÉÓÕÐ

ÕÏÉÍÐÍ

ÔÐÉÒÑÏ

Ì

Ì

Ì

Ì


¿



¨
¡

Ì
Ì
Ì

ú

ŌgIÎō
lz/ÎÒÍÌÌÒ

ŏŒýZúú¤þÅÅŌ?#NĘ-ĂĊÿČÿĔĎĔ2ēûyĄĊÿėZ¤ĘąđĊ£­ĄĊāĈăÿüō
Zú¤úĎú1ú

WFG

M?Â
«Â
åe

ENÍÒFGENÎÍFG]3ÒÏFG



Z¤¾



Î

ÍÉÐÑÑËÐÒŕ
ÔÐÐËÒÓŕÎ
ÍÉÌÌÓËÍŕÎ

AV

yV

f¨

#¸¿

#

ÕÓ
ÓÔ
ÎÓ

ÎÍÓÉÏÌÕ

ÍÌÔÉÒÑÐ

?#N

Ì

ŋ

ÏÑ
ÎÐ
ÏÏ

ùú?#Nčĕė#fċĄĊĉćY<čĕĖûWŌ(ōċi¬ĄĊ<"Ąć¾ýŉ¤þúŌ?#NĘ-ĂĊÿČÿĔĎďûČĔĎĎĒĘ£­ĄĊāĈăÿüō
ŉ¤Ď1

WFG

9úúz

.úúV

^ºV

Ō(ō

f¨

#¸¿

#

Ō ō
rqŅŊĦŊÀJ¹ħĩĮĽENÎÑFG ÖÍäÈěľŊĨňĢħĩĮĽ

ENÎÑFG áôìõìööé

$ b½ENÍÎFG ÛÖØåÅØéñðê÷õ

Í
Í
Í

ÏÉÐÎÐ
ÒÉÓÏÓ
ÎÉÓÏÌ

Ŕ
Ŕ
Ŕ

ÐÎÉÒÍÕ
ÐÍÉÕÌÎ
ÏÌÉÌÓÓ

ÎÍÉÎÎÕ ?#NÍÕÉÕÑÌ ?#NÍÑÉÌÏÔ ?#N

Í
Í
Í
Í
Í

ÍÉÕÏÌ
ÎÕÒ
ÏÉÔÌÑ
ÒÉÒÑÌ
ÑÉÒÏÔ

Ŕ
Ŕ
Ŕ
Ŕ
Ŕ

ÍÎÉÓÍÑ
ÒÉÑÎÌÎÒÉÎÑÌ
ÏÕÉÕÕÕ
ÏÕÉÎÐÏ

ÔÉÐÐÑ ?#NÐÉÎÔÐ ?#NÍÍÉÕÎÔ ?#NÎÒÉÒÒÒ ?#NÎÒÉÍÒÎ ?#NŌ ¤ō
Ä°nENÎÑFG ÞØßåÊÎÌÎÌ

ġņĻİĢłķ©·bĳěĺĠħęÆ

¶ÇŇŊġĩĮŊħŁň

ENÎÑFG ÝàçÝçáÐÌÌ

ENÎÐFG ÜÓÎÍÍÖ
ÞØÊÝØâÊßåħĩĮĽ
ŅŊĦŊĩĠĿňÀJ¹ ENÍÔFG ÞåßÑÍÌßÚæÖ
x ´ >|v bħĩĮĽ ENÍÒFG ×ðóäóêóöÚèÍ

ŌL;w»¤ō
Ŕ
Ŕ
Ŕ
Ŕ

ŏœú
 ¨ĎTuk
ĮŊĻÍ
FúúúG
ÅÅEN
ÎÑ
DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō¡¨TŌ%5ō
U ¨T
¡
U

yh64

8úúúú_
¡

ÏÏÓ ?

,Đ

ÍÍÉÐÐÌ ¦û@Ã$t

*"

¸úú¿

úúČúúúúBúúúúúúúú¨úúúúTúúúú

ÏÏÓ \a?

úÍÍÉÐÐÌ ¦ÆÐÉÐÍÏÇû@ÃyÆÑÉÎÔÔÇûĆĎÆÍÉÓÏÔÇ

ÍÍÉÓÓÓ
ÍÍÉÓÓÓ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúúÌ¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÏÉÒÐÎ  yh6ÏÉÒÐÎ ÀJ¹yįĨīńğľłú
ÏÉÒÐÎ

ÏÉÒÐÎ

ŌgIÎōlz/úúúÎÒÍÌÌÒ

úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÎ
ÅÅEN
ÎÑ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō
¡

ÐÔ ?

*"

ÔÉÐÏÏ ¦ûúúČúúúúBúúúúúúúú¨úúúúTúúúúÐÔ åÛääÝÎÌÍÐúÔÉÐÏÏ ¦ÆÎÉÍÎÔÇû@ÃyÆÏÉÑÔÌÇûĆĎÆÎÉÓÎÐÇ

ÔÉÐÔÍ
ÔÉÐÔÍ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

,Đ

¸úú¿

Ì
¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō

yh648úúúú_¡

Ìúúúúúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÏ
ÅÅEN
ÎÑ

DÅÅÅÅ~Túú¿múú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō¡¨TŌ%5ō
U ¨T
¡
U

yh64

Ō(ō
FG

úČúú®
Uúúúúúúúúúúúú

ÐÓÍ ?

,Đ

*"

ÑÉÔÑÑ @Ãyû¦û@Ã$túúúúúú¥¸úú¿úúČúúúúBúúúúúúúú¨úúúúTúúúúÐÓÍ ÎÍ7śţŝŚŤŞŖŘŠŜŘŜťşŧŜŦřšú'{?ŞŗŘŢšÎÌÍÏúÑÉÔÑÑ ¦ÆÍÉÓÕÎÇû@ÃyÆÎÉÏÎÍÇûĆĎÆÍÉÓÐÍÇ

ÒÉÏÎÒ
ÒÉÏÎÒ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúúÌ¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÐÉÌÍÐ  yh6ÐÉÌÍÐ ÞðîïöÅØøëñìõÅàéòóħĩĮĽúŌgIÎō
lz/
8úúúú_
¡

ÐÉÌÍÐ
úúú

ÎÒÍÌÌÒ

ÐÉÌÍÐúúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÍ
ÅÅEN
ÎÒ

DÅÅÅÅ~Túú¿úúúúúú¥úČúú®
Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō
¡

ÐÑÌ ?

,Đ

*"

¸úú¿
úúČúúúúBúúúúúúúú¨úúúúTúúúúÐÑÌ ÔÔ7\aw?

FúÍÎÉÌÒÒ @Ã$tû¦ÍÎÉÌÒÒ ¦ÆÎÉÔÍÔÇû@ÃyÆÔÉÍÒÔÇûĆĎÆÍÉÌÔÌÇ
ÍÎÉÑÍÒ
ÍÎÉÑÍÒ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

Ō(ō
FG

yh64

Ì
¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÎÉÍÏÌ  yh6ÎÉÍÏÌ ŃęńīěĽâØäú

8úúúú_
¡

ÎÉÍÏÌ
úúú

ÎÉÍÏÌ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÎ
ÅÅEN
ÎÒ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō
¡
¨T

ÕÍ ?

,Đ

ÕÉÌÎÎ ¦û@Ãy

*"

¸úú¿

úúČúúúúBúúúúúúúú¨úúúúTúúúúÕÍ \a?

ÏÒFúÕÉÌÎÎ ¦ÆÐÉÌÎÎÇû@ÃyÆÐÉÏÑÌÇûĆĎÆÒÐÕÇ

ÕÉÍÍÏ
ÕÉÍÍÏ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúúŌgIÎō
lz/Ō%5ō
U ¨T¡UÎÒÍÌÌÒ

Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō

yh648úúúú_¡

Ìúúúúúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÏ
ÅÅEN
ÎÒ

DÅÅÅÅ~Túú¿úČúú®
Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō
¡

ÍÑÒ ?

,Đ

*"

úúúúúú¥¸úú¿úúČúúúúBúúúúúúúú¨úúúúTúúúúÍÑÒ ÎÐ7\a'{?

FúÒÉÐÍÐ @Ãyû¦ÒÉÐÍÐ ¦ÆÍÉÔÌÎÇû@ÃyÆÏÉÌÏÎÇûĆĎÆÍÉÑÔÌÇ
ÒÉÑÓÌ
ÒÉÑÓÌ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

Ō(ō
FG

Ì

yh64

¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÏÉÍÒÒ  yh6ÏÉÍÒÒ ª oķŃŊĦŊú8úúúú_
¡

ÏÉÍÒÒ
úúú

ÏÉÍÒÒ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÍ
ÅÅEN
ÎÓ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢X

ÏÍÕ ?

,Đ

*"

¸úú¿

úúČúúúúBúúúúúúúú¨úúúúTúúúúÏÍÕ xhċ!ŜťşŧŜŦřšúŌgIÎōlz/ŌúúúÍÌÉÓÍÌ @Ã$tû¦

ú¨úúō
¡

ÍÍÉÌÎÕ
ÍÍÉÌÎÕ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T¡UÎÒÍÌÌÒ

ÍÌÉÓÍÌ ¦ÆÐÉÏÏÏÇû@ÃyÆÑÉÍÎÕÇûĆĎÆÍÉÎÐÔÇ

Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎōÕÕÏ  yh6ÕÕÏ ĥŊĻńĥěġłŊÓÏ _
ÓÏ ÙÙåĠĿŃę ĹņİĤń¼Å

yh648úúúú_
¡

ÍÉÌÒÒ
úúú

ÍÉÌÒÒ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÎ
ÅÅEN
ÎÓ

DÅÅÅÅ~

Túú¿

Ō(ō
FG

múú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō¡úČúú®
Uúúúúúúúúúúúú

ÍÔÔ ?

,Đ

*"

ÓÉÏÑÕ û@ÃyÓÉÑÐÓúúúúúú¥¸úú¿úúČúúúúBúúúúúúúú¨úúúúTúúúúÍÔÔ ÎÌÍÑØäåúÓÉÏÑÕ ¦ÆÎÉÐÍÓÇû@ÃyÆÐÉÑÓÑÇûĆĎÆÏÒÓÇ
ÓÉÑÐÓęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

yh64

Ì
¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÍÉÑÐÐ  yh6ÍÉÑÐÐĜĞĩīňĸņĭİěľŊĨňĢħĩĮĽØÊÙðÜðö8úúúú_
¡

ÍÉÑÐÐ
úúú

ÍÉÑÐÐ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÏ
ÅÅEN
ÎÓ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨¸úú¿úúČúúúúBúúúúúúúú¨úúúúTúúúúŌgIÎō
lz/úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúúú ú¨úúō
¡

ÍÏÏ ?

*"

ÍÏÏ ':}ŉHŉcÁ

OúÒÉÐÎÎ ¦û¶ÒÉÐÎÎ ¦ÆÎÉÎÕÏÇû@ÃyÆÏÉÐÑÏÇûĆĎÆÒÓÒÇ
ÒÉÑÑÑ
ÒÉÑÑÑ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

,Đ

ÎÒÍÌÌÒ

yh64Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÎÉÑÓÐ  yh6ÎÉÑÓÐ ßðññðÊãÅäìíìõìòëìÅ8úúúú_
¡

ÎÉÑÓÐ
úúú

ÎÉÑÓÐ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÍ
ÅÅEN
ÎÔ

DÅÅÅÅ~Túú¿múú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúú ú¨úúō
¡

Ō(ō
FG

úČúú®
Uúúúúúúúúúúúú

ÏÏÒ ?

,Đ

*"

úúúúúú¥¸úú¿úúČúúúúBúúúúúúúú¨úúúúTúúúú

ÏÏÒ \aw?

FÅÕÉÌÒÕ @Ã$tû¦ÕÉÌÒÕ ¦ÆÎÉÑÍÕÇû@ÃyÆÑÉÑÏÎÇûĆĎÆÍÉÌÍÓÇ

ÕÉÐÌÑ

ÕÉÐÌÑ

ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

yh64

8úúúú_¡

Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÐÉÔÏÍ  yh6ÐÉÔÏÍ ģļńļěľŊĨňĢħĩĮĽ
ÐÉÔÏÍ
úúú

ŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨¡ÌÐÉÔÏÍúúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŌgIÎō
lz/
FúúúG

ĮŊĻÎ
ÅÅEN
ÎÔ

DÅÅÅÅ~Túú¿ÎÒÍÌÌÒ ¨ĎTukŌ(ōFGúúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúú ú¨úúō¡¸úú¿úúČúúúúBúúúúúúúú¨úúúúTúúúúÒÉÌÐÎ @Ã$tû¦ÒÉÌÐÎ ¦ÆÍÉÔÔÏÇû@ÃyÆÏÉÔÕÓÇûĆĎÆÎÒÌÇ
ÒÉÌÐÎ
ÒÉÌÐÎ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T¡Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō

U

yh64

8úúúú_¡

Ìúúúúúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÏ
ÅÅEN
ÎÔ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúú ú¨úúō¡ÓÉÕÕÒ @Ã$tû¦
ÓÉÕÕÒ

¸úú¿

úúČúúúúBúúúúúúúú¨úúúúTúúúúÓÉÕÕÒ ¦ÆÏÉÏÌÐÇû@ÃyÆÐÉÐÎÔÇûĆĎÆÎÒÏÇ
ÓÉÕÕÒęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

yh64

8úúúú_¡

Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÎÉÌÏÐ  yh6ÎÉÌÏÐ J·Ä°³Kh
ÎÉÌÏÐ
úúú

ŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨ÎÉÌÏÐúúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŌgIÎō
lz/ÎÒÍÌÌÒÌ¡ ¨ĎTuk
FúúúG

ĮŊĻÍ
ÅÅEN
ÎÕ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúú ú¨úúō
¡

ÍÕÎ ?

*"

úúČúúúúBúúúúúúúú¨úúúúTúúúúÍÕÎ ú\a?

ÍÏÔF



ÔÉÌÐÔ @Ã$tû¦ÔÉÌÐÔ ¦ÆÎÉÕÌÑÇû@ÃyÆÏÉÐÑÐÇûĆĎÆÍÉÒÔÔÇ
ÔÉÎÐÌ
ÔÉÎÐÌ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T
¡
U

,Đ

¸úú¿

yh64

Ì
¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÐÉÔÎÑ  yh6ÐÉÔÎÑ ĤňĵġİĮĚĭħŀĹņĪĭĥŊ8úúúú_
¡

ÐÉÔÎÑ
úúú

ÐÉÔÎÑ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÎ
ÅÅEN
ÎÕ

DÅÅÅÅ~

Túú¿

Ō(ō
FG
úúúúúú¥úČúú®

Uúúúúúúúúúúúúmúú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúú ú¨úúō¡ÒÉÍÍÍ @Ã$tû¦
ÒÉÍÍÍ

¸úú¿

úúČúúúúBúúúúúúúú¨úúúúTúúúúÒÉÍÍÍ ¦ÆÍÉÍÍÔÇû@ÃyÆÐÉÍÓÍÇûĆĎÆÔÎÎÇ
ÒÉÍÍÍęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúú¨TŌ%5ō
U ¨T¡Ì¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō

U

yh64

8úúúú_

ŌgIÎō
lz/
¡

Ì
úúú

ÎÒÍÌÌÒ

úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ
ĺĩİŉıġīŊ


TRQ±¨Ì¡ ¨ĎTuk
FúúúG

ĮŊĻÏ
ÅÅEN
ÎÕ

DÅÅÅÅ~Túú¿múú4ú¨úsújú¨
¯²S¨
)a¨
[¨¯¨
;µŉ=¢XŌúú ú¨úúō¡¨TŌ%5ō
U ¨T
¡
U

yh64

8úúúú_¡

úúúúúú¥úČúú®
Uúúúúúúúúúúúú

ÍÏÏ ?

*"

ÍÏÏ ÎÓ7\a'{?

FÌ¤ÅÅ»ÅÅTÅŌŏ+ďŏĎdĀŐŎŎ`pĎĔĎō
ÎÉÏÍÓ  yh6ÎÉÏÍÓ ĪķĮĚŊĠĿĶĲĭİ
ÎÉÏÍÓ
úúú

ĺĩİŉıġīŊ
TRQ±¨

¡

,Đ

¸úú¿
úúČúúúúBúúúúúúúú¨úúúúTúúúúÌÔÉÑÑÓ @Ã$tû¦ÔÉÑÑÓ ¦ÆÏÉÓÕÍÇû@ÃyÆÐÉÑÎÏÇûĆĎÆÎÐÍÇ
ÔÉÒÕÌ
ÔÉÒÕÌ
ęúúúńúúúĴúúúěúúúİúúú»úúúúúúTúúúŃĥŊĬŉęħĩīňİ


Ō(ō
FG

Ì

ÎÉÏÍÓ
úúúĩúúúīúúúĭúúúķúúú»úúúúúúTúúú